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Abstract
Pathological left ventricular hypertrophy is a maladaptive cardiomyocyte growth response to
various cardiovascular conditions such as hypertension, and is a major risk factor for heart
failure and stroke. The majority of drugs used to treat cardiovascular diseases target G protein
coupled receptors (GPCRs), which are regulated by regulator of G protein signalling (RGS)
proteins. RGS2 is a GTPase activating protein which limits Gq- and Gs-mediated signalling,
which are known to play major roles in the development of pathological cardiac hypertrophy.
In addition to its G protein effects, we have previously shown that RGS2 can also inhibit
protein synthesis and cultured cardiomyocyte growth via a region in its RGS domain, RGS2eb,
which inhibits the rate-limiting eIF2B/eIF2 step of protein synthesis initiation. Thus, we
hypothesized that the in vivo expression of RGS2eb could limit the development of
experimentally induced hypertrophy. Herein, we demonstrate that the in vivo cardiomyocyte
specific overexpression of RGS2eb prevents the development of cardiac hypertrophy in a
transverse aortic constriction (TAC) model of experimental pressure overload, as well as
functional loss and the expression of “fetal” genes associated with hypertrophy and heart
failure. Although we further hypothesized that the expression of RGS2eb in Rgs2-/- mice (which
are highly sensitive to hypertrophy and heart failure following pressure overload) could
compensate for the loss of endogenous RGS2, we were limited in our characterizations by poor
survival rates in Rgs2-/- animals following TAC surgery.
Cardiovascular dysfunction is also known to be directly influenced by obesity and weight gain,
which reflects the importance of understanding the mechanisms behind metabolic
dysregulation. We have previously demonstrated that Rgs2-/- mice exhibit a lean phenotype on
a normal chow diet, but still gain weight on a high fat diet. We thus sought to further
characterize the metabolic role of RGS2 via Comprehensive Lab Animal Monitoring System
(CLAMS) metabolic cages and gene expression analysis of skeletal rather than adipose tissue.
Here we report that loss of RGS2 leads to greater use of carbohydrates and significant increases
in basal metabolism, as well as increases in associated metabolism-related genes. Altogether,
these studies provide new insights into the role of RGS2 in cardiovascular health and
metabolism.

Keywords
Regulator of G protein signalling 2 (RGS2), RGS2eb, G protein-coupled receptors (GPCRs),
eukaryotic initiation factor 2 (eIF2), eukaryotic initiation factor 2B (eIF2B), cardiac
hypertrophy, CLAMS metabolic cages, metabolism, lean phenotype.
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1

INTRODUCTION

1

Regulator of G protein signalling (RGS) proteins
Agonist binding of G protein coupled receptors (GPCRs) promotes G protein activation, which
is achieved by catalyzing GDP–GTP exchange on the Gα subunit; a conformational change in
the GTP–bound α subunit is thought to lead to the dissociation of Gα from the stable G-βγdimer, thus enabling the regulation of downstream effectors. These signalling events are
terminated as a consequence of the intrinsic GTPase activity of the Gα subunit, which
hydrolyzes GTP to GDP, resulting in a return to the inactive form of the G protein heterotrimer.
The intrinsic GTPase activity of Gα subunits is generally insufficient to explain the observed
physiological rates of G protein inactivation (Tang and Insel, 2004), and has been found to be
accelerated by GTPase–activating proteins (GAPs) such as regulator of G–protein signalling
(RGS) proteins.
RGS proteins are a family of GAPs that bind to G–proteins and inactivate them by increasing
the intrinsic rate of GTP hydrolysis. They thus function to limit the intensity and duration of
GPCR-initiated signalling, and this is mainly accomplished via a conserved, ~120 amino acid
RGS domain that is responsible for their GAP activity (Popov et al., 1997; Ross and Wilkie,
2000). Most RGS proteins act as GAPs towards Gαi –mediated signalling and can be classified
into four subfamilies (R4, RZ, R7, and R12) (Berman, Kozasa and Gilman, 1996; AbramowNewerly et al., 2006; Jayaraman et al., 2009). There are currently no RGS proteins known to
inhibit Gαs activity, although RGS2 has been shown to inhibit Gαs pathways in a GAPindependent manner (Salim et al., 2003; Roy, Baragli, et al., 2006). The GAP activity of RGS
proteins is sensitive to a variety of factors such as cations and phospholipids (Wang et al.,
1997; Tu, Woodson and Ross, 2001; Cladman and Chidiac, 2002; Ishii, Inanobe and Kurachi,
2002); post-translational modifications can also influence RGS intracellular localization as
well as interactions with G proteins and other binding partners (Chidiac and Roy, 2003).
Although the RGS domain is necessary and sufficient to confer GAP activity (Popov et al.,
1997), other domains can also determine cellular localization, increase substrate specificity,
and provide additional activities (Snow et al., 1998; Traver et al., 2004; Wang et al., 2005).

2

Regulator of G protein signalling 2 (RGS2)
RGS2 is part of the B/R4 subfamily of RGS proteins (RGS1-5, RGS8, RGS13, RGS16,
RGS18, RGS21) which are relatively small and simple in structure (~20-30 kDa), and contain
a conserved RGS domain flanked by short N- and C-terminal domains (Riddle et al., 2005).
While almost all RGS proteins function as GAPs on Gαi/o signalling, RGS2 is unique; it
demonstrates a low affinity for Gαi/o, and instead selectively inhibits Gαq and Gαs–mediated
signalling via GAP–dependent and GAP–independent mechanisms (Heximer et al., 1997,
1999; Bernstein et al., 2004; Hague et al., 2005; Roy, Baragli, et al., 2006). The Gαq selectivity
of RGS2 is largely due to three Gαq amino acid residues (Cys106, Asn184, and Glu191) which
appear to reduce RGS2 affinity for Gαi by steric hindrance, whereas inhibition of Gαs signalling
is due at least in part to direct interactions of RGS2 with adenylate cyclases I, II, and VI via its
N-terminal domain. (Salim et al., 2003; Roy, Baragli, et al., 2006). In addition, the N-terminal
domain of RGS2 can bind other proteins such as spinophilin, muscarinic receptors, αadrenergic receptors, TRPV6 calcium channels, and tubulin (Bernstein et al., 2004; Hague et
al., 2005; Wang et al., 2005; Heo et al., 2006; Schoeber et al., 2006); we have also
demonstrated that RGS2 can inhibit protein synthesis in a GAP-independent manner, which
will be addressed in detail further below (Nguyen et al., 2009; Chidiac et al., 2014).

1.2.1

Expression and regulation of RGS2

RGS2 is found ubiquitously, with its mRNA expressed in organs such as the heart, brain, lungs,
and kidneys, as well as in cell types including pre-adipocytes, vascular smooth muscle cells,
osteoblasts, and chondrocytes (Miles et al., 2000; Huang et al., 2003; Larminie et al., 2004).
Various signalling pathways and stimuli can induce Rgs2 gene transcription. In human
neuroblastoma cells, carbachol stimulation of muscarinic receptors, which are coupled to the
phosphoinositide signal transduction system, results in rapid and lasting increases in Rgs2
mRNA levels (Song, De Sarno and Jope, 1999). Gq agonists such as angiotensin II and
phenylephrine, as well as Gs agonists which increase cAMP levels or intracellular Ca2+, have
also been shown to upregulate Rgs2 gene expression in multiple cell types including vascular
smooth muscle cells, neonatal cardiomyocytes, and HEK293 cells lines (Grant et al., 2000;
Zou et al., 2006). In addition, conserved cAMP response bindings elements in the RGS2
3

promoter are critical for cAMP-response element binding protein (CREB) binding and RGS2
promoter activation; three single nucleotide polymorphisms (SNPs) have been identified in the
human RGS2 promoter CREB binding site in hypertensive patients, with the corresponding
point mutations reducing the RGS2 inhibition of forskolin-stimulated adenylyl cyclase activity
(Nunn et al., 2010; Xie et al., 2011; Nguyen et al., 2012).
Endogenous RGS2 protein is rapidly degraded via proteasomal mechanisms (Bodenstein,
Sunahara and Neubig, 2007; Osei-Owusu et al., 2007). Polymorphisms which enhance RGS2
degradation have been associated with hypertension and cardiovascular dysfunction, and
suggest that stabilizing RGS2 protein expression may result in beneficial effects (Bodenstein,
Sunahara and Neubig, 2007; Gu, Tirgari and Heximer, 2008; Hahntow et al., 2009; Sjogren et
al., 2012). Indeed, more than 30 RGS2 gene polymorphisms have been identified in human
hypertensive patients (Yang et al., 2005; Riddle et al., 2006; Semplicini et al., 2006; Zhao et
al., 2008); conversely, hypotensive patients with Bartter/Gitelman syndrome have increased
RGS2 expression (Calò et al., 2004). In addition, RGS2 deficiency or dysfunction has been
linked to anxiety disorders and airway hyper-responsiveness (Xie et al., 2012; Hettema et al.,
2013), further highlighting the importance of RGS2 regulation.

1.2.2
1.2.2.1

RGS2eb regulates mRNA translation
Regulation of protein synthesis during translation initiation

The rate of global protein synthesis is controlled primarily at the initiation level, and is divided
into multiple stages: (1) GTP-bound eukaryotic initiation factor 2 (eIF2) recognizes and binds
initiator tRNA (Met-tRNAMeti), forming the ternary complex eIF2-GTP-Met-tRNAMeti,
followed by binding of the complex to the 40S ribosomal subunit; (2) In cap-dependent
initiation, the cap structure at the 5’end of mRNA is recognized and bound by eIF4F, which
guides the activated 40S subunit to the 5’ end of the mRNA; (3) mRNA-bound 40S travels
along the 5’–untranslated end of the mRNA, scanning until it reaches an AUG start codon; (4)
Upon start codon detection, the 60S subunit binds to the 40S subunit, initiation factors are
released, and the Met-tRNAMeti becomes positioned in the ribosomal P site in preparation for
the elongation phase (Jackson, Hellen and Pestova, 2010) .
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1.2.2.2

Rate limiting step of translation initiation: eIF2 and eIF2B

Of particular importance in the regulation of initiation is the heterotrimeric initiation factor
eIF2 which, when bound to GTP, is active and recruits Met–tRNAMeti to the ribosomal
initiation complex. eIF2 is inactivated by the hydrolysis of GTP; in order for reactivation to
occur, GDP must first dissociate. This intrinsically slow process is sped up by the
heteropentameric protein eIF2B (α – ε) , which acts as a guanine nucleotide exchange factor
(GEF) by binding to eIF2, and catalyzing GDP/GTP exchange (Abbott and Proud, 2004). Thus,
the rate limiting step of initiation is ultimately eIF2B-facilitated GDP/GTP exchange on eIF2
(Rolfe et al., 2005; Singh et al., 2006; Elsby et al., 2011). This makes the modulation of eIF2B
activity an important aspect in the regulation of global protein synthesis. Stimuli that promote
cell growth may do so by causing the dephosphorylation and consequent activation of eIF2B
(Wek, Jiang and Anthony, 2006; Chidiac et al., 2014). Conversely, phosphorylation of eIF2B,
as well as eIF2, inhibits their activity and results in the attenuation of cell growth (Hardt et al.,
2004).

1.2.2.3

RGS2eb binds to eIF2B and inhibits protein translation

While the G-protein dependent effects of RGS2 are well established, studies have also shown
that RGS2 can bind and regulate other targets (Wang et al., 2005; Heo et al., 2006; Schoeber
et al., 2006; Zhang and Mende, 2011). Our lab has previously discovered a novel binding
partner for RGS2. We have shown that RGS2 can bind to the ε subunit of eIF2B, resulting in
the inhibition of mRNA translation (Nguyen et al., 2009). By binding to eIF2Bε, RGS2 inhibits
its ability to facilitate GDP dissociation on eIF2, which ultimately leads to the attenuation of
de novo protein synthesis. This novel, G-protein independent property of RGS2 has been
mapped to a 37 amino acid domain (residues 79-115) that is homologous to a region in the β
subunit of eIF2 that binds to eIF2Bε, suggesting that RGS2 may inhibit initiation by competing
or otherwise interfering with binding between eIF2 and eIF2B.
We have shown that the eIF2Bε binding domain, RGS2eb, to be both necessary and sufficient
for the inhibition of protein synthesis by RGS2; a corresponding 37-oligomer peptide based on
this region also dose-dependently decreased in vitro mRNA translation (Nguyen et al., 2009).
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In addition, the cellular expression via adenoviral infection of RGS2eb or full-length RGS2
decreased levels of protein synthesis to a comparable extent (Nguyen et al., 2009).
Furthermore, the rate of protein synthesis was increased in cells from RGS2 knockout animals,
which suggests that the effect of RGS2 on protein synthesis is physiologically relevant
(Nguyen et al., 2009). Thus, RGS2, and more specifically its eIF2Bε binding domain, appears
to be an important regulator of mRNA translation.
This novel mechanism of eIF2B inhibition adds to a group of studies which demonstrate that
inhibition of eIF2B leads to decreased protein synthesis. Glycogen synthase kinase 3 (GSK3)
can directly phosphorylate eIF2Bε at serine 540 in intact cells, which inhibits eIF2B GEF
activity by up to 80% (Welsh et al., 1998). It has also been shown that the effects of eIF2B on
eIF2 can be decreased by the binding of eIF2 to eIF5. The primary function of eIF5 is to
promote GTP hydrolysis by eIF2; when present at elevated levels, eIF5 may act to sequester
eIF2 from eIF2B, thereby impeding protein synthesis (Singh et al., 2006). Other groups have
successfully used eIF2Bε siRNA (Deng et al., 2008) in vitro, as well as adeno-associated
viruses (AAVs) in vivo to specifically inhibit eIF2Bε (Guo et al., 2016; Merentie et al., 2016).
However, cardiac specific overexpression of full-length RGS2 (which contains the RGS2eb
domain) does not appear to confer protective effects against hypertrophy in a pressure overload
model (Park-Windhol et al., 2012). As previously mentioned, RGS2 possesses multiple
properties not known to be shared by either RGS4 or RGS5, although the latter two are also
able to inhibit cardiac hypertrophy when overexpressed (Heximer et al., 1999; Chidiac and
Roy, 2003; Roy, Nunn, et al., 2006; Tokudome et al., 2008; Endale et al., 2010; Li et al., 2010;
Sethakorn, Yau and Dulin, 2010; Chidiac et al., 2014). Since our studies suggest that the
RGS2eb region specifically, and exclusively, inhibits eIF2/eIF2B interactions (and thus protein
synthesis) (Nguyen et al., 2009), it is possible that the other properties of RGS2 may have
confounded or attributed to the limited cardioprotection that was observed by groups
expressing full-length RGS2. Thus in the context of cardiovascular health, the protein synthesis
inhibitory effects of RGS2eb could be a major contributor to the reported beneficial effects of
RGS2.
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Signalling pathways of cardiac hypertrophy
1.3.1

Physiological hypertrophy is regulated by PI3K-Akt signalling

Physiological and pathological hypertrophies differ not only in terms of phenotype, but can be
distinguished by the different signalling cascades that drive them. Exercise or
developmentally-induced growth is primarily mediated by growth hormones, and a critical
pathway for physiological hypertrophy is the phosphoinositide 3-kinase (PI3K)–Akt pathway
(Hunter and Chien, 1999; McMullen and Jennings, 2007). When IGF-1, insulin, and other
growth factors bind to their membrane tyrosine receptor kinases, the PI3K isoform p110α is
activated, and phosphorylates membrane phosphatidylinositols at the 3' position of the inositol
ring (Dorn and Force, 2005). This phosphorylation results in the recruitment of the protein
kinase Akt (also known as PKB) and its activator 3-phosphoinositide-dependent protein
kinase-1 (PDK1). Activation of Akt by PDK1 leads to the activation of mammalian target of
rapamycin (mTOR), which is a central regulator of protein synthesis via its ability to activate
translational machinery and ribosome biogenesis (Dorn and Force, 2005). In addition, Akt can
phosphorylate and inhibit the activity of glycogen synthase kinase-3 (GSK-3), a constitutively
active negative regulator of cardiac hypertrophy (Haq et al., 2000; Hardt and Sadoshima, 2004;
Kerkelä, Woulfe and Force, 2007).
Several studies have demonstrated the importance of PI3K-p110α/PDK1/Akt signalling for
adaptive cardiac hypertrophy. Transgenic mice constitutively overexpressing the p110α
isoform of PI3K exhibited exercise-induced hypertrophy that did not transition into
pathological growth (Shioi et al., 2000). Furthermore, cardiac expression of a mutant
dominant-negative p110α prevented exercise-induced growth, but maladaptive hypertrophy
still occurred in response to pressure overload (McMullen et al., 2003). Together, these studies
demonstrate the critical role that PI3K-p110α/PDK1/Akt signalling plays in the regulation of
physiological hypertrophy.
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1.3.2

Pathological cardiac hypertrophy is regulated by GPCR
signalling

While adaptive hypertrophy is mediated by receptor tyrosine signalling, the critical pathways
for maladaptive growth are initiated by G-protein coupled receptors (Dorn and Force, 2005;
Heineke and Molkentin, 2006; Hendriks-Balk et al., 2008). GPCRs are seven transmembrane
domain proteins involved in signal transmission. With more than 800 members, they represent
the largest and most diverse family of cell surface receptors existing in the mammalian genome
(Oldham and Hamm, 2008); cardiovascular cells alone possess greater than 100 different
GPCRs (Tang and Insel, 2004). GPCRs play a critical role in linking messages from
extracellular ligands to signalling pathways within the cell. With a wide variety of activating
ligands and with their localization at the cell membrane, GPCRs represent the largest class of
drug targets – more than one-third of current drugs on the market act by binding to GPCRs
(Ma and Zemmel, 2002; Wise, Gearing and Rees, 2002; Dror et al., 2011).
Isoforms of the Gα subunit result in four heterotrimeric G protein families: Gαs, Gαi/o, Gαq/11,
and Gα12. While both Gq/11 and Gs signalling can result in cardiomyocyte growth, Gq in
particular has been widely shown to play a crucial role in the development of pathological
hypertrophy (D’Angelo et al., 1997; Mende et al., 1998; Bernardo et al., 2010).

1.3.3

Prolonged Gαq/11 signalling leads to maladaptive cardiac
hypertrophy

Heterotrimeric Gq and the functionally similar G11 transduce signals from hypertrophic
receptors for angiotensin, endothelin, norepinephrine, and other neurohormones (Rockman,
Koch and Lefkowitz, 2002). When activated, the Gαq/11 subunit recruits phospholipase C beta
(PLCβ) to the cell membrane, where it hydrolyzes phosphatidylinositol 4,5-bisphosphate
(PIP2), resulting in the release of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
IP3 can then bind to receptors in the sarcoplasmic reticulum (SR), causing calcium release into
the cytosol. At this point, two pathways can contribute to a hypertrophic response. Calcium
release along with DAG can activate protein kinase C (PKC), which leads to the subsequent
inhibition of GSK-3. It can also affect MAP kinase (MAPK) signalling through proteins such
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as ERK1/2, JNK and p38 (Frey and Olson, 2003). Alternatively, Ca2+ release can cause the
messenger protein calmodulin to activate calcineurin, which dephosphorylates the
transcription factor NFAT. Subsequently, NFAT can translocate to the nucleus, and activate
the transcription of hypertrophic response genes (Dorn and Force, 2005).
The importance of Gαq/11 signalling in the maladaptive hypertrophic response has been
demonstrated in several studies. Transgenic mice with cardiac-specific transgenic
overexpression of Gαq/11 –linked receptors demonstrate severe cardiac hypertrophy and
dysfunction, upregulation of the “fetal” gene response, and premature death (D’Angelo et al.,
1997; Mende et al., 1998). Conversely, mice overexpressing a dominant-negative Gαq/11
peptide or which lacked Gαq/11 were resistant to hypertrophy following pressure overload, but
still exhibited exercise-induced physiological cardiac growth (Akhter et al., 1997;
Wettschureck et al., 2001). Altogether, these studies indicate that Gq/11 signalling is sufficient
for pathophysiological hypertrophy to occur.
In addition to PLCβ-mediated hypertrophy, Gαq/11 signalling can also act through the PI3KAkt pathway that is normally associated with physiological growth. Gαq/11 stimulated PI3K
differs from physiological PI3K in that the activated isoform is changed from p110γ to p110α.
However, since both types of PI3K can go on to activate Akt and its downstream mTOR and
GSK-3 pathways, it is not well understood how these events can result in different forms of
hypertrophy (Dorn and Force, 2005).

1.3.4

Gαs signalling mediates β-adrenergic induced hypertrophy

Although Gαq/11 signalling is the major mediator of maladaptive hypertrophy, Gαs also plays a
significant role in cardiomyocyte growth. In the heart, Gαs proteins are mainly coupled to β1adrenergic receptors. Upon agonist binding (e.g. isoproterenol), the Gα subunit activates
adenylyl cyclase (AC), which in turn catalyzes the conversion of ATP into the second
messenger cAMP (Dorn and Force, 2005). Increased concentrations of cAMP can then activate
protein kinase A (PKA) which, among other functions, inhibits GSK-3 and causes an increase
in protein synthesis. Overexpression of β1-receptors in the hearts of transgenic mice has been
shown to initially increase contractile function and responsiveness to isoproterenol, which can
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initially be seen as beneficial during early heart failure (Bisognano et al., 2000; Engelhardt et
al., 2002). However, chronic stimulation of these receptors results in progressive deterioration
of cardiac function, as well as increased hypertrophy and fibrosis (Bisognano et al., 2000;
Engelhardt et al., 2002; Bernardo et al., 2010). Thus in addition to Gq signalling, Gs –mediated
cell growth and heart function also contributes to the maladaptive hypertrophic response.

Regulation of protein synthesis in cardiac hypertrophy
1.4.1

Overview of protein synthesis

In order for either adaptive or maladaptive cardiac hypertrophy to occur, individual
cardiomyocytes must increase in size, and such growth requires increased global protein
synthesis. Thus, regardless of the initial stimuli and receptors involved, hypertrophic signals
will ultimately result in increased mRNA translation/protein synthesis.
Protein synthesis consists of three main stages: initiation, elongation, and termination. During
eukaryotic initiation, an initiator methionyl tRNA forms a complex with a 40S ribosomal
subunit, and is then positioned at the start codon of an mRNA molecule (Jackson, Hellen and
Pestova, 2010). Binding of the 60S ribosomal subunit allows for elongation to occur, during
which amino acids are sequentially added to a growing polypeptide chain via specific tRNA
molecules. When a stop codon is reached, protein synthesis is terminated by the release of the
newly formed peptide chain and separation of the ribosomal-mRNA complex (Proud, 2007).

1.4.2

Regulation of eIF2Bε

As previously mentioned, regeneration of GTP-bound eIF2 requires eIF2B, and specifically
the ε subunit, which contains the catalytic domain towards its C-terminus (Welsh and Proud,
1993; Wang et al., 2001; Gomez, Mohammad and Pavitt, 2002). eIF2B can be activated by
multiple stimuli that increase mRNA translation, including insulin and growth factors (Welsh
and Proud, 1992; Welsh et al., 1996; Kleijn et al., 1998). Overexpression of eIF2Bε has also
been shown to enhance growth in neonatal cardiomyocytes (Hardt et al., 2004). The
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importance of eIF2B regulation can be seen by the convergence of hypertrophic signals on
constitutively active glycogen synthase kinase 3. GSK-3, and more specifically its β isoform
(GSK-3β), has been shown to be the predominant kinase for mediating eIF2B phosphorylation
(Hardt and Sadoshima, 2002; Hardt et al., 2004). Under resting conditions, GSK-3β
phosphorylates the catalytic ε subunit of eIF2B at a highly conserved serine (Ser540), resulting
in the inhibition of eIF2B activity (Hardt et al., 2004). In addition to Ser540, the epsilon subunit
of eIF2B has several other regulatory phosphorylation sites (Wang et al., 2001; Proud, 2007),
which suggests that its regulation, and consequently that of eIF2, is critical in the control of
global protein synthesis.
Hypertrophic signals can promote the phosphorylation and deactivation of GSK-3β. As
previously discussed, several pathways in both adaptive (e.g. IGF1-PI3K-Akt) and
maladaptive cardiac hypertrophy (e.g. Gq and Gs-mediated) can result in the inhibition of GSK3β. Studies using β-receptor agonists have shown that inhibition of GSK-3β results in greater
eIF2B activity and marked increases in cell size and protein synthesis; conversely,
overexpression of GSK-3β decreases levels of eIF2B activity (Hardt et al., 2004). In addition,
GSK-3β has been found to block hypertrophy in response to the Gq-agonists endothelin and
phenylephrine (Dorn and Force, 2005). Together, these studies not only suggest that GSK-3β
is the predominant kinase in eIF2Bε regulation, but demonstrate that regardless of the initial
stimuli, eIF2Bε is required for hypertrophy to occur. Thus, targeting eIF2B for inhibition could
prevent or decrease the levels of protein synthesis associated with pathological cardiac
hypertrophy.

RGS proteins in the heart
Several RGS proteins are expressed in mammalian hearts and have been detected in both
cardiomyocytes and fibroblasts (Kardestuncer et al., 1998; Doupnik, Xu and Shinaman, 2001;
Riddle et al., 2005; Zhang and Mende, 2011). In failing human hearts, variable expression
results have been obtained, although the expression profiles of RGS2, RGS3, and RGS4 are
noticeably altered (Riddle et al., 2005). Some groups have found RGS4 mRNA to be increased
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but not RGS2 or RGS3 (Mittmann et al., 2002), whereas others have shown an apparent
upregulation of RGS3 and RGS4 mRNA (Owen et al., 2001); other groups have identified
decreases in RGS2 protein levels (Takeishi et al., 2000). Overall, it appears that RGS2 is
normally highly expressed in the ventricles, whereas RGS4, RGS5, and RGS10 are mainly
localized to the atria (Doupnik, Xu and Shinaman, 2001; Mittmann et al., 2002; Larminie et
al., 2004; Gu et al., 2009; Miao et al., 2016), suggesting that targeting RGS2 is physiologically
relevant.
Animal overexpression and knockout models have demonstrated the cardiovascular roles of
various RGS proteins. Gene expression studies have found RGS2, RGS3, and RGS5 to be the
most highly expressed RGS proteins in the myocardium, (Larminie et al., 2004), and RGS4
and RGS6 to be concentrated in the sinoatrial node (Grillet et al., 2005; Cifelli et al., 2008,
Yang et al., 2010). A cardiac mouse model with transgenic overexpression of RGS4 transiently
decreased cardiac hypertrophy and heart failure in Gαq– overexpressing mouse hearts (Rogers
et al., 2001), although it should be noted that endogenous levels of RGS4 are virtually absent
in the ventricular myocardium (Grillet et al., 2005; Cifelli et al., 2008). An overexpression
model of RGS5 was protected against pressure overload-induced experimental cardiac
hypertrophy and fibrosis, whereas marked cardiac hypertrophy, fibrosis, and dysfunction
occurred in RGS5 knockout mice (Li et al., 2010). Recently, RGS10 was found to be
downregulated in failing mouse hearts; similarly to RGS5, cardiac-specific overexpression led
to decreased cardiac hypertrophy and fibrosis following experimentally induce pressure
overload (Miao et al., 2016).
RGS proteins also play an essential role in regulating heart rate. Knock-in mice expressing a
RGS–resistant form of Gαi2 displayed enhanced carbachol–induced bradycardia (Fu et al.,
2006, 2007). RGS4 and RGS6 knockout models also suggest key roles in regulating
parasympathetic heart rate control, as their loss resulted in severe bradycardia in response to
in vivo parasympathetic stimulation (Cifelli et al., 2008; Posokhova et al., 2010; Yang et al.,
2010). RGS2 in particular has been shown to play a significant role in cardiovascular function.
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1.5.1

Cardioprotective role of RGS2

Because of the critical roles that Gαq and Gαs signalling play in the induction of pathological
hypertrophy, the inhibitory effects of RGS2 on these signals makes it a potential target in the
study of cardiovascular disease (Heineke and Molkentin, 2006; Hendriks-Balk et al., 2008). In
addition to the heart, RGS2 is expressed in the brain, vasculature and kidneys (Kehrl and
Sinnarajah, 2002) . Along with RGS1, 4, and 5, RGS2 is detectable at both the mRNA or
protein level in endothelial or vascular smooth muscles cells of the arterial system (Bondjers
et al., 2003; Heximer et al., 2003; Wang et al., 2008; Timofeeva et al., 2009). Rgs2-/- mice
have been reported to exhibit elevated blood pressures (Heximer et al., 2003), and Gq mediated smooth muscle contraction is enhanced in several regions of the vasculature (e.g.
mesenteric and renal arteries) (Hercule et al., 2007; Osei-Owusu et al., 2007; Osei-Owusu and
Blumer, 2015). Interestingly, although global deletion of RGS2 has been observed to induce
hypertension, vascular smooth muscle or endothelium-specific deletion of RGS2 does not
appear to increase blood pressure (Osei-Owusu et al., 2012). However, transplanting Rgs2-/kidneys into wild type recipient mice is sufficient to induce hypertension, with the reverse
transplantation (i.e. WT kidneys transplanted in Rgs2-/- mice) “rescuing” Rgs2-/- animals from
an observed hypertensive phenotype (Gurley et al., 2010), suggesting that renal RGS2 is
important in maintaining normal levels of blood pressure.
RGS2 appears to be necessary for the antihypertrophic and vasodilatory effects of cGMP and
nitric oxide (Sun et al., 2005; Takimoto et al., 2009). Studies in cultured cardiomyocytes have
shown that hypertrophy caused by prolonged Gαq–coupled receptor stimulation, such as that
induced by phenylephrine (PE), can be blocked by the overexpression of RGS2 (Hao et al.,
2006; Zou et al., 2006). Moreover, RGS2 negatively regulates angiotensin II-induced
signalling in cardiac fibroblasts (Zhang et al., 2011). RNAi–mediated knockdown of RGS2
also leads to increased endothelin and phenylephrine–induced cardiomyocyte hypertrophy
(Zhang et al., 2006, Nunn et al., 2010, Zou et al., 2006). A similar effect has been seen against
Gαs mediated cardiomyocyte hypertrophy induced by isoproterenol (ISO) (Nunn et al., 2010).
The cardiovascular role of RGS2 has been further demonstrated in knockout animal studies.
Under normal conditions, the absence of RGS2 appears to have minimal effects on cardiac
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function, although studies have shown Rgs2-/- or Rgs2+/- mice to be hypertensive (Heximer et
al., 2003; Tang et al., 2003). However, experimentally induced pressure overload causes
marked hypertrophy, heart failure, and death, as well as increased expression of cardiac fetal
genes in RGS2 knockout mice (Takimoto et al., 2009). In addition, Rgs2-/- mice have been
shown to have increased susceptibility to atrial fibrillation (AF) via enhanced M3 muscarinic
receptor activity, which is known to be involved in vagally induced atrial fibrillation (Tuomi,
Chidiac and Jones, 2010; Jones, Tuomi and Chidiac, 2012).
Endogenous RGS2 protein is rapidly degraded via proteasomal mechanisms (Bodenstein,
Sunahara and Neubig, 2007), and low RGS2 protein levels have been associated with
cardiovascular dysfunction and hypertension in human patients (Heximer et al., 2003; Tsang
et al., 2010); RGS2 is also selectively downregulated in pressure overload mouse models of
cardiac hypertrophy and heart failure (Zhang et al., 2006), notwithstanding its acute
upregulation in cardiomyocytes in response to hypertrophy-inducing Gq and Gs-coupled
receptor stimulating agonists (Zou et al., 2006; Nunn et al., 2010) These observations suggest
that overexpressing, or stabilizing RGS2 protein expression may result in cardioprotective
effects. Digoxin and other cardiotonic steroids, which are used to treat atrial fibrillation and
heart failure (Gheorghiade, Adams and Colucci, 2004), have been shown to act as selective
stabilizers of RGS2 in vitro (Sjogren et al., 2012). Digoxin has also been shown to be
cardioprotective in a drug–induced model of cardiac hypertrophy and injury, an effect which
was lost in similarly treated RGS2 knockout mice (Sjögren et al., 2016).
Surprisingly, cardiac specific overexpression of full-length RGS2 does not appear to offer
substantial cardioprotection against either hypertrophy or dysfunction in a pressure overload
mouse model (Park-Windhol et al., 2012). RGS2 possesses multiple properties not known to
be shared by either RGS4 or RGS5 (Chidiac et al., 2014), including low affinity for Gαi/o
(Heximer et al., 1999), ability to inhibit Gs-stimulated adenylyl cyclase signalling (Roy,
Baragli, et al., 2006), nuclear localization (Chidiac and Roy, 2003), and the apparent ability to
promote apoptosis (Endale et al., 2010). In addition, although RGS2 is selectively upregulated
in cultured cardiomyocytes following Gαq or Gαs stimulation (Hao et al., 2006; Zou et al., 2006;
Nunn et al., 2010), it is progressively downregulated in in vivo models of hypertrophy and
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heart failure (Zhang et al., 2006). Since complete ablation of RGS2 signalling is
unambiguously detrimental (Takimoto et al., 2009), it follows that optimal RGS2 levels under
pathological conditions may be lower than those needed under basal conditions.
Our lab has also shown that expression of either full-length RGS2 or RGS2eb can both block
increases in cardiomyocyte size induced by phenylephrine (PE) or isoproterenol (ISO) (Zou et
al., 2006; Chidiac et al., 2014). In addition, the reactivation of “fetal” genes such as ANP and
β-MHC, which are indicators of pathological hypertrophic growth, were suppressed in
cardiomyocytes expressing RGS2eb (Chidiac et al., 2014). An important distinction between
full length RGS2 and RGS2eb is that while the latter prevents hypertrophy, it does not have
GAP activity for Gαq, and also seems to have no inhibitory effect on ISO-induced Gαs signalling
(Nguyen et al., 2009; Chidiac et al., 2014). This indicates that in addition to the established
role of the RGS2 GAP domain as an inhibitor of G-protein and GPCR signalling, the RGS2eb
region further regulates G-protein induced hypertrophy through its binding to eIF2Bε, which
leads to the direct, G-protein independent inhibition of protein synthesis.

Clinical aspects of pathological left ventricular hypertrophy
(LVH)
1.6.1

General characteristics cardiac hypertrophy

During fetal development, mammalian cardiomyocytes rapidly proliferate; this growth ceases
during the perinatal period, and the heart is thus generally regarded as a post-mitotic organ,
with further increases in heart mass thought to be mainly achieved through increases in cell
size, i.e. hypertrophy (Ahuja, Sdek and MacLellan, 2007; Shimizu and Minamino, 2016). In
the adult heart, various intrinsic and extrinsic stimuli can increase biomechanical stress and
lead to a thickening of ventricular heart walls. Depending on the stimuli, either physiological
or pathological hypertrophy can occur (Fig. 1.1). Physiological cardiac hypertrophy mainly
develops in response to growth of the body (e.g. childhood growth) or chronic exercise
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training, whereas pathological cardiac hypertrophy occurs in a disease setting (Levy et al.,
1990).
Physiological and pathological hypertrophy can be further subclassified as either concentric or
eccentric hypertrophy (McMullen and Jennings, 2007). During concentric hypertrophy, which
is induced by pressure overload on the heart, sarcomeres in cardiomyocytes are added in
parallel, leading to an increase in myocyte cell width and a subsequent increase in heart wall
thickness; this results in hearts with thick walls and relatively small ventricular cavities
(Grossman, Jones and McLaurin, 1975; Bernardo et al., 2010). In a physiological context,
concentric hypertrophy develops following isometric or static exercise such as weight lifting,
which involves developing muscular tension against resistance with little movement (Pluim et
al., 2000; McMullen and Jennings, 2007). Pathological stimuli such as hypertension or aortic
stenosis similarly cause pressure overload on the heart and the development of concentric
hypertrophy (Frey and Olson, 2003). In contrast, eccentric hypertrophy results in sarcomeres
being added in series to increase myocyte cell length, leading to relatively thinner walls and
larger ventricular cavities (Bernardo et al., 2010). Isotonic exercise, such as running and
swimming, involves the movement of large muscle groups; vasodilation of the skeletal
vasculature produces eccentric hypertrophy due to increased venous return to the heart, which
results in volume overload (Zak, 1984; McMullen and Jennings, 2007). Pathological stimuli
such as aortic regurgitation and arteriovenous fistulas can increase diastolic wall stress, and
also result in eccentric hypertrophy (Grossman, Jones and McLaurin, 1975; Pluim et al., 2000).
While both physiological and pathological hypertrophies are characterized by an increase in
cardiomyocyte size due to increased global protein synthesis, the two conditions differ in
multiple aspects. In physiological hypertrophy, cardiomyocytes increase in size but display a
normal phenotype, and this is associated with normal cardiac function (Shimizu and
Minamino, 2016). Fatty acid oxidation is the main metabolic pathway for ATP production,
with the heart capable of switching to glucose and lactate metabolism depending on workload
(van der Vusse et al., 1992). In contrast, pathological hypertrophy results in a switch to
increased glucose metabolism and structural changes such as increased fibrosis, as well as
functional abnormalities (Conrad et al., 1995; Bernardo et al., 2010). Pathological hypertrophy
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Figure 1.1. Characteristics of physiological and pathological hypertrophy.
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is also characterized by a return to the “fetal” gene program, which includes increased
expression of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and α-skeletal
actin, as well as alterations in the cardiac contractile proteins α-and β-myosin heavy chain
(Hannan et al., 2003; Bernardo et al., 2010; Taegtmeyer, Sen and Vela, 2010; Kuwahara,
Nishikimi and Nakao, 2012). Maladaptive hypertrophy can drastically affect cardiovascular
health. Aside from age, left ventricular hypertrophy is the most potent predictor of poor
cardiovascular outcomes in hypertensive patients, and is an independent risk factor for sudden
death, stroke, coronary heart disease, and heart failure (Levy et al., 1990; Cipriano et al., 2001;
Gardin et al., 2001; Verdecchia, Carini, et al., 2001; Verdecchia, Porcellati, et al., 2001;
Gradman and Alfayoumi, 2006). With cardiovascular disease as the leading cause of mortality
in many nations (Schou et al., 2013), identifying regulators of pathological hypertrophy is of
great interest and importance.

1.6.2

General overview of LVH in patient populations

Since the left ventricle is responsible for pumping oxygenated blood throughout the body, the
majority of ventricular hypertrophy in a disease setting develops in the left myocardium. Most
LVH develops in early response to chronic hypertension; patients with transient elevations in
blood pressure, such as during mental stress or exercise, are also prone to hypertrophy (Daniels,
Meyer and Loggie, 1990; Schnall et al., 1990). Although hypertension is the leading cause of
LVH, factors other than blood pressure can also be important in the development of
hypertrophy, including angiotensin II and catecholamine levels, body mass or obesity, genetic
background, age of onset of high blood pressure, and insulin sensitivity (Simpson, 1983; Levy
et al., 1988; Sasson et al., 1993; Schunkert et al., 1994; Ichikawa et al., 1996; Re, 2003). In
addition, genetics may play a role in the development of LVH; mutations in genes encoding
sarcomeric proteins have been shown to directly correlate with hypertrophic cardiomyopathy
(Maron, 2002), and some patients with mild hypertension appear genetically predisposed to
LVH development (Liebson et al., 1993; Martinez et al., 2003).
The test of choice for accurate estimation of patient LV heart mass comes from 2D
echocardiography (Lorell and Carabello, 2000); although cardiac MRI is the gold standard test
for LVH due to its accuracy and reproducibility, it is cost prohibitive for regular clinical use
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(Bottini et al., 1995; Bauml and Underwood, 2010). In hypertensive patients, LVH usually
presents as an increase in wall thickness, which may are may not be accompanied by an
increase in the size of the LV cavity (Douglas and Kaplan, 2017). Interestingly, patients
without an increase in absolute LV mass but with an increase in their wall thickness–to–cavity
diameter ratio (concentric remodelling) have the same adverse risk for cardiovascular disease
and death as patients who develop concentric hypertrophy (increase in both mass and wall
thickness–to–cavity diameter ratio) (van Hoeven and Factor, 1990; Jain et al., 1996). While
hypertension induces pressure overload on the heart, concurrent volume overload due to
coronary artery disease or valvular conditions can further increase LVH and reduce cardiac
function (Zabalgoitia et al., 2001).

1.6.3

LVH increases cardiovascular risk

Diagnosed left ventricular hypertrophy comes with an increased risk of multiple cardiac events
including angina and myocardial infarction (MI), arrhythmias, stroke, heart failure, and death
(Levy et al. 1990; Koren et al. 1991; Verdecchia, Porcellati, et al. 2001; Haider et al. 1998;
Drazner et al. 2004; D Levy et al. 1989). Increases in cardiovascular risk have been found to
be directly related to the degree of increase in LV mass; this effect is also independent from
that of blood pressure (Levy et al. 1990; Koren et al. 1991). In a study of ~1000 patients over
50 years of age with primary hypertension and no previous cardiovascular events, LVH was
associated with a 40% increased risk for a major cardiovascular event (e.g. MI, severe heart
failure, severe kidney failure) even after adjustment for other risk factors (Verdecchia, Carini,
et al., 2001). In the Framingham Heart Study, which originally followed more than 5000 men
and women between the ages of 30 and 62 who had not yet developed overt symptoms of
cardiovascular disease, a subset population of ~3000 individuals over the age of 44 were found
to have a 22% prevalence of LVH; even after adjusting for other risk factors, these patients
were found to be twice as likely to suffer from sudden death (Haider et al., 1998).
LVH can cause electrophysiological alterations such as altered repolarization of the heart, nonuniform action potential prolongation, and early afterpotentials; this can lead to an increased
risk of atrial fibrillation, ventricular tachycardia, arrhythmias, and even sudden death (Gardin
et al., 2001; Okin et al., 2006; Sarganas et al., 2014). Increases in cardiac risk associated with
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LVH may also arise in part due to myocardial ischemia, which can be induced by multiple
factors (Douglas and Kaplan, 2017). Enlarged cardiomyocytes, and thus increased muscle
mass, can limit the ability of coronary arteries to properly dilate in response to vasodilatory
stress (e.g. during exercise) or decreased perfusion (e.g. during an arrhythmic event);
endocardial capillaries may also be directly compressed (Beache et al., 2001). These factors
can result in adverse clinical implications as well as decreases in coronary flow reserve (the
ratio between resting and maximal coronary artery blood flow), an important indicator of
cardiovascular risk (Douglas and Kaplan, 2017). In patients with LVH, coronary occlusion
events are associated with greater degrees of myocardial infarction and increased mortality
rates (Carluccio et al., 2000). In cases of sudden cardiac death, patients with LVH and
hypertension tend to have less extensive coronary artery disease than normotensive cases of
sudden death, suggesting that hypertrophied myocardium may be more susceptible to the
effects of ischemia (Burke et al., 1996). Progressive LVH results in deleterious ventricular
remodelling as well as depressed systolic and diastolic ventricular functions (Norton et al.,
2002). If improperly treated, LVH may ultimately lead to the development of irreversible heart
failure, and is one of the greatest independent risk factors for this condition (Cipriano et al.,
2001).

1.6.4

Non-pharmacological interventions

Strategies to manage hypertension and co-morbidities such as obesity can contribute to
lowering LV mass by reducing pressure overload on the heart. A high prevalence of
hypertension in obese patients (>60%) accounts for more than 60% of incident hypertension
(a systolic/diastolic blood pressure greater than 140/90 mmHg) in women and almost 80% of
incident hypertension in men. Regression of LVH in patients with primary hypertension has
been shown to occur with weight loss and exercise. Sympathetic signalling mechanisms play
a well-established role in the development of hypertrophy, and weight loss in obese patients
has been reported to reduce indices of sympathetic activity (e.g. plasma and urinary
norepinephrine excretion, resting heart rate) (Ostman-Smith, 1981; Reisin et al., 1983; Sen,
1983). Weight reduction also decreases plasma aldosterone levels and renin activity,
components of the renin-angiotensin II system which have been implicated in the development
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of hypertension and LVH (Iwai, Shimoike and Kinoshita, 1995; Lambert et al., 2014; Seravalle
et al., 2014). In patients with hypertension and measurable LVH, calorie restriction-induced
weight loss alone can decrease left ventricular mass by up to 20% (MacMahon, Wilcken and
Macdonald, 1986). Thus, managing patient weight through diet and exercise can help limit the
development of LVH. In addition to weight loss, sodium restriction can inhibit LVH
progression. Obese patients often have hyperinsulinemia (excess levels of circulating insulin)
leading to increased sodium reabsorption through the renal tubules, which can exacerbate
already elevated blood pressures (Jula and Karanko, 1994; Kim et al., 2015). Recommended
daily amounts of sodium range between 1000 – 1500 mg; average Canadians consume around
~3400mg of sodium daily, with many eating well in excess of 5000 mg per day (Government
of Canada, 2013). Dietary sodium restriction (<1600 mg/day) has been shown to reduce LVH
through decreases to blood pressure and body fluid retention in patients with moderate primary
hypertension and above average LV mass (Jula and Karanko, 1994). However, although diet
and weight loss may markedly benefit patients, clinical studies have demonstrated that such
lifestyle modifications are difficult to maintain in the long term (Whelton et al., 1992; Stamler,
1997; Hedayati, Elsayed and Reilly, 2011). Thus, pharmacological intervention is often
required to moderate the progression of LVH and associated hypertension.

1.6.5

Pharmacological treatments

Regression of LVH has been shown with multiple drugs including angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), some calcium channel
blockers (e.g. verapamil, amlodipine, and diltiazem), renin inhibitors (e.g. aliskiren), and some
sympatholytic agents (e.g. alpha–blockers and methyldopa) (Franz, Tönnesmann and Müller,
1998; Okin et al., 2006; Cuspidi, Negri and Zanchetti, 2008; Os et al., 2008; Solomon et al.,
2009). Direct vasodilators appear to be largely ineffective in regards to LVH regression, which
may be due to reflex stimulation of angiotensin II and norepinephrine release (both of which
can directly promote the development of LVH) (Klingbeil et al., 2003). Although ARBs,
calcium channel blockers, and ACE inhibitors produce significantly more LVH regression than
diuretics and beta blockers, there is currently no evidence that a more rapid regression of LVH
is associated with improved long-term health outcomes (Kaplan and Douglas, 2017).
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ARBs have been demonstrated to be the most efficacious class of drugs for reducing LV mass
(11% reduction in LV mass), followed by calcium channel blockers (11%), ACE inhibitors
(10%), diuretics (8%), and beta-blockers (6%) (Klingbeil et al., 2003; Bauml and Underwood,
2010). An important component in LVH development is myocardial fibrosis, which
compromises cardiac function via initial diastolic dysfunction followed by progressive systolic
dysfunction (Weber et al., 1990); angiotensin II has been shown to induce the development of
fibrosis in the myocardium of hypertensive patients (González et al., 2002), and may be an
additional mechanism of action by which ACE inhibitors and ARBs exhibit their beneficial
effects in cardiac hypertrophy. As such, ACE inhibitors and ARBs are recommended as firstline treatments for LVH, unless contraindicated in the individual patient (Bauml and
Underwood, 2010).

Altered RGS2 expression in humans is associated with
cardiovascular dysfunction
Various studies have suggested a potential role of RGS2 dysfunction in human hypertension.
Human skin fibroblasts and peripheral blood mononuclear cells from hypertensive patients
display decreased RGS2 mRNA expression, increased Ang II-induced MAPK/ERK
phosphorylation, and elevated Ca2+ release from internal stores (Semplicini et al., 2006).
Multiple Rgs2 SNPs have been identified in genetic groups from China (Zhao et al., 2008;
Zhang et al., 2010), Japan (Yang et al., 2005), the Netherlands (Riddle et al., 2006), and the
United States (Hettema et al., 2013). Destabilizing N-terminal mutations appear to increase
RGS2 susceptibility to arginylation/ubiquitination and subsequent proteasomal degradation
(Bodenstein, Sunahara and Neubig, 2007), while other SNPs can affect RGS2 localization and
impair GAP activity (Gu, Tirgari and Heximer, 2008). In contrast, RGS2 overexpression has
been found in patients with Bartter/Gitelman syndrome, a kidney disorder caused by loss of
function mutations of the thiazide-sensitive sodium-chloride symport that is characterized in
part by hypotension and an increased risk for ventricular arrhythmia (Deschenes, Feldmann
and Doucet, 2002; Foglia et al., 2004; Knoers and Levtchenko, 2008). The dysfunction of
RGS2 in patients suggests that its study in relation to hypertension and hypertrophy may be
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clinically relevant, and that stabilizing its expression or function may increase or decrease
blood pressure; indeed, stabilizing RGS2 expression appears to be beneficial in in vitro and in
animal models of cardiac hypertrophy (Sjögren, Blazer and Neubig, 2010; Sjogren et al., 2012;
Sjögren et al., 2016), and suggests that RGS2 could be a potential target for drug discovery in
cardiovascular disease.

Animal models of cardiac hypertrophy
1.8.1

Transverse aortic constriction

Transverse aortic constriction (TAC) in murine animals is a well-established technique of
experimental pressure overload on the heart to induce cardiac hypertrophy and dysfunction,
and has been used in multiple studies to examine the role of RGS2 in cardiovascular health
(Wang et al., 2008; Takimoto et al., 2009; Takimoto, 2011; Park-Windhol et al., 2012) Briefly,
following anaesthesia and intubation, the chest cavity is entered via the second intercostal
space through a small incision, and aortic constriction is performed by tying sutures against a
needle to yield a narrowing of the aorta once the needle is removed (Rockman et al., 1991).
Since its initial development (Rockman et al., 1991), TAC has been extensively used as a
model of human cardiovascular disease and for the study of signalling processes involved in
hypertrophic responses and heart failure. In comparison to other experimental models of heart
failure, such as coronary artery ligation (which results in complete occlusion of the vessel),
TAC provides a more gradual model of cardiac hypertrophy development (deAlmeida, van
Oort and Wehrens, 2010), which can be modified by both the duration (Mohammed et al.,
2012) and severity of the constriction (i.e. the gauge of the needle); TAC initially induces
compensatory cardiac hypertrophy, which can often present as temporarily enhanced cardiac
contractile function. Over time, chronic pressure overload leads to maladaptive cardiac
hypertrophy and fibrosis, which can ultimately devolve into heart failure and cardiac dilation
(Patten and Hall-Porter, 2009).
A major advantage of TAC is the ability to measure the pressure gradient that is created across
the aortic stricture (Patten and Hall-Porter, 2009); since the constriction is performed on the
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aorta between the left and right carotid arteries, arterial pressures (as measured by conductance
catheters) should be measurably higher in the right carotid artery, thus validating the success
of TAC surgery. The utility of this model can be seen from the promising and novel
therapeutics targets that have been identified through its use (Braz et al., 2004; Wilkins et al.,
2004; Takimoto et al., 2005; Jeong et al., 2006)

1.8.2

Osmotic pump infusion

Although the TAC method is a highly reproducible (Rockman et al., 1991) and useful model
of cardiac hypertrophy and heart failure, the acute onset of severe hypertension via aortic
stricture may lack direct clinical relevance (Patten and Hall-Porter, 2009). Multiple studies
have used continuous drug infusion to induce systemic hypertension (and thus hypertrophy)
via angiotensin II (Bueno et al., 2002; Freund et al., 2005; Kee et al., 2006), which is arguably
a more clinically relevant model in light of the major role of the renin-angiotensin system
(RAS) in the development of human hypertension and cardiac hypertrophy (Weber and Brilla,
1991; Dostal and Baker, 1999). Other groups have chronically infused isoproterenol to
stimulate β-adrenergic signalling, and often do so in conjunction with angiotensin and/or TAC
models (Soonpaa and Field, 1994; Kudej et al., 1997; Saadane, Alpert and Chalifour, 1999;
De Windt et al., 2001; Bueno et al., 2002; Freund et al., 2005).
Following the initial development of an osmotic pump concept (Rose and Nelson, 1995),
simplified mini-osmotic pumps have been designed which can systemically deliver sustained
doses of desired drugs in a relatively non-invasive manner. Briefly, osmotic pumps operate via
an osmotic pressure difference between a salt sleeve that surrounds a flexible and impermeable
reservoir (containing a desired drug/solution) and the environment in which the pump is
implanted (e.g. subcutaneous or intraperitoneal) (Alzet, 2017). The high osmolality of the salt
sleeve draws water through a semipermeable membrane into the pump, leading to compression
of the drug-containing reservoir; the drug/solution is thus displaced out of the pump (through
a flow moderator) at a controlled rate which is predetermined by the water permeability of the
pump’s outer membrane (Theeuwes and Yum, 1976).
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Cardiovascular health and obesity
Cardiovascular dysfunction is known to be directly influenced by obesity and weight gain,
which are major risk factors for cardiovascular diseases such as coronary heart disease, atrial
fibrillation, hypertension, venous thromboembolisms, and congestive heart failure (Klein et
al., 2004; Poirier et al., 2006; Tedrow et al., 2010; Wattanakit et al., 2012). In 2011 to 2012,
only 65% of children and 31% of adults in the United States met body mass indexes (kg/m2)
which correlated with ideal cardiovascular health (Lloyd-Jones et al., 2010). Conversely, 32%
of US children and 69% of adults are currently estimated to be overweight or obese
(Mozaffarian et al., 2016). The health and economic costs of obesity and its related comorbidities, such as cardiovascular diseases, are substantial. In 2008, the estimated medical
cost of obesity was $147 billion; costs related to the current prevalence of obesity and weight
gain in children and adolescents is projected to be $254 billion ($46 billion in direct medical
costs, and $208 billion in lost productivity due to morbidities and mortality) (Finkelstein et al.,
2009; Lightwood et al., 2009). Although addressing obesity requires a multifactorial response
involving clinical, biomedical, and socio-economic approaches, we will focus on examining
the physiological mechanisms underlying weight regulation and metabolism, which may
provide beneficial insights into treatments and novel drug targets.

Regulation of energy balance by GPCRs
Multiple GPCRs have been shown to be involved in energy metabolism. Adiposity is
determined by energy intake (e.g. food intake) versus energy expenditure (e.g. physical
activity, adaptive thermogenesis, basal metabolism), and possible sources of energy imbalance
in cases of obesity or conversely, loss of body weight, could come from dysfunctions in food
intake/nutrient absorption, lipid storage, metabolic rate, physical activity, or CNS-related
changes.
Several studies have demonstrated the involvement of a vast range of GPCR signalling in
appetite and satiation. Brain cannabinoid receptors play a physiological role in the control of
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appetite and body weight, and cannabinoid CB1 receptor antagonists reduce appetite and
decrease body weights in non-obese Wistar rats (Colombo et al., 1998). Patients with eating
disorders exhibit several clinical features and biologic findings indicative of serotonin (5hydroxytryptamine/5-HT) dysregulation (Brewerton, 1995), and ghrelin infusion has been
shown to enhance appetite and increase food intake in humans (Wren et al., 2001).
Furthermore, histamine, which acts as a central neurotransmitter, acts as an appetite
suppressant via stimulation of histamine H1 receptors, thereby mediating the inhibitory effects
of leptin on appetite (Jørgensen et al., 2007). In addition, amylin, a peptide secreted from the
pancreas following a meal or in response to oral glucose ingestion, acts as a satiation factor,
and has been found to be overexpressed in genetically obese animals due to receptor
insensitivity (Morley et al., 1995). Oxyntomodulin (OXM) is another peptide released from
the gut following food intake and binds to both glucagon-like peptide-1 receptor (GLP1R) and
the glucagon receptor; both systemic and brain-specific injection of (OXM) in rats reduces
food intake and weight gain (Cohen et al., 2003). Interestingly, some orphan GPCRs, including
GPR61 and GPR82, appear to be involved in regulating food intake; loss of GRP61 and GPR82
in mice resulted in hyperphagia and lower food intake, respectively (Engel et al., 2011; Nambu
et al., 2011).
Gastrointestinal (GI) motility, digestion, and nutrient sensing also involve GPCRs. Taste
receptors belong to the T1R and T2R families of GPCRs; ligand (amino acid) binding triggers
signal transduction and neurotransmitter release, and taste receptors can also be found in
certain regions of the gut to regulate gastric inhibitory polypeptide (GIP) and GLP-1 stimulated
insulin secretion (Chaudhari and Roper, 2010; Efeyan, Comb and Sabatini, 2015). The
neuropeptide cholecystokinin (CCK) can slow gastric emptying (via induction of acetylcholine
release from the GI tract) (Paton et al., 1971), and additionally acts as an appetite suppressant
(Crawley and Corwin, 1994). In addition, endogenous opioids of three known classes have
been found throughout the gastrointestinal tract (Kromer, 1988), and exogenous opioids are
well known to depress GI motility (Schaumann, 1955); localization of peptide YY (PYY), a
ligand for neuropeptide Y receptors, also decreases intestinal blood flow and motility
(Lundberg et al., 1982). Overall, this non-exhaustive list of GPCRs and their related signalling
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pathways demonstrates the fundamental role of these receptors in mediating energy
metabolism.

Altered G protein signalling in lean and obese phenotypes
Alterations in G protein signalling can lead to both lean and obese phenotypes. Loss of
melanocortin 4 signalling results in severe obesity that is associated with hyperphagia,
hyperinsulinemia, and hyperglycemia (Huszar et al., 1997); a triple knockout of β1/2/3adrenergic receptors in mice led to weight gain on a standard chow diet, and the development
of massive high fat diet induced obesity, which was attributed to a failure to initiate dietinduced thermogenesis (Bachman et al., 2002). Conversely, mice without Gβ5, a G protein β
subunit that dimerizes with RGS proteins of the R7 family instead of Gγ, displayed a lean
phenotype, were resistant to a high-fat diet, and demonstrated increased thermogenesis (Wang
et al., 2011). Mice lacking the M3 muscarinic acetylcholine receptor are lean and hypophagic,
indicating M3 receptor-mediated facilitation of food intake (Yamada et al., 2001). Moreover,
loss of the neuropeptide melanin-concentrating hormone (MCH), which normally promotes
feeding, led to reduced body weight due to hypophagia (Shimada et al., 1998). In addition,
full-body RGS4 (Grillet et al., 2005) and RGS5 (Cho et al., 2008) knockout mice weight
significantly less than WT counterparts, although lack of RGS5 has also been reported to
exacerbate obesity, inflammation, hepatic steatosis, and insulin resistance (Deng et al., 2012).
Rgs2-/- mice are also lean and display a hyperphagic phenotype, which will be subsequently
discussed in detail.

Skeletal tissue is a major site of energy metabolism via
thyroid hormone (TH) regulation
Thyroid hormone (TH) signalling is critical for numerous biological functions including
development and growth, energy expenditure, and thermogenesis. TH primarily acts through
nuclear-receptor mediated stimulation or inhibition of gene transcription (Yen, 2001; Mebis et
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al., 2009). This activity is mainly mediated by the alpha isoform of the thyroid hormone
receptor in skeletal muscle. Thyroid hormone receptors in the unliganded state are usually
bound to TH-responsive elements in various genes along with other proteins, leading to active
repression of gene transcription (Yen, 2001); upon ligand binding, repression of the target gene
is lifted and transcription is stimulated by co-activator recruitment to the complex (Brent,
2012). In skeletal tissue, proteins which are transcriptionally regulated by TH include
SERCA1A (Simonides et al., 1996), SERCA2A (Hartong et al., 1994), GLUT-4 (glucose
transporter) (Zorzano, Palacin and Guma, 2005) , UCP3 (muscle-specific) (Solanes et al.,
2005), malic enzyme (ME1) (Desvergne, Petty and Nikodem, 1991), and glycerol – 3phosphate dehydrogenase (Dümmler, Müller and Seitz, 1996). In addition to modifying the
glycolytic and oxidative capacities of skeletal tissue, TH affects mitochondrial capacity via
transcription of the gene for PGC1α, a regulator of mitochondrial biogenesis (Weitzel, Iwen
and Seitz, 2003).
Resting metabolic rates in almost all tissues depend on thyroid hormone availability. TH has
been shown to increases the rates of muscle contraction and relaxation, which is related to
changes in the expression of proteins involved in intracellular Ca2+ flux (e.g. SERCA isoforms)
(Salvatore et al., 2013). By promoting a shift from slow type I fibre phenotypes to the faster
type II skeletal fibres, TH induces the increased expression of myosin and SERCA, leading to
greater energy turnover and the generation of heat during activity (Thomas, Auwerx and
Schoonjans, 2008). In skeletal muscle, TH signalling can alter the metabolic rate by uncoupling
ATP synthesis in the mitochondria or by decreasing metabolic efficiency; a potential
mechanism through which energy is “wasted” in the form of heat dissipation includes
decreasing ATP synthesis efficiency via proton leak through skeletal tissue specific
mitochondrial uncoupling protein 3 (UCP3) (de Lange et al., 2001). Since skeletal tissue
comprises approximately 40-50% of total body mass, it is the largest single contributor to the
metabolic resting state of an organism, as well as towards heat generation (Thomas, Auwerx
and Schoonjans, 2008).
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TH regulation of metabolism and glucose homeostasis
requires deiodinase type 2 (DIO2) for T4-T3 conversion
In order for thyroid hormone to regulate various metabolic processes, it must be converted
from its inactive prohormone form T4/thyroxine (3,5,3',5'-tetraiodothyronine) to the active
thyroid hormone/T3 (3,5,3'-triiodothyronine, T3). Thyroid hormone signalling in individual
tissues can change even as serum T4 concentrations remain normal due to local activation or
inactivation of thyroid hormone, the underlying mechanism of which is deiodination by the
intracellular iodothyronine deiodinases type I, II, and III (DIO1, DIO2, and DIO3) (St.
Germain and Galton, 1997; Bianco et al., 2002). DIO1, 2, and 3 regulate thyroid hormone
activity via removal of iodine moieties from T4 (2); DIO2 converts T4 to T3, whereas DIO3
inactivates T3 (DIO1 function remains to be clarified) (Wondisford, 2003; Bianco and Kim,
2006). Thus, the deiodinases, and specifically DIO2, are critical determinants of intercellular
T3 levels.
Glucose uptake into mammalian cells is mediated via the tissue specific transport proteins
GLUT1-4, a process which is often a rate-limiting step in tissue glucose metabolism (Torrance
et al., 1997). In skeletal muscle, insulin-sensitive GLUT-4 (or SLC2A4) is the main isoform
expressed, and functions to rapidly remove circulating glucose from the blood following a
meal; indeed, skeletal muscle accounts for more than 85% of whole body insulin-stimulated
glucose uptake (Torrance et al., 1997). As previously mentioned, GLUT-4 protein and mRNA
expression are regulated by TH (specifically T3); in conjunction, GLUT-4 translocation to the
cell surface is an insulin-dependent event, and normal muscle responsiveness to insulin has
been shown to require the DIO2-mediated conversion of T4 to T3 (Mills et al., 1987; Zorzano,
Palacin and Guma, 2005; Grozovsky et al., 2009). The importance of DIO2 regulation of T3
production and insulin action can be seen through in vitro and animal models. Cultured
myotubes lacking DIO2 have decreased phosphorylated Akt (a downstream effector of insulin)
(Grozovsky et al., 2009), and mice with targeted deletion of Dio2 are insulin resistant and
susceptible to diet-induced obesity (Marsili et al., 2011).
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Role for RGS2 in metabolic pathways
Human polymorphisms that result in the over- or under-expression of RGS2 point to the
clinical relevance of RGS2 in the context of metabolism. A common polymorphism in the 3’
untranslated region of RGS2 has been shown to decrease RGS2 expression, and is considered
to be a genetic marker that can predict male predisposition to weight gain and obesity (Sartori
et al., 2008). Conversely, a C to G substitution in the RGS2 promoter region has been shown
to increase RGS2 expression in adipocytes and is associated with the metabolic syndrome
(Freson et al., 2007). RGS2 has been shown to have various effects on energy storage and
usage; in vitro studies have demonstrated the role of RGS2 in mediating GLUT-4 (insulinresponsive glucose transporter) translocation in adipocytes (Imamura et al., 1999), as well as
GIP (glucose-dependent insulinotropic polypetide)-induced insulin release from pancreatic β
cells (Tseng and Zhang, 1998). Thus, RGS2 may be involved in glucose entrance in adipocytes.
RGS2 may also regulate metabolism via inhibitory effects on thyroid stimulating hormone
receptor (TSHR)-induced Gq signal transduction; the TSHR ligand TSH is a pituitary hormone
which stimulates the thyroid gland to produce T4 (Eszlinger et al., 2004). RGS2 also appears
to promote the differentiation of adipocytes and expression of adipogenic markers, and is
transiently and rapidly upregulated in differentiating mouse preadipocyte cells (Imagawa,
Tsuchiya and Nishihara, 1999; Nishizuka et al., 2001). Other energy-dependent processes
affected by RGS2 include the regulation of protein synthesis (Nguyen et al., 2009; Chidiac et
al., 2014), as well as ATP hydrolysis by PMCA (plasma membrane Ca2+ ATPase) and SERCA
(sarco/endoplasmic reticulum Ca2+) pumps (Wang et al., 2004), which altogether suggests an
important role for RGS2 in body metabolism.

Rgs2-/- mice display a lean phenotype and are hyperphagic
Rgs2-/- mice, which are a well-established strain, demonstrate normal circadian activity and
motor function; phenotypes include increased anxiety, decreased male aggression, reduced T
cell proliferation and heightened sensitivity to TAC-induced cardiac hypertrophy, as well as
mild to moderate levels of hypertension. (Oliveira-Dos-Santos et al., 2000; Heximer et al.,
2003; Takimoto et al., 2009). Our lab has previously reported a novel phenotype in Rgs2-/30

mice, such that they are resistant to age-related, normal body weight gain until their end-oflife (~24 months-old) (Nunn et al., 2011). In addition to decreased body weights, Rgs2-/- mice
are hyperphagic, display increased insulin sensitivity, decreased serum lipids, smaller brown
and white adipose tissue deposits, and smaller adipocytes. Since RGS2 appears to promote
adipocyte differentiation (Nishizuka et al., 2001), it would follow that its loss would result in
impaired adipocyte function. Surprisingly, Rgs2-/- mice were not resistant to high fat dietinduced obesity, and gained weight at similar rates to WT controls. Furthermore, the increased
insulin sensitivity observed under ad libitum diet conditions was abrogated by the high fat diet
(Nunn et al., 2011). Our observations suggest that even though adipocytes in Rgs2-/- animals
are significantly smaller compared to WTs, lipid metabolism may not be impaired, and that it
is rather carbohydrate or protein metabolism which is altered. Given that our characterization
of the lean metabolic phenotype mainly focused on adipocyte-related functions, exploring
potential alterations in Rgs2-/- skeletal tissue, a major metabolic contributor, could lead to a
more in-depth understanding of the role of RGS2 in energy metabolism

Diet-induced models of weight gain and loss
1.16.1

High-fat diets

Surrogate animal models are important for studying the molecular aspects of obesity and its
pathophysiological effects, as patient complications can often take years to develop (Wang and
Liao, 2012). Since their introduction three decades ago (Surwit et al., 1988), high-fat diets have
been used extensively to study the pathophysiologies of weight gain (e.g. glucose intolerance
and type 2 diabetes) and for the development of novel obesity treatments (Ahrén et al., 2000;
Reimer, Holst and Ahrén, 2002). Wild-type animals on a high fat diet (particularly the
C57/Bl/6 strain) gradually gain weight over time, and progressively develop increased
hyperinsulinemia, which is indicative of worsening insulin resistance (Winzell and Ahrén,
2004). While standard chow has an approximate composition of less than ~10% kcal from fat,
high fat diets can range from ~40% to ~60% kcal from fat content (Wang and Liao, 2012).
Numerous high-fat studies use either lard (animal fat) or shortening (hydrogenated vegetable
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oil) (Silva et al., 2006; Lionetti et al., 2014; Fujiwara et al., 2015; Magri et al., 2015); vegetable
shortening may also differ in their fatty acid composition depending on whether a partially
hydrogenated soybean/palm oil or a partially hydrogenated soybean/cottonseed oil formulation
is used (Kubant et al., 2015). Recent studies have found that lard-based high-fat diets increase
weight gain and the development of obesity and insulin resistance to a greater extent than
hydrogenated vegetable shortening diets (Kubant et al., 2015); this highlights the importance
of identifying the fatty acid composition of diets used to examine the role of dietary fats.

1.16.2

Dietary restriction

Diet restriction models have most often been used in the context of aging and metabolism
(Weindruch and Walford, 1982; Hursting et al., 2003; Bordone and Guarente, 2005); 30-50%
food intake restrictions on ad libitum fed rats and mice have been shown to markedly increase
longevity and delay the onset of age-associated diseases (Masoro, 2000). Intermittent fasting
(e.g. 24 hours with/without access to food) has been shown to reduce serum glucose and insulin
levels as well as neuronal resistance to injury (Anson et al., 2003). Chronic diet restriction, in
which a group of animals is taken down to a set percentage of food intake (e.g. 70% of ad
libitum intake), also has purported beneficial effects (McCarter, Masoro and Yu, 1985) Both
chronic and acute (fasting) diet restriction conditions can be used to characterize mice with
metabolic phenotypes; altered responses to dietary challenges compared to WT mice may
reveal whether proteins or genes of interest are required for a normal response to caloric
restriction (Boily et al., 2008).

Summary
Overall, RGS2 appears to play multiple roles in both cardiovascular disease and metabolism.
The following chapters will explore novel ways in which the in vivo expression or lack of
RGS2 impacts cardiovascular health and metabolism.
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2

HYPOTHESES AND SPECIFIC AIMS
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Specific Aim 1
To determine if RGS2eb is cardioprotective against experimentally-induced cardiac
hypertrophy
Based on our previous studies and the findings of others, RGS2 is known to play a protective
role against cardiac hypertrophy (Chidiac et al. 2014). In addition, loss of RGS2 in cell and
animals studies is characterized by increased protein synthesis and severe cardiac hypertrophy
(Takimoto et al. 2009). In conjunction with our previously reported cell data, in vivo studies
would provide a more comprehensive view of the antihypertrophic and possible
cardioprotective effects of RGS2eb under both pathological and physiological conditions.
Our principle goal is to study the effects of RGS2eb in animal models, and thus establish its in
vivo importance as a protective mechanism against cardiac hypertrophy and heart failure. Our
specific objectives are:
i) To determine whether expression of RGS2eb protects against experimentally-induced
cardiac hypertrophy (Study 1A),
ii) To perform loss of function studies to determine in vivo mechanisms of RGS2eb
cardioprotection (Study 1B),

2.1.1

Study 1A: Protective effect of RGS2eb in animal models of cardiac
hypertrophy

Regardless of the initial stimulus, de novo protein synthesis is required for cardiomyocyte
hypertrophy. We have previously shown that expression of RGS2eb in cultured neonatal rat
cardiomyocytes can inhibit hypertrophy via the attenuation of mRNA translation (Chidiac et
al. 2014). However, it is unknown whether the protective effect of RGS2eb extends to whole
animals with experimentally-induced cardiac hypertrophy.
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The objectives of this study are:
i) To determine whether animals with targeted myocardial expression of RGS2eb show
resistance to the development of pressure overload induced cardiac hypertrophy in
comparison to wild-type controls.
ii) To determine whether animals with targeted myocardial expression of RGS2eb
demonstrate improved cardiovascular function in an experimental pressure overload
model in comparison to wild-type controls.
We hypothesize that due to the ability of RGS2eb to inhibit protein synthesis, transgenic mice
will show decreased severity of cardiac hypertrophy and potentially improved cardiac function
in comparison to wild type mice.

2.1.2

Study 1B: Rescue effect of RGS2eb in RGS2 knockout animals

Rgs2-/- mice are characterized by severe cardiac hypertrophy and heart failure following
experimentally induced pressure overload (Takimoto et al. 2009). This demonstrates the
protective cardiac effects of RGS2. However, the degree to which the inhibition of global
protein synthesis by RGS2eb contributes to this effect is unknown. In addition, the possible
protective effect of RGS2eb against drug-induced hypertrophy has not been explored.
The objectives of this study are:
i) To determine whether expression of RGS2eb in Rgs2-/- mice can compensate for the
loss of the full length RGS2 protein in comparison to null RGS2 mice following
experimentally-induced pressure overload.
ii) To characterize the effects of drug-induced hypertrophy in Rgs2-/- with cardiacspecific expression of RGS2eb.
We hypothesize that via its inhibition of protein synthesis, RGS2eb will, to some extent,
decrease the severity of cardiac hypertrophy and heart failure resulting from experimentally
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induced pressure overload or drug-induced hypertension and hypertrophy, thereby
compensating for the absence of full-length RGS2.

Specific Aim 2
To determine the metabolic effects of RGS2 under multiple diet modalities
Aside from an increased sensitivity to pressure-induced cardiac hypertrophy (Takimoto et al.
2009), Rgs2-/- mice display several additional phenotypes, including decreased male
aggression, increased anxiety, elevated blood pressure, and reduced T-cell proliferation
(Oliveira-Dos-Santos et al. 2000; Heximer et al. 2003). Our lab has previously determined that
Rgs2-/- mice exhibit a weight-related phenotype, such that they fail to develop the gains in body
fat that normally occur in freely-feeding laboratory mice (Nunn et al. 2011). We demonstrated
that resistance to age-related body weight gain was accompanied by smaller adipose tissue
deposits and adipocytes, lower levels of serum lipids, and increased insulin sensitivity; these
data suggest that RGS2 may play a novel role in the regulation of fat production and energy
metabolism. Rgs2-/- mice were found to be slightly hyperphagic over time in comparison to
WT controls, and did not have impaired nutrient absorption. However, measurements of resting
O2 consumption (VO2) using a basic open flow respirometry system suggested a lower
metabolic rate in Rgs2-/- mice compared to WT animals (Nunn et al. 2010). Thus, it would
seem that although Rgs2-/- mice expend less energy at rest, eat more, and absorb the same
amount of nutrients, they still weigh less in comparison to WT controls. Furthermore, we were
not able in our previous studies to detect any increase in resting VO2 in Rgs2-/- mice using a
basic open flow respirometry system. Our previous studies have provided contradictory
evidence for the reduction of weight gain in RGS2 KO mice. To resolve this seeming paradox,
extended and acute measurements of metabolic indicators may provide a more comprehensive
understanding of RGS2 and its role in metabolism and weight gain.
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Our principle goal is to understand the effects of loss of RGS2 on body metabolism, and thus
establish its in vivo role. Our specific objectives are:
i) To determine baseline metabolic characteristics of Rgs2-/- mice in comparison to agematched WT controls (Study 2A),
ii) To perform diet restriction studies to further characterize the Rgs2-/- metabolic
phenotype (Studies 2B and 2C)

2.2.1

Study 2A: Baseline characterization of the Rgs2-/- metabolic
phenotype

In comparison to WT controls, Rgs2-/- mice are resistant to age-related weight gain. However,
previous measurements of metabolic activity have offered paradoxical evidence on the
potential reasons for this lean phenotype. The objective of this study is:
i) To determine whether metabolism in Rgs2-/- is altered, particularly during the dark
phase of a 12 hour light-dark cycle in comparison to WT controls, as measured via
Comprehensive Laboratory Animal Monitoring System (CLAMS) metabolic cages
We hypothesize that Rgs2-/- will display increased metabolism as demonstrated by various
metabolic and biological indices in comparison to WT controls.

2.2.2

Study 2B: Chronic diet restriction model

We have previously shown that while Rgs2-/- mice are resistant to age-related weight gain on a
standard rodent diet (Teklad Global 18% Protein Rodent Diet), they still gain at least as much
weight as WT mice when placed on a high fat diet. However, it is currently unknown how
Rgs2-/- mice would respond metabolically to a diet restriction. The objective of this study is:
i) To determine whether metabolism in Rgs2-/- mice is altered in response to dietary
restriction in comparison to WT controls.
We hypothesize that Rgs2-/- mice will display greater metabolism than their counterpart WT
controls, as demonstrated by various metabolic and biological indices.
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2.2.3

Study 2C: Acute diet restriction model

It is also currently unknown how Rgs2-/- mice would respond metabolically to acute dietary
restriction (i.e. fasting conditions); this may also potentially offer insight into the resistance of
Rgs2-/- mice to age related weight gain. The objective of this study is:
i) To determine whether Rgs2-/- metabolism is altered after acute fasting in
comparison to WT controls.
We hypothesize that Rgs2-/- mice will display greater metabolism under acute caloric restriction
than corresponding WT controls.
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Introduction
Pathological cardiac hypertrophy is a maladaptive growth response of the heart to a variety of
disease stimuli. Induced by factors such as hypertension or valvular diseases, prolonged
pathological hypertrophy has been associated with an increased risk of sudden death, as well
as myocardial infarctions and arrhythmias (Levy et al., 1990; Weber and Brilla, 1991; Heineke
and Molkentin, 2006). Moreover, maladaptive hypertrophy is a major risk factor for heart
failure (Heineke and Molkentin, 2006). Given the high mortality rates following heart failure
diagnoses and the current lack of a cure, reducing risk factors such as pathological cardiac
hypertrophy may prove therapeutically beneficial.
G protein-coupled receptors (GPCRs) which signal via heterotrimeric Gαq and Gαs proteins are
well established as critical players in the induction of pathological hypertrophy (Dorn and
Force, 2005; Heineke and Molkentin, 2006; Hendriks-Balk et al., 2008). Clinically effective
treatments for heart failure, such as angiotensin II converting enzyme (ACE) inhibitors and
beta-adrenergic receptor antagonists, demonstrate the effectiveness of targeting Gq- and Gscoupled receptors (Campbell et al., 2001). However, the effectiveness of these drugs is limited
to slowing, rather than reversing, the progression of heart failure. Regulator of G protein
signalling 2 (RGS2) is a GTPase accelerating protein (GAP) found ubiquitously throughout
the body. RGS2 selectively inhibits Gq- and Gs-mediated signalling (some effects on Gi/o
signalling have also been reported (Anger et al., 2007; Chakir et al., 2011), thus making it an
important target in the study of cardiovascular disease (Heximer et al., 1997, 1999; Roy,
Baragli, et al., 2006). Studies in vivo and in cardiomyocytes have shown that hypertrophy
caused by prolonged Gq-coupled receptor stimulation, such as that induced by phenylephrine,
can be blocked by the overexpression of RGS2 (Roy, Nunn, et al., 2006; Zou et al., 2006). A
similar effect has been seen against Gs-mediated cardiomyocyte hypertrophy induced by
isoproterenol (Nunn et al., 2010). These observations suggest that RGS2 plays an important
role in the regulation of hypertrophy; This has been further demonstrated in knockout animal
studies. In RGS2 null mice, experimentally induced pressure overload causes marked
hypertrophy, heart failure, and death, as well as increased expression of cardiac fetal genes
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(Takimoto et al., 2009). Thus, RGS2 is an essential element in the prevention of pathological
cardiac hypertrophy.
While the G protein inhibitory effects of RGS2 are well established, studies have also shown
that RGS2 can bind to and regulate other targets, including TRPV6 calcium channels and
tubulin (Wang et al., 2005; Heo et al., 2006; Schoeber et al., 2006). We have previously shown
that RGS2 can bind to the ε subunit of eukaryotic initiation factor 2B (eIF2B), a component of
the rate-limiting step of the initiation of mRNA translation (Nguyen et al., 2009). By
interacting with eIF2Bε, RGS2 limits GDP dissociation on eukaryotic initiation factor 2 (eIF2),
which ultimately leads to the attenuation of de novo protein synthesis. This property of RGS2
has been mapped to a 37 amino acid domain (residues 79-115) termed RGS2eb, that is
homologous to a region in the β subunit of eIF2 (Nguyen et al., 2009).
Since the heart is considered to be a post-mitotic organ (Anversa et al., 2007), hypertrophic
growth is thought to be dependent on the enlargement of a pre-existing cardiomyocyte
population rather than cell division (Carvalho, 2010). Therefore, regardless of the initial stimuli
and receptors involved, all hypertrophic signals will ultimately result in increased mRNA
translation and de novo protein synthesis. Our previous studies have shown that RGS2eb
expression in cultured neonatal cardiomyocytes is able to inhibit both protein synthesis and
agonist induced hypertrophy at levels comparable to full-length RGS2 (Chidiac et al., 2014).
Based on these previous findings, we hypothesized that the in vivo expression of RGS2eb in the
murine heart could attenuate the development of pathological cardiac hypertrophy.
To determine whether RGS2eb could act as an in vivo anti-hypertrophic agent, we developed a
line of transgenic mice with cardiomyocyte-specific overexpression of RGS2eb, and used
transverse aortic constriction (TAC) to induce pressure overload on the heart. Here we report
that following 4 weeks of aortic constriction, RGS2eb transgenic mice were protected not only
from pressure overload-induced cardiac hypertrophy, but were able to maintain heart function
at significantly improved levels compared to WT TAC mice. Moreover, reactivation of the
“fetal gene program”, an indicator of hypertrophy and heart failure, was suppressed. Notably,
cardiomyocyte size was decreased in RGS2eb TG compared to WT TAC controls, further
supporting our earlier in vitro studies which showed RGS2eb inhibition of de novo protein
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synthesis. Together, these findings suggest that in addition to its G-protein inhibitory actions,
the RGS2eb region may be contributing to the cardioprotective effects of full-length RGS2 in
vivo via the inhibition of de novo protein synthesis.

Methods
3.2.1

Generation of myosin heavy chain promoter (MHC) – RGS2eb
transgenic mice

The RGS2eb gene was targeted to the heart using the mouse α-MHC promoter (kindly provided
by Jeffrey Robbins, Cincinnati Children’s Hospital Medical Center)(Subramaniam et al.,
1991). Transgenic mice were generated in the FVB background (London Regional Transgenic
and Gene Targeting Facility) and identified by polymerase chain reaction (PCR). Briefly, ear
biopsies were taken from three-week old mice and purified for genomic DNA using the
QIAquick PCR purification kit (Qiagen). PCR was performed using DreamTaq Green PCR
Master

Mix

(Thermo

Scientific).

Primers

for

detection

of

transgenic

mice

(CTGCTAGCCAGCAAATATGGTC forward, CCTACAGGTTGTCTTCCCAACT reverse)
and

control

primers

for

endogenous

RGS2

expression

(CCGAGTTCTGTGAAGAAAACATTG forward, ATGCTACATGAGACCAGGAGTCCC
reverse) were designed using the OligoPerfect Designer (ThermoFisher), OligoCalc (Kibbe,
2007), and Primer-BLAST (NCBI) programs, resulting in a 293 bp and 342 bp fragment,
respectively. RGS2eb TG transgenic mice were back-crossed with C57Bl/6 mice (Charles
River) for at least seven generations before animal experiments were performed. Animals were
maintained in accordance with the Institute of Laboratory Animal Research Guide for the Care
and Use of Laboratory Animals. These studies were approved by the Animal Care Committee
at the University of Western Ontario, and complied with the guidelines of the Canadian
Council on Animal Care.
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3.2.2

Transverse aortic constriction (TAC)

TAC was used to induce pressure overload on the hearts of 12 week old male C57BL/6 wildtype mice and RGS2eb TG littermates. Mice were anaesthetized with a ketamine (50 mg/kg)
and xylazine (12.5 mg/kg) cocktail intramuscularly, intubated, and ventilated with a respirator
(SAR-830, CWE, Ardmore, PA, USA). To access the chest cavity, thoracotomy was performed
at the second intercostal space under a surgical microscope (Rockman et al., 1991). A 6-0 silk
suture was placed between the brachiocephalic and left carotid arteries. Two knots were tied
against a 25-gauge blunt needle placed parallel to the transverse aorta. The needle was removed
immediately after the second tied knot followed by closure of the chest. Control WT and
RGS2eb TG mice were subjected to sham operations without aortic constriction.

3.2.3

Assessment of cardiac function

Hemodynamic measurements were performed as previously described (Detombe et al., 2008;
Pacher et al., 2008) : four weeks post-surgery, mice were again anaesthetized with a ketamine
and xylazine cocktail and ventilated. A Millar micro-tip pressure catheter was inserted into the
left carotid artery to assess carotid artery pressure, followed by removal of the catheter and
insertion into the right carotid artery for pressure readings, and then advanced into the left
ventricle (LV) to measure LV pressures, volumes, and heart rate at steady state and during
transient preload reduction via mechanical occlusion of the inferior vena cava. All data were
recorded using a PowerLab data acquisition system and analysed by LabChart 7.0
(ADInstruments) and PVAN 3.4 software (Millar).

3.2.4

Heart weight/body weight ratios

Upon completion of hemodynamic recordings, mice were immediately euthanized via a 10%
KCl injection into the left jugular vein to ensure cardiac arrest in the diastolic state. Hearts
were excised, weighed after removal of the atria, then cut transversely into three equal sections,
with the middle section reserved for histological analysis, and the remaining tissue sections
stored at -80°C for subsequent RNA isolation.
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3.2.5

Histological analysis

Heart samples were fixed in 4% paraformaldehyde overnight at 4°C, dehydrated, and paraffin
embedded. Samples were sectioned into 5 µm thick slices with a Leica RM2255 microtome,
mounted onto positively charged slides, and then stained with haematoxylin and eosin. Images
of left ventricles were captured at 400X magnification with a Zeiss Observer D1 microscope
using AxioVision 4.7 software (Zeiss) for cardiomyocyte size measurements and
immunohistochemical imaging; images of the LV for wall thickness measurements were
captured at 100X magnification.

3.2.6

Cardiomyocyte Cell Size and LV wall thickness

Haematoxylin and eosin stained tissue sections were used to determine left ventricular
cardiomyocyte cell size and wall thickness of LV free walls and septum. The size of an
individual cardiomyocyte was determined by measuring its cross-sectional area. All
cardiomyocytes with a well-defined border were manually outlined and then filled in the open
source GNU Image Manipulation Program (GIMP). Images were then opened in the image
processing program ImageJ and analyzed after setting the threshold. Cardiomyocytes with a
circularity ratio of ≥1.2 were excluded to eliminate cells sectioned tangentially (Helms et al.,
2010). Areas of at least 33 cells per animal were measured, and were scored blind to surgeries
and strain.
Heart wall thickness of the LV free wall was measured using AxioVision 4.7 software (Zeiss)
in three distinct areas within and between the anterior and posterior regions of the free wall;
three measurements were taken from each area for a total of 9 averaged measurements per
sample. For the septal wall, single measurements were taken from three distinct areas of the
wall and averaged for each sample.

3.2.7

Immunohistochemistry

Immunohistochemical staining was performed on 5 µm thick paraffin heart sections. Samples
underwent a deparaffinisation process and antigen retrieval was carried out in sodium citrate
buffer (pH 6.0) at 92°C using a BP-111 laboratory microwave (Microwave Research and
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Applications). Sections were incubated with primary antibody anti-6X His tag-ChIP Grade
(Abcam) overnight followed by biotinylated secondary antibody, and signal was detected using
avidin-biotin complex (ImmunoCruz ABC staining kit, Santa Cruz). Diaminobenzidine (DAB)
substrate solution was used for antigen visualization with haematoxylin as a counterstain.
Following staining, the LV free wall was imaged in three distinct locations within and between
the anterior and posterior walls. Slides were imaged at 400X magnification with a Zeiss
Observer D1 microscope using AxioVision 4.7 software. To ensure accurate comparisons of
antigen visualization, sections from WT and RGS2eb TG genotypes were stained
simultaneously and all images were captured using the same microscopic parameters.

3.2.8

Dot blotting

Using mechanical disruption (Sonic Dismembrator Model 100, Fisher Scientific), LV heart
and kidney tissues from RGS2eb TG and WT mice were lysed in 20mM, pH 7.5 Tris-HCl buffer
containing cOmplete Mini protease inhibitor cocktail (Sigma). Samples were centrifuged at
100,000 g for 1 hour at 4°C in an Optima TLX micro-ultracentrifuge (Beckman Coulter), and
supernatants were kept for experiments. Following protein concentration determination by
Bradford assay, equal amounts of sample protein were spotted directly on to Amersham
Protran 0.2 µm pore size nitrocellulose membrane (GE Healthcare Life Sciences). Purified
histidine-tagged RGS-16 (His-RGS16) was also dotted on to membranes to serve as a positive
control. Dried membranes were blocked in 5% milk-TBST, followed by overnight incubation
in 1:2000 ChIP grade anti-6X Histidine primary antibody (Abcam) and then 1:5000 goat antirabbit secondary antibody HRP conjugate (Invitrogen). Signal was detected using SuperSignal
West Pico chemiluminescent substrate (Thermo Fisher Scientific) and imaged with the
Versadoc MP 5000 system and Quantity One software (Bio-Rad).

3.2.9

Quantitative reverse transcriptase qPCR

Total RNA was isolated from heart tissue using the TriZol (Invitrogen) extraction method.
Reverse transcription reaction was performed using the High-Capacity cDNA Reverse
Transcription Kit with RNase Inhibitor (Invitrogen). SensiFAST SYBR No-ROX Kit
mastermix (FroggaBio) was used for real-time thermal cycling. Primers for RGS2
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(TGGGATTATGTGGCCTTAGC forward, AAGAACGTCAACACCCTTGC reverse), hGH
(TGGGAAGACAACCTGTAGGG forward, AATCGCTTGAACCCAGGAG reverse), βMHC

(CTGAGACGGAGAATGGCAAGAC

forward,

ACTTGTTAGGGGTTGACGGTGAC reverse), ANP (ATTCCTGAGACGTCCCCTTT
forward,

CATTTCCATCCACAGCTCCT

reverse),

and

BNP

(TGGGAATTAGCCATGTGAGAG forward, TTTGGGTGTTCTTTTGTGAGG reverse)
were designed using the OligoPerfect Designer (ThermoFisher), OligoCalc (Kibbe, 2007) and
Primer-BLAST (NCBI) programs. Samples were amplified for 35 cycles using the Eppendorf
Mastercycler Realplex Real-Time PCR machine. The mRNA quantity for each gene of interest
was determined using standard curve analysis and normalized to 28S ribosomal expression.

3.2.10

Statistical analysis

All data were analyzed using GraphPad Prism 6.01 (GraphPad). All statistical analyses were
performed using two-way ANOVA followed by Bonferroni post-tests and presented as mean
± SEM. Differences were considered significant at P<0.05.

Results
3.3.1

Generation of transgenic mice with cardiomyocyte specific
expression of RGS2eb

We previously demonstrated that the in vitro expression of RGS2eb was sufficient to inhibit
drug-induced hypertrophy in isolated neonatal rat cardiomyocytes (Chidiac et al., 2014). To
elucidate the potential in vivo protective role of RGS2eb, we developed a novel strain of
transgenic mice with targeted myocardial overexpression of polyhistidine-tagged RGS2eb
under the control of the α-myosin heavy chain promoter (Fig. 3.1A). Genotyping with primers
for a portion of the hGH polyA region, which was only present in the transgenic sequence of
RGS2eb mice, was used to differentiate between RGS2eb TG and wildtype mice. Both RGS2eb
TG and WT controls displayed a band at 342 bp indicating the presence of endogenous fulllength RGS2 (Fig. 3.1B); Only RGS2eb transgenic mice displayed an additional 293 bp band,
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which indicated the presence of the hGH poly A region. Due to the short length of the RGS2eb
transgene and difficulty in immunoblotting (Chidiac et al., 2014) , immunohistochemical
staining, qPCR for RGS2 and the human growth hormone (hGH), as well as dot blot
visualization for the polyhistidine tag was used to confirm expression of the RGS2eb transgene.
Following DAB visualization, WT mice showed an absence of staining for polyhistidine,
whereas RGS2eb TG mice displayed positive antigen staining (Fig. 3.1C). Endogenous RGS2
appears to be decreased in both WT and RGS2eb TG mice following TAC (Fig. 3.1D), which
has been previously demonstrated (Zhang et al., 2006); Expression of a region of hGH, which
should only be present in transgenic mice, is significantly higher in RGS2eb TG mice than in
WT animals (Fig 1E). In addition, LV heart tissues from RGS2eb TG mice showed positive
signal for polyhistidine when visualized on dot blots, whereas no signal was detected in noncardiac tissue (i.e. kidney) and LV samples from WT mice (Fig. 3.2F). Together, these results
indicate successful generation of transgenic mice with cardiomyocyte specific overexpression
of RGS2eb.

3.3.2

Improved cardiac function in RGS2eb transgenic mice following
pressure overload

Transverse aortic constriction (TAC) was used to induce experimental pressure overload on
wildtype and RGS2eb TG hearts. Following 4 weeks of constriction, systolic pressure was
significantly increased in the right carotid artery, but significantly reduced downstream of the
TAC site in the left carotid artery in both WT and RGS2eb TG mice (Fig. 3.3A and 3.3B. This
resulted in a 61 mmHg difference in maximal systolic pressure between the left and right
carotid arteries of WT sham and TAC mice, and a 65 mmHg difference between RGS2eb TG
sham and TAC mice (Fig. 3.3C). These data, as well as summary hemodynamic parameters in
Table 3.1, confirm that pressure overload had indeed been induced upon TAC hearts. Increased
vascular resistance was reflected by significantly higher end-systolic pressures in TAC mice;
increased afterload as well as cardiac dilation or hypertrophy in TAC mice was also suggested
by significant increases in the end systolic and end diastolic volumes (Table 3.1). Heart rate
under anaesthesia was maintained at similar levels in all surgery groups (Fig. 3.3D). Following
pressure-volume loop analysis, RGS2eb TG mice demonstrated improved cardiac function as
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measured by various systolic and diastolic indices. Summary data for contractility and
relaxation (maximal elastance, ejection fraction, left ventricular systolic pressure, arterial
elastance, LV +dP/dt, LV –dP/dt, and time constant tau) are provided in Figure 3. Notably,
Millar catheter measurements of the maximal and minimal rates of pressure change in the left
ventricle (LV +dP/dt and LV –dP/dt, respectively), which are important indices of cardiac
contractility, were significantly greater in RGS2eb TG TAC mice compared to WT TAC
counterparts (Fig. 3.4F and 3.4G). In addition, WT TAC mice had significant increases in the
Tau relaxation constant (Fig. 3.4H), indicating impairment of active properties of diastolic
relaxation. These data suggest that RGS2eb TG mice demonstrated improved compensation
following 4 weeks of TAC compared to WT TAC animals.

3.3.3

Cardiac hypertrophy is inhibited in RGS2eb transgenic mice

following pressure overload
Following 4 weeks of TAC, heart weight/body weight (HWT/BWT) ratios, LV and septal wall
thickness, and the cross-sectional areas of cardiomyocytes were used to evaluate the
development of cardiac hypertrophy. Although WT TAC mice developed significant cardiac
hypertrophy (as measured by HWT/BWT) compared to sham controls, RGS2eb TG mice
displayed limited hypertrophic growth compared to WT TAC animals (Fig 3.5A). Some
hypertrophy does still appear to have occurred, as both WT and RGS2 eb TG mice had
significantly increased LV free wall thickness compared to sham controls (Fig. 3.5B, 3.5F and
Fig. 3.6A (representatives)); Septal wall thickness was not significantly changed in TAC
surgery groups compared to sham controls (Fig 3.5D). In addition, RGS2eb TG TAC mice did
not show marked changes in LV free wall cardiomyocyte size compared to TG sham controls,
and were significantly smaller in size than cardiomyocytes from WT TAC mice (Fig. 3.5E and
3.6B (representative)). No changes were observed in measured cardiomyocytes from the septal
wall (Fig. 3.5F). These data suggest that RGS2eb may confer a protective effect in
cardiomyocytes against pressure-induced cardiomyocyte hypertrophy.
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3.3.4

Expression of cardiac hypertrophy markers is suppressed in

RGS2eb transgenic mice
Induction of “fetal” cardiac genes is often a common feature in animal models of pathological
hypertrophy and heart failure (Parker, Packer and Schneider, 1990; Razeghi et al., 2001). RNA
was isolated from left ventricular tissue after 4 weeks of TAC or sham surgery, and qPCR was
performed to determine expression levels of β-myosin heavy chain (β-MHC), atrial natriuretic
peptide (ANP), and brain natriuretic peptide (BNP). WT mice which underwent TAC showed
significantly increased levels of both β-MHC and ANP compared to sham controls (Fig. 3.7A
and B). In contrast, β-MHC and ANP expression in RGS2eb TG mice after TAC was
comparable to sham levels (Fig. 3.7A and B). BNP expression demonstrated a similar trend to
that seen with β-MHC and ANP, but this did not attain statistical significance between RGS2eb
TG and WT mice after TAC (Fig. 3.7C). Since the expression of fetal cardiac genes is
postulated to be indicator of cardiac dysfunction, the absence of elevated levels in RGS2eb TG
mice after TAC suggests that the presence of RGS2eb is cardioprotective in a pressure overload
model of cardiac hypertrophy.
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Figure 3.1. Generation of transgenic mice with cardiomyocyte specific expression of
RGS2eb
(A) Construct used for the generation of mice with cardiomyocyte-specific overexpression of
RGS2eb under the control of α-myosin heavy chain. (B) Genotyping for a region which includes
the hGH PolyA sequence results in a positive band for RGS2eb TG mice and the absence of a
band in WT controls (lanes 8 and 10), while genotyping for endogenous RGS2 resulted in
bands for both RGS2eb TG and WT controls (lanes 1, 3, 5, 7, and 9). (C) Representative
immunostaining in the left ventricle of WT mice shows an absence of polyhistidine staining,
whereas RGS2eb TG mice display positive immunostaining for polyhistidine. (D) RGS2 and
(E) hGH qPCR expression in WT and RGS2eb TG mice following sham or TAC surgery. Data
represent means ± SEM, n = 5-6 per group. **P<0.01, and ***P<0.001 using two-way
ANOVA with Bonferroni’s post hoc test for multiple comparisons.
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Figure 3.2. Dot blot detection of histidine-tagged RGS2eb
Signal for polyhistidine was only detected in the LV tissue of RGS2eb TG mice and His-RGS16
positive controls, with no signal detected in non-cardiac tissue or WT mice.
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Figure 3.3. Pressure overload model of cardiac hypertrophy
(A) Following 4 weeks of aortic constriction between the left and right carotid arteries, systolic
pressure in the LCA was reduced while (B) systolic pressure in the RCA was significantly
increased. (C) Change in systolic pressure between the RCA and LCA following 4 weeks TAC
was significantly increased in both WT and RGS2eb TG mice. (D) Heart rate remained at
similar levels for all experimental and genotype groups. Data represent means ± SEM, n = 79 per group. *P<0.05 and ***P<0.001 using two-way ANOVA with Bonferroni’s post hoc test
for multiple comparisons.
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Table 3.1. Hemodynamic parameters in 4 week sham and TAC mice.

Data represent means ± SEM **P<0.05 and **P<0.001 vs. sham controls using two-way
ANOVA with Bonferroni’s post hoc test for multiple comparisons.
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Figure 3.4. Indices of systolic and diastolic function
(A) Representative PV loops during preload reduction by inferior vena cava occlusion in sham
(solid line) and 4 week TAC animals (dotted line). (B) Slope of left upper relation (maximal
elastance [Emax]) reflected contractile function. (C) Ejection fraction was significantly reduced
in WT but not RGS2eb TG mice following pressure overload, while (D) LV systolic pressure
(LVSP) was significantly elevated following TAC in both WT and RGS2eb mice. (E) Effective
arterial elastance (Ea; an index of total ventricular afterload) was also increased following
TAC. (F) LV +dP/dt and (G) –dP/dt were significantly improved in RGS2eb mice following
TAC, and (H) Tau relaxation time constant remained comparable to sham groups. Data
represent means ± SEM, n = 6-9 per group. *P<0.05 and ***P<0.001 using two-way ANOVA
with Bonferroni’s post hoc test for multiple comparisons.
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Figure 3.5. Cardiac hypertrophy is reduced in RGS2eb transgenic mice
following pressure overload
(A) After 4 weeks of aortic constriction, cardiac hypertrophy in RGS2eb TG mice was
significantly less than WT TAC. (B) Representative whole hearts for WT and RGS2eb TG mice
following 4 weeks of sham or TAC surgery; (C) LV free wall thickness was increased in both
TAC groups; (D) septal wall thickness did not increase. (E) Cardiomyocyte size was
significantly reduced in RGS2eb TG mice compared to WT TAC in the LV free wall, with (F)
no noticeable changes to size in the septal wall.
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A

B

Figure 3.6. LV cross sections and cardiomyocytes
A) Representative H&E staining of WT and RGS2eb LV cross sections of WT and RGS2eb TG
cardiomyocytes following sham or TAC surgery. (B) Representative H&E staining of WT and
RGS2eb cardiomyocytes.
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C

Figure 3.7. Markers of cardiac hypertrophy
(A) β-MHC expression was significantly increased in WT TAC but not RGS2eb TG mice after
4 weeks of aortic constriction. (B) ANP expression was also significantly elevated in WT TAC
mice, while RGS2eb TG mice maintained near-sham levels of expression. (C) BNP expression.
Data represent means ± SEM, n = 4-8 per group. *P<0.05, **P<0.01, and ***P<0.001 using
two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons.
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Discussion
In order for maladaptive cardiac hypertrophy to occur, individual cardiomyocytes must
increase in size; such growth requires increased global protein synthesis, the rate of which is
controlled primarily at the initiation level (Sugden et al., 2009). Of particular importance is the
heterotrimeric initiation factor eIF2, which is activated by the heteropentameric protein eIF2B
(Abbott and Proud, 2004). Notably, eIF2B has been shown to play a critical role in the
development of -adrenergic receptor induced hypertrophy in cultured cardiomyocytes (Hardt
et al., 2004). A major role for eIF2Bε in controlling cell size is also evident from its regulation
by glycogen synthase kinase 3β (GSK3β), which constitutively phosphorylates eIF2Bε at
serine 540 in intact cells, thereby inhibiting its GEF activity by up to 80% (Welsh et al., 1998).
In a cultured cardiomyocyte model, overexpression of a mutant eIF2Bε which could not be
phosphorylated by GSK3β increased cell size and abolished the antihypertrophic effects of
GSK3β, suggesting that eIF2Bε is a direct mediator of cardiac myocyte hypertrophy (Hardt et
al., 2004). Importantly, further expression of a dominant-negative mutant of eIF2Bε inhibited
isoproterenol-induced cardiac hypertrophy, indicating the critical role of eIF2Bε in protein
synthesis and cell growth (Hardt et al., 2004).
We have previously shown that the cellular effects of eIF2Bε are blocked by RGS2eb as well
as by full length RGS2 (Nunn et al., 2010; Chidiac et al., 2014). The goal of the present study
was to determine whether the ability of RGS2 to inhibit protein synthesis and cardiomyocyte
growth in vitro could be extended to an animal model of pathological cardiac hypertrophy. We
therefore developed a mouse line with cardiomyocyte specific expression of RGS2eb, and
examined the functional, histological, and biochemical consequences of experimental pressure
overload in our transgenic mice and WT littermates. To the best of our knowledge, this is the
first study to demonstrate that expression of a portion of RGS2, namely the RGS2eb binding
domain, can reduce pathogenic growth without adversely affecting in vivo cardiac function.
Although a random insertion effect cannot be entirely excluded, expression of this transgene
inhibited TAC-induced increases in heart weight/body weight ratio (Fig. 3.5A) and expression
of hypertrophy-related gene markers (Fig. 3.7), as well as associated functional loss (Fig. 3.4).
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These results likely reflect the ability of RGS2 eb to inhibit protein synthesis in vivo, and the
consequent suppression of the hypertrophic response and cardioprotective effects.
Using qPCR, immunohistochemistry and dot blotting methods, we have demonstrated the
cardiac-specific expression of RGS2eb in our transgenic mice (Fig. 3.1). However, due to the
short length of the RGS2eb transgene and difficulty in immunoblotting (Chidiac et al., 2014), a
limitation of our study is our inability to fully demonstrate an eIF2B-RGS2eb complex.
Although RGS2eb expression is associated with a decrease in cardiac hypertrophy and
improved cardiac function, and our previous in vitro studies suggest that this is due to the
inhibition of eIF2Bε, we cannot definitively attribute our in vivo observations to the direct
inhibition of protein synthesis, and thus cannot exclude other off target effects as the
mechanism behind our observed cardioprotection.
Although LV free wall thickness was significantly increased in both WT and RGS2eb TG mice
following 4 weeks of TAC (Fig. 3.5C), HWT/BWT ratios indicated the development of
significant TAC-associated cardiac hypertrophy in WT, but not RGS2eb TG mice (Fig. 3.5A).
Furthermore, measurements of cardiomyocyte cross-sectional after area showed a
corresponding increase in cell size for WT TAC but not RGS2eb TG mice (Fig. 3.5E). These
data suggest that de novo protein synthesis in response to pressure overload, and thus
hypertrophy, is inhibited in RGS2eb TG mice.
Our previous work showed that the adenoviral expression of RGS2eb in neonatal ventricular
myocytes was able to attenuate the expression of genetic markers of hypertrophy to a
comparable extent as full-length RGS2 (Chidiac et al., 2014). Thus, we examined whether
RGS2eb could also attenuate in vivo increases in the “fetal gene program”, a group of molecular
markers associated with the hypertrophy phenotype, including β-MHC, ANP, and BNP
(Molkentin and Dorn, 2001; Frey and Olson, 2003; Petrich and Wang, 2004). Four weeks of
aortic constriction induced an increase in the levels of β-MHC and ANP in WT mice (Fig. 3.7).
These increases were completely abrogated in RGS2eb TG animals. Reactivation of fetal gene
expression during cardiac hypertrophy is initially an adaptive process which increases the
excitability, contractility, and plasticity of cardiac myocytes in response to pathological stress
(Kuwahara, Nishikimi and Nakao, 2012). However, sustained fetal gene expression plays a
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causative role in maladaptive cardiac remodelling, leading to cardiac dysfunction and often the
pathogenesis of heart failure (Hannenhalli et al., 2006). In addition, our assessment of cardiac
function obtained from pressure-volume loop analyses also suggests that RGS2eb TG mice
were able to maintain significantly improved cardiac function after TAC compared to WT
mice, as evidenced by both systolic and diastolic indices (Fig. 3.4). Our data suggest that the
expression of RGS2eb appears to not only inhibit cardiac hypertrophy, but also improves
cardiac function without activation of fetal cardiac genes after 4 weeks of TAC, although the
effect on fetal gene expression may more likely be due to an indirect effect of the inhibition of
cardiac hypertrophy and apparent improvement in cardiac function, rather than a direct
mechanistic connection between RGS2eb and the re-expression of fetal genes. Further studies,
such as prolonged exposure to TAC, may clarify the extent to which these effects are sustained.
Following transverse aortic constriction, RGS2 knockout mice have been found to develop
severe cardiac hypertrophy and heart failure, as well as increased mortality compared to
corresponding controls (Takimoto et al., 2009). Although this clearly indicates that the
presence of RGS2 is cardioprotective in vivo, many details of this beneficial effect remain to
be elucidated (Chidiac et al., 2014). In cultured ventricular myocytes, RGS2 is acutely and
selectively upregulated in response to activators of Gq and Gs signalling (Hao et al., 2006; Zou
et al., 2006; Nunn et al., 2010). However, RGS2 has been found to be ultimately
downregulated in vivo following experimentally-induced hypertrophy and heart failure (Zhang
et al., 2006). Furthermore, cardiac-specific overexpression of full-length RGS2 does not result
in demonstrable cardioprotective effects in mice subjected to TAC (Park-Windhol et al., 2012).
Conversely, the overexpression of either RGS4, RGS5, or RGS10 has been shown to reduce
cardiac hypertrophy (Rogers et al., 1999, 2001; Li et al., 2010; Miao et al., 2016), although it
may be noted that unlike RGS2, these proteins tend to localize to the atria rather than the
ventricles (Doupnik, Xu and Shinaman, 2001; Mittmann et al., 2002; Larminie et al., 2004;
Gu et al., 2009; Miao et al., 2016) . It is possible that the optimal level of RGS2 is decreased
under conditions of hypertrophic stress, however a complete lack of RGS2 is clearly
detrimental under pressure overload (Takimoto et al., 2009).

99

The lack of an observable protective effect of full-length RGS2 overexpression in the
myocardium (Park-Windhol et al., 2012) stands in contrast to the present findings that
expression of its isolated eIF2B-interacting domain (RGS2eb) can protect against pathological
cardiac hypertrophy and dysfunction in vivo. We have previously shown that the ability of
RGS2eb to inhibit drug-induced cell hypertrophy is independent of the G-protein inhibitory
effects of full-length RGS2 (Chidiac et al., 2014). Along with our current findings, it follows
that the RGS2eb region may be an important contributor to the reported beneficial cardiac
effects of RGS2. Since our previous studies suggest that the RGS2eb region specifically binds
to eIF2B and thereby inhibits protein synthesis (Nguyen et al., 2009), it is possible that some
function of full length RGS2 may produce detrimental effects in the context of pathological
hypertrophy, consistent with its observed downregulation in the latter condition (Zhang et al.,
2006). Negative RGS2 effects could conceivably arise from its inhibition of beneficial G
protein-mediated signals (e.g. the protective effects of adenosine) or alternatively via its effects
on non-G protein targets such as tubulin or TRP channels (Heo et al., 2006; Schoeber et al.,
2006). To examine the importance of the RGS2eb region per se, future studies would be in
order, with expression of this truncated form targeted to the myocardium of full-body or
cardiac-specific RGS2 knockout mice.

Conclusions
The present results suggest that expression of the eIF2B-interacting domain of RGS2, RGS2eb,
can protect against pathological cardiac hypertrophy and dysfunction in vivo, and that this may
be via the direct inhibition of protein synthesis. We have previously shown the ability of
RGS2eb to inhibit drug-induced cardiomyocyte hypertrophy; along with our current findings,
this suggests that the RGS2eb region is an important contributor to the reported beneficial
cardiac effects of RGS2.
Currently, the majority of drugs for cardiovascular diseases target GPCRs. Although these
medications can offer significant benefits to patients, heart failure continues to be a global
leading cause of morbidity and mortality. A better understanding of the various components
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that are part of the GPCR signaling pathways may lead to improved therapeutics, and interest
in RGS2 and other RGS proteins as possible drug targets is on the rise (Le and Coffman, 2003;
Sjögren and Neubig, 2010; Sjögren, Blazer and Neubig, 2010; Sjogren et al., 2012; Turner et
al., 2012; Go et al., 2013; Sjögren et al., 2016). In summary, this study has demonstrated that
RGS2eb is important in regulating in vivo cardiac hypertrophy and physiology, and suggests
that this region of full-length RGS2 may be a key component of its reported cardioprotective
effects.
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4

EFFECTS OF TRANSVERSE AORTIC CONSTRICTION
AND DRUG INDUCED EXPERIMENTAL PRESSURE
OVERLOAD HYPERTROPHY ON Rgs2-/- MICE WITH
CARDIOMYOCYTE SPECIFIC OVEREXPRESSION OF
RGS2eb
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Introduction
Regulator of G protein signalling (RGS) proteins function as GTPase activating proteins
(GAPs) to limit the intensity and duration of GPCR-mediated signalling. RGS2 is a member
of the R4 subfamily of RGS proteins, and selectively inhibits Gq-mediated signalling via its
GAP activity and also via a GAP-independent mechanism (Abramow-Newerly et al., 2006).
RGS2 can also inhibit Gs signalling through its direct binding to some adenylyl cyclase
isoforms and possibly also via its binding to Gαs (Abramow-Newerly et al., 2006).
Additionally, effects on Gi/o have also been reported (Chakir et al., 2011) notwithstanding the
relatively low affinity of RGS2 for Gαi/o proteins (Heximer et al., 1999) . Since Gq- and Gsmediated signalling play well established roles in the development of cardiovascular disease,
the ability of RGS2 to selectively inhibit these pathways makes it an important target of study
(Heximer et al., 1997, 1999; Roy, Baragli, et al., 2006).
Pathological cardiac hypertrophy, which often results from chronic hypertension, is a leading
risk factor for various cardiovascular conditions (Levy et al., 1990; Cipriano et al., 2001); aside
from age, left ventricular hypertrophy is the most reliable predictor of poor cardiovascular
outcomes in hypertensive patients, and is an independent risk factor for sudden death, stroke,
coronary heart disease, and heart failure (Gardin et al., 2001; Verdecchia et al., 2001; Gradman
and Alfayoumi, 2006). Thus, identifying regulators of pathological hypertrophy is of great
interest and importance. Studies in vivo and in cardiomyocyte models of hypertrophy have
shown that increased cell growth caused by prolonged Gq-coupled receptor stimulation, such
as that induced by phenylephrine, can be inhibited by RGS2 overexpression (Roy, Nunn, et
al., 2006; Zou et al., 2006), with a similar effect seen against Gs-mediated cardiomyocyte
hypertrophy induced by isoproterenol (Nunn et al., 2010). The importance of RGS2 in the
regulation of hypertrophy has been further demonstrated in knockout animal studies. In Rgs2/-

mice, experimentally induced pressure overload via transverse aortic constriction causes

severe hypertrophy, heart failure, and death (Takimoto et al., 2009). In addition, chronic
angiotensin II infusion has been shown to significantly increase blood pressures in Rgs2-/- mice
compared to WT controls (Hercule et al., 2007)
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While the G protein inhibitory effects of RGS2 are well established, RGS2 can also bind to
and regulate other targets, including TRPV6 calcium channels and tubulin (Wang et al., 2005;
Heo et al., 2006; Schoeber et al., 2006). We have previously shown that RGS2 can also bind
to the ε subunit of eukaryotic initiation factor 2B (eIF2B), a component of the rate-limiting
step of the initiation of mRNA translation (Nguyen et al., 2009). This property of RGS2 has
been mapped to a 37 amino acid domain (residues 79-115) termed RGS2eb that is homologous
to a region in the β subunit of eIF2 (Nguyen et al., 2009), and we have also demonstrated that
RGS2eb expression in cultured neonatal cardiomyocytes is able to inhibit both protein synthesis
and agonist induced hypertrophy at levels comparable to full-length RGS2 (Chidiac et al.,
2014).
Recently, we reported that following four weeks of transverse aortic constriction (TAC), mice
with cardiomyocyte specific overexpression of RGS2eb (herein referred to as Rgs2+/+(eb) mice)
were protected from pressure overload-induced cardiac hypertrophy, and maintained heart
function at significantly improved levels compared to WT counterparts (see Chapter 3) (Lee
et al., 2017). Reactivation of the fetal gene response was suppressed in Rgs2+/+(eb) mice
following TAC, and cardiomyocyte size was decreased in Rgs2+/+(eb) mice compared to WT
TAC controls. These findings suggest that in addition to its G-protein inhibitory actions, the
RGS2eb region may contribute to the cardioprotective effects of full-length RGS2 in vivo via
the inhibition of de novo protein synthesis.
Since full-length RGS2 was still being endogenously expressed in the Rgs2+/+(eb) mice from
our previous studies (Lee et al., 2017), the use of Rgs2-/- mice would provide further insights
into the cardioprotective role of the RGS2eb region. Based on our previous findings, we
hypothesized that the cardiomyocyte-specific overexpression of RGS2eb in Rgs2-/- mice could
decrease the severity of cardiac hypertrophy and heart failure resulting from experimentally
induced pressure overload, thereby compensating for the absence of full-length RGS2. Here
we report the generation of novel transgenic Rgs2-/- mice with cardiomyocyte specific
overexpression of RGS2eb (Rgs2-/-(eb)). Unexpectedly, we observed that the mortality rate for
Rgs2-/- animals significantly exceeded that of WT controls following 28 days of transverse
aortic constriction (TAC), suggesting an impaired ability to recover from cardiovascular insult.
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Due to the unexpectedly high mortality rate of Rgs2-/ - mice, the TAC-induced model of
pressure overload was determined to be unsuitable for the evaluation of cardiac hypertrophy,
and discontinued before the addition of Rgs2-/-(eb) mice to the study. The effects of druginduced models of hypertension on Rgs2-/- mice were also evaluated. Chronic infusion of
angiotensin II via osmotic pumps for 28 days (1.44 mg/kg/day) significantly increased blood
pressures of experimental animals (Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb)), except for WT mice.
Although cardiac function was impaired in Rgs2-/- animals compared to basal levels, cardiac
hypertrophy was not observed in any experimental groups compared to saline controls. Further
studies with angiotensin II infusion at higher concentrations (3.0 mg/kg/day for 14 days) in
WT and Rgs2-/- mice also failed to induce clearly detectable cardiac hypertrophy. Additional
pilot studies were subsequently performed using twice daily injections of isoproterenol (ISO)
for 14 days, with preliminary results suggesting that a full study with prolonged injections
beyond 14 days may result in cardiac hypertrophy. Overall, owing in large part to the general
lack of efficacy and/or safety of established methods with respect to the induction of cardiac
hypertrophy in our experimental animals, our results do not support our original hypothesis
that RGS2eb expression in an RGS2 null background would provide a “rescue” effect. In
addition, the present findings provide little if any support for the notion that mice lacking RGS2
exhibit greater levels of experimentally-induced cardiac hypertrophy.

Methods
4.2.1

Generation of Rgs2-/- mice with cardiac specific overexpression
of RGS2eb

Rgs2+/+(eb) were crossed with Rgs2−/− mice to produce heterozygous Rgs2+/- animals with or
without the expression of RGS2eb (Rgs2+/- (eb) or Rgs2+/-, respectively). Rgs2+/- (eb) mice were
then crossed with Rgs2−/− mice to obtain RGS2 knockout animals expressing RGS2 eb (Rgs2-/). Subsequent crosses of Rgs2-/-(eb) with Rgs2−/− animals enabled the establishment of a

(eb)

mouse colony which produced Rgs2-/-(eb) mice and Rgs2−/− littermates (Fig. 4.1).
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Colonies for Rgs2-/- and Rgs2+/+(eb) mice are well established in our laboratory (Roy, Nunn, et
al., 2006; Lee et al., 2017). Briefly, during our initial generation of Rgs2+/+(eb) mice, the RGS2eb
gene was targeted to the heart using the mouse α-MHC promoter (kindly provided by Jeffrey
Robbins, Cincinnati Children’s Hospital Medical Center) (Subramaniam et al., 1991). Primers
for the detection of transgenic Rgs2+/+(eb) mice and control primers for endogenous RGS2
expression have been previously described in Chapter 3 (Lee et al., 2017); the genotyping of
Rgs2−/− mice has also been previously described (Oliveira-Dos-Santos et al., 2000). Three to
five month old male mice were used for experimental studies; all mouse lines are in C57Bl/6
backgrounds. Animals were maintained in accordance with the Institute of Laboratory Animal
Research Guide for the Care and Use of Laboratory Animals. These studies were approved by
the Animal Care Committee at the University of Western Ontario, and complied with the
guidelines of the Canadian Council on Animal Care.

4.2.2

Transverse aortic constriction (TAC)

TAC was used to induce pressure overload on the hearts of 12 week old male C57BL/6 wildtype (i.e., Rgs2+/+) and Rgs2-/- mice, and as described in Chapter 3 (Lee et al., 2017). Briefly,
two knots were tied against a 25-gauge blunt needle placed parallel to the transverse aorta,
which was immediately removed after the second tied knot followed by closure of the chest.
Control WT and Rgs2-/- mice were subjected to sham operations without aortic constriction.

4.2.3

Drug treatments

28 day angiotensin (Ang) II infusion: Ang II (A9525, Sigma-Aldrich, Canada) was dissolved
in sterile saline and added to osmotic pumps (Model 1004, Alzet, New York, NY, USA) as per
manufacturer’s protocols (Alzet, 2017a); control pumps were filled with saline. The pump
filling concentration of Ang II required to deliver the drug at a dose of 1.44 mg/kg/d was
calculated using the mean pumping rates for each lot of osmotic pumps and the Alzet drug
concentration calculator (Alzet, 2017b). Pumps were implanted subcutaneously under
isoflurane anaesthesia. Echocardiography and blood pressure measurements were performed
for pre-implantation (basal), 14 day, and 28 day time points. Experimental animals included
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Rgs2-/- and Rgs2-/-(eb) animals, as well as control WT and Rgs2+/+(eb) mice. Animals were
sacrificed after 28 days for tissue collection.
14 day angiotensin II infusion: Ang II (12-1-34, American Peptide Company, CA, USA) was
dissolved in sterile saline and added to osmotic pumps (Model 1002, Alzet); control pumps
were filled with saline. The pump filling concentration of Ang II required to deliver the drug
at a dose of 3.0 mg/kg/d was as described above. Echocardiography was performed on day 14,
followed by animal sacrifice and tissue collection. Only Rgs2-/- and WT mice were used for
this study.
Isoproterenol (ISO) injections: ISO (I6504, Sigma-Aldrich) was dissolved in sterile saline and
injected subcutaneously at a dose of 15 mg/kg or 50 mg/kg twice daily (at 0900 h and 2100 h)
for 12 days or 14 days, respectively; control mice were injected with sterile saline.
Experimental animals included Rgs2-/- and Rgs2-/-(eb)animals, as well as control WT and
Rgs2+/+(eb) mice. Mice were weighed daily and sacrificed on day 12 or day 14 for tissue
collection.

4.2.4

Assessment of blood pressure

Non-invasive tail-cuff blood pressures and heart rates were measured using the CODA tailcuff blood pressure system (Kent Scientific, USA) as previously described (Tutunea-Fatan et
al., 2015). For angiotensin II osmotic pump studies, heart rates and tail-cuff blood pressures
were recorded in conscious mice for basal, 14 day, and 28 day time points.

4.2.5

Assessment of cardiac function

M-mode (motion mode) echocardiography was performed after Ang II or saline treatments as
previously described (Liu et al., 2014; Roy et al., 2016). Briefly, cardiac function was
measured using the Vevo 2100 imaging system (VisualSonics, Canada). Using a dynamically
focused 40MHz probe, 2-dimensional heart images were obtained in short-axis view for the
left ventricle (LV).
M-mode recordings were assessed for the determination of various cardiovascular parameters
using the Cardiac Measurement Package (PSLAX protocol) and averaged from 3 cycles
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(VisualSonics, 2008). Anterior and posterior wall thickness, as well as LV internal diameter
were directly measured from M-mode recordings for both systolic and diastolic phases.
Ejection fraction, fractional shortening, LV volume, and corrected LV mass were derived from
established formulas calculated by the VisualSonics analysis report function (VisualSonics,
2008). Detailed measurement and calculation definitions from VisualSonics are described in
Supplemental Table C1.

4.2.6

Tissue collection

Upon completion of studies, anaesthetized mice were euthanized via a 10% KCl injection into
the left jugular vein to ensure cardiac arrest in the diastolic state. Hearts were excised, weighed
after removal of the atria, and stored at -80°C for subsequent RNA isolation. For 50 mg/kg
ISO experiments, lungs were also excised and rinsed in saline, then weighed. Tibias from each
animal were excised, cleaned, and measured for heart weight/tibia length calculations.

4.2.7

Quantitative reverse transcriptase qPCR

Total RNA was isolated from LV heart tissue using the TriZol (Invitrogen) extraction method
for 1.44 mg/kg/day Ang II experiments. Reverse transcription reaction was performed using
the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Invitrogen,
Canada). SensiFAST SYBR No-ROX Kit mastermix (FroggaBio, Canada) was used for realtime thermal cycling. Primers for β-MHC, ANP, and BNP were previously described in
Chapter 3 (Lee et al., 2017), and were designed using the OligoPerfect Designer
(ThermoFisher, Canada), OligoCalc (Kibbe, 2007) and Primer-BLAST (NCBI) programs.
Samples were amplified for 35 cycles using a CFX384 real-time thermal cycler (Bio-Rad,
Canada). The mRNA quantity for each gene of interest was determined using standard curve
analysis and normalized to 28S ribosomal expression.

4.2.8

Statistical analysis

All data were analyzed using GraphPad Prism 6.01 (GraphPad). Statistical analyses were
performed using two-way ANOVA followed by Bonferroni post-tests, Log rank test (for
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survival curves), or Student’s t-test and presented as mean ± SEM. Differences were
considered significant at P<0.05.

Results
4.3.1

Generation of transgenic mice with cardiomyocyte-specific
overexpression of RGS2eb

We previously demonstrated that the vivo expression of RGS2eb inhibited pressure overload
induced cardiac hypertrophy and improved cardiac function (Lee et al., 2017). Since
endogenous RGS2 was still present in our previous studies, we used well established Rgs2-/and Rgs2+/+(eb) mouse lines in our laboratory to develop a novel strain of Rgs2-/- mice with
targeted myocardial overexpression of RGS2eb (Rgs2-/-(eb)) (Fig. 4.2A). As previously
mentioned in Chapter 3, genotyping with primers for a portion of the hGH polyA region, which
was only present in the transgenic sequence of Rgs2+/+(eb) mice, was used to identify mice
expressing RGS2eb. Primers for endogenous RGS2 and a region of the RGS2 knockout
construct (Oliveira-Dos-Santos et al., 2000), were used to identify wildtype and Rgs2-/animals, respectively. Together, these results indicate the successful generation of Rgs2-/- mice
with cardiomyocyte specific overexpression of RGS2eb.

4.3.2

Increased mortality in Rgs2-/- mice following pressure overload

Transverse aortic constriction (TAC) was used to induce experimental pressure overload on
wildtype and Rgs2-/- mice. Since Rgs2-/- mice have been previously reported to be highly
sensitive to pressure overload induced hypertrophy and heart failure (Takimoto et al., 2009),
initial TAC studies were performed with Rgs2-/- animals to establish whether the previous
surgery conditions used in Chapter 3 were suitable. Survival rates for Rgs2-/- mice subjected to
TAC surgery were found to be significantly lower than sham controls, with 70% of Rgs2-/mice dying within two days of TAC surgery (Fig. 4.2A); a similar effect was not observed for
WT TAC mice (Fig. 4.2B). Due to the low survival rate of Rgs2-/- mice, we concluded that
TAC was too severe of a procedure for our goal of producing a hypertrophy model. Due to
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these observations, we did not continue this study with our remaining experimental groups (i.e.
with Rgs2+/+(eb) and Rgs2-/-(eb) mice).

4.3.3

28 day angiotensin II treatment at 1.44 mg/kg/day

As an alternative to TAC, we investigated the effects of drug-induced hypertension in Rgs2-/(eb)

and Rgs2-/- mice. Chronic Ang II infusion has been previously shown to reproducibly

increase blood pressure and induce the development of cardiac hypertrophy in C57Bl/6 mice
(Francois et al., 2004; Crowley et al., 2006). Tail cuff systolic and diastolic blood pressure
measurements as well as HR were taken one to five days prior to pump implantation (basal)
and at 14 days and 28 days following infusion of saline or Ang II at a dose of 1.44 mg/kg/day
in WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb) mice. In Ang II treated Rgs2+/+(eb) mice, significant
increases in systolic BP were observable by day 14 and remained elevated through day 28
compared to basal levels (Fig. 4.3A) Similar significant systolic BP changes were observed at
day 28 in Rgs2-/- and Rgs2-/-(eb) mice (Fig. 4.3A). However, WT systolic BP Ang II treatment
at 28 days was not significantly increased compared to basal (P=0.062, Fig. 4.3A). Significant
elevations in diastolic BP were observed at 28 days in Rgs2-/- and Rgs2-/-(eb) mice (Fig. 4.3B).
No changes in systolic or diastolic BPs occurred in saline controls (Fig. 4.3C and D), and heart
rates were comparable between all genotypes and treatment groups (Table 4.2).
Although hypertension was evident in WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb) mice following
chronic Ang II treatment, cardiac hypertrophy was not observed in any strains or treatment
groups following the 28 day time point, as measured by either heart weight/tibia length (Fig.
4.4A and C) or echocardiography for LV mass (Fig. 4.4C and D). In addition,
echocardiography measurements for LV diastolic and systolic internal diameters (LVID) in
saline and Ang II treated groups did not provide evidence for chamber dilation or hypertrophy
(Figure 4.5). Echocardiography measurements for posterior and anterior LV wall thickness
during diastole and systole provided further evidence for a lack of cardiac hypertrophy (Figure
4.6 and 4.7); LV volume was also comparable to basal levels (Figure 4.8). Overall, these results
suggest that experimental hypertension induced by Ang II infusion was insufficient for the
development of cardiac hypertrophy in any of the groups tested.
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4.3.4

Decreased cardiac function in Rgs2-/- mice following 28 days of
angiotensin II treatment

In addition to hypertrophy parameters, cardiac function was also assessed in WT, Rgs2+/+(eb),
Rgs2-/-, and Rgs2-/-(eb) mice following 28 days of saline of Ang II infusion. Ejection fraction
(EF) and fractional shortening (FS) in Rgs2-/- mice were significantly decreased compared to
Rgs2-/- basal values (Fig. 4.9A and C). No significant decreases in EF or FS were observed in
WT, Rgs2+/+(eb), or Rgs2-/-(eb) following Ang II or saline treatment (Fig. 4.9).

4.3.5

Expression of fetal genes in LV tissue of 28 day 1.44
mg/kg/day chronic angiotensin II treated mice

Induction of “fetal” cardiac genes is often a common feature in animal models of pathological
hypertrophy and heart failure (Parker, Packer and Schneider, 1990; Razeghi et al., 2001). RNA
was isolated from left ventricular tissue after 28 days of Ang II or saline, and qPCR was
performed to determine expression levels of β-myosin heavy chain (β-MHC), atrial natriuretic
peptide (ANP), and brain natriuretic peptide (BNP) in WT and Rgs2-/- mice. Surprisingly, WT
mice treated with Ang II were found to express significantly lower levels of β-MHC compared
to Ang II Rgs2-/- animals and saline controls (Fig. 4.10 A). ANP was significantly increased in
Rgs2-/- compared to WT Ang II mice (Fig. 4.10B), while BNP was significantly decreased in
Rgs2-/- compared to WT saline mice (Fig. 4.10 C).
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Figure 4.1. Breeding schematic for generation of Rgs2-/-(eb) mice
Rgs2-/- and Rgs2+/+(eb) mouse lines were crossed to obtain heterozygous mice with transgene
expression (Rgs2+/-(eb)). Subsequent crosses with Rgs2-/- mice produced a colony of Rgs2-/- and
Rgs2-/-(eb) littermates.
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Figure 4.2. Survival and cardiac hypertrophy following 28 days TAC in WT and
Rgs2-/- mice
(A) Significantly lower survival was observed for Rgs2-/- TAC mice compared to sham
controls, which was not seen in (B) WT TAC animals. WT survival data is based on sham and
TAC surgeries completed for Chapter 3 studies. Data represent means ± SEM, n = 5-22 per
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Figure 4.3. Tail-cuff blood pressure measurements for basal, 14 day, and 28 days
during saline of Ang II 1.44 mg/kg/day
TG and KOT designations indicate Rgs2+/+(eb) and Rgs2-/-(eb) mice, respectively. (A) Systolic
and (B) diastolic blood pressures (BP) were significantly altered at multiple time points in Ang
II treated mic. (C) Systolic and (D) diastolic BPs for saline treated mice remained stable
throughout the 28 days. Data represent means ± SEM, n=8-18 per genotype group for Ang II,
and n=2 per genotype group for saline treated. *P<0.05 and ***P<0.001 using two-way
ANOVA with Bonferroni’s post hoc test for multiple comparisons.
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Table 4.1. Heart rates for Ang II and saline treated WT, Rgs2+/+(eb) , Rgs2-/-, and Rgs2-/-(eb)
mice (beats per minute)

Saline

WT

TG

KO

KOT

n

2

2

2

2

Basal

673

670

639

636

14 day

687

645

641

617

28 day

632

672

671

607

Ang II

WT

TG

KO

KOT

n

5-16

6-9

5-15

7-9

Basal

690± 14

670± 12

639± 19

636± 47

14 day

704± 25

660± 31

651± 22

607± 27

28 day

681± 42

707± 42

653± 43

604± 23

TG and KOT columns indicate Rgs2+/+(eb) and Rgs2-/-(eb) mice, respectively.
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Figure 4.4. Heart weight/tibia length ratios and LV mass, 1.44 mg/kg/day Ang II or saline
treatment
Heart weight/tibia length was measured for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb)
(KOT) mice in Ang II and saline treated after 28 days. LV mass was also measured from
echocardiography images at basal, 14 days, and 28 days of treatment. Data represent means ±
SEM, n=3 (saline) or 8 (Ang II-treated) per genotype group. Statistical analysis was performed
using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons.
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(A) (B) LVID;d and (C
Figure 4.5. LV internal diameters (LVID) at diastole and systole, 1.44 mg/kg/day Ang II or
saline treatment
(A)(B) LVID;d (C)(D) LVID;s were comparable between both Ang II and saline treatment
groups, as well as between genotypes for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb)
(KOT) mice. LVID was measured from echocardiography images at basal, 14 days, and 28
days of treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype
group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc
test for multiple comparisons.
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Figure 4.6. Anterior wall (AW) thickness, diastole and systole, 1.44 mg/kg/day Ang II or
saline treatment
(A) (B) AW;d and (C) (D) AW;s were comparable between both Ang II and saline treatment
groups, as well as between genotypes for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb)
(KOT) mice. AW was measured from echocardiography images at basal, 14 days, and 28 days
of treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype
group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc
test for multiple comparisons.
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Figure 4.7. Posterior wall thickness (PW), diastole and systole, 1.44 mg/kg/day Ang II
or saline treatment
(A) (B) PW;d and (C) (D) PW;s were comparable between both Ang II and saline treatment
groups, as well as between genotypes for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb)
(KOT) mice. PW was measured from echocardiography images at basal, 14 days, and 28 days
of treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype
group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc
test for multiple comparisons.
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Figure 4.8. LV vol, diastole and systole, 1.44 mg/kg/day Ang II or saline treatment
(A) (B) LV;d and (C) (D) LV;s were comparable between both Ang II and saline treatment
groups, as well as between genotypes for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb)
(KOT) mice. LV was measured from echocardiography images at basal, 14 days, and 28 days
of treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype
group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc
test for multiple comparisons.
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Figure 4.9. Ejection fraction and fractional shortening, 1.44 mg/kg/day Ang II or
saline treatment
(A) EF in Rgs2-/- (KO) was significantly reduced after 28 days of ang compared to basal Rgs2/-

(KO) levels. Changes to EF compared to basal were not observed for WT, (B) Rgs2+/+(eb)

(TG) or Rgs2-/-(eb) (KOT) mice. Similarly, (C) FS was significantly reduced in Rgs2-/- (KO) was
significantly reduced after 28 days of ang compared to basal, with no changes observed in WT,
(D) Rgs2+/+(eb) (TG) or Rgs2-/-(eb) (KOT) mice. EF and FS were calculated from LV vol and
LVID parameters (see Suppl. Table C1 for equations) at basal, 14 days, and 28 days of
treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype group.
Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc test for
multiple comparisons.
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Figure 4.10. Markers of cardiac hypertrophy
(A) After 28 days of Ang II or saline, WT mice treated with Ang II were found to express
significantly lower levels of β-MHC compared to Ang II Rgs2-/- animals and saline controls.
(B) ANP was significantly increased in Rgs2-/- compared to WT Ang II mice, while (C) BNP
was significantly decreased in Rgs2-/- compared to WT saline mice (Fig. 4.10 C). Data represent
means ± SEM, n=6 per group. *P<0.05 and **P<0.01 using two-way ANOVA with
Bonferroni’s post hoc test for multiple comparisons.
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4.3.6

14 day angiotensin II treatment at 3.0 mg/kg/day

Since Ang II treatment at 1.44 mg/kg/day was sufficient to increase blood pressure, but did not
appear to induce cardiac hypertrophy, 3.0 mg/kg/day of Ang II was tested in WT and Rgs2-/mice for 14 days to determine whether an increase in drug dosage could produce a hypertrophic
response. Significant cardiac hypertrophy did not occur in either WT or Rgs2-/- mice compared
to saline controls (Fig. 4.11A). Furthermore, echocardiography for systolic and diastolic
diameters (Fig. 4.11 B and C), as well as EF and FS (Fig. 4.11D and E), were similar between
all treatment groups and strains.

4.3.7

Effect of twice daily isoproterenol injections

Due to a lack of inducible cardiac hypertrophy in our Ang II models, we tested whether a
different drug and mode of delivery could improve our attempts to characterize the Rgs2-/-(eb)
mouse. Isoproterenol was injected subcutaneously at a dose of 15 mg/kg for 12 days. To
determine feasibility, initial tests were performed only in WT mice. Following ISO injection,
WT heart rates (under anaesthesia) rapidly increased from approximately 400 bpm to 700 bpm
thirty seconds after injection and plateaued at that level (Fig. 4.12A), indicating that a
pharmacologically relevant dose was used. HR measurements 8 hours and 24 hours after ISO
delivery showed a gradual return to baseline, suggesting that twice daily doses of ISO would
be appropriate to maintain animal HRs at elevated levels (Fig. 4.12A). Following twelve days
of ISO or saline injections, statistically significant levels of hypertrophy were not observed
(data not shown). Therefore, ISO dosage was subsequently increased to 50 mg/kg twice daily
for 14 days to WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb) mice; body weights were recorded daily
and animals were tracked for survival (Suppl. Fig. C1). Wet lung weight/tibia length was
similar between all strains and conditions, and did not suggest the development of congestion
(Fig. 4.13A). Similar to the twelve day ISO studies, the development of hypertrophy in Rgs2/-

mice compared to saline controls was not statistically significant (P=0.08) (Fig. 4.13B).
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Discussion
Maladaptive cardiac hypertrophy is a common condition that often develops in settings of
hypertension, and is a major risk factor for heart failure and sudden death. Since the heart is
thought to be an essentially post mitotic organ, cardiomyocyte growth requires de novo protein
synthesis, which is controlled primarily at the initiation of mRNA translation stage (Sugden et
al., 2009). We have previously shown that the in vitro expression of RGS2eb, a region of fulllength RGS2, can block protein synthesis and cultured cardiomyocyte growth by inhibiting
eIF2B, a key component of the rate-limiting step of protein synthesis initiation (Nguyen et al.,
2009; Chidiac et al., 2014). Furthermore, we recently developed a transgenic mouse line with
cardiomyocyte specific overexpression of RGS2eb (i.e. Rgs2+/+(eb) mice). Using a pressure
overload model, we demonstrated that expression of RGS2eb inhibited TAC-induced increases
in cardiac hypertrophy and the expression of hypertrophy-related gene markers, as well as
associated functional loss (Lee et al., 2017). These results likely reflected the ability of RGS2eb
to inhibit protein synthesis in vivo, and the consequent suppression of the hypertrophic
response and cardioprotective effects. In the present studies, we attempted to extend our earlier
work to study the potential protective effect of RGS2eb expression targeted to the myocardium
in whole body RGS2 knockout mice, but this effort was abandoned due to unacceptably high
mortality of the TAC procedure in Rgs2-/- animals. We also were unable to establish whether
the hypothesized protective/rescue effect could be observed with drug-induced experimental
cardiac hypertrophy due to generally poor efficacies of established hypertrophy-inducing drug
treatments in our experimental animals. Finally, the majority of our results do not support the
notion the Rgs2-/- mice are prone to more severe experimental hypertrophy, in contrast to the
previous findings of Takimoto and colleagues (Takimoto et al., 2009).
Our previous work demonstrated the anti-hypertrophic effects of RGS2eb expression in a
C57Bl/6 background where endogenous expression of full-length RGS2 (which contains the
RGS2eb region) was still present. The goal of the present study was to determine whether the
apparent ability of RGS2eb to confer cardioprotection could be extended in part to Rgs2-/- mice,
which have previously been reported to be highly sensitive to TAC induced pressure
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Figure 4.11. Heart weight/tibia length, LVID, EF, and FS in 3.0 mg/kg/day Ang
II or saline treated WT and Rgs2-/- mice
(A) Significant cardiac hypertrophy did not occur in WT or Rgs2-/- mice compared to saline
controls. Echocardiography for (B) diastolic and (C) systolic parameters, as well as (D)
ejection fraction (EF) and (E) fractional shortening (FS) were similar between all treatment
groups and strains. Data represent means ± SEM, n=3-8 per group. Statistical analysis was
performed using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons.
133

H e a rt ra te (b p m )

800

600

400

200

W T1
W T2

0
0s

5s 10s 15s

30s

60s

8h

24h

T im e p o s t -in je c t io n
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Following ISO injection, WT heart rates (under anaesthesia) rapidly increased from
approximately 400 bpm to 700 bpm thirty seconds after injection, and plateaued at that level.
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suggesting that twice daily doses of ISO would be appropriate to maintain animal HRs at
elevated levels. Data points represent individual animals.
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suggest the development of congestion. (B) Although statistical significance was not attained,
heart weight/tibia length ratios indicated the development of hypertrophy in Rgs2-/- (KO) and
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performed using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons.
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overload (Takimoto et al., 2009). In order to develop a line of Rgs2-/- mice with cardiomyocyte
specific overexpression of RGS2eb (Rgs2-/-(eb)), we crossed Rgs2+/+(eb) and Rgs2-/- mice from
well-established mouse lines in our laboratory to obtain intermediate animals with
heterozygous RGS2 expression. Mice were genotyped to identify those with expression of the
RGS2eb transgene, then crossed back with Rgs2-/- animals to obtain Rgs2-/-(eb) mice, which were
subsequently crossed with Rgs2-/- animals to establish a novel Rgs2-/-(eb) / Rgs2-/- mouse line
(Figure 4.1).
High mortality rates of Rgs2-/- mice after TAC led to the discontinuation of our initial TAC
studies. However, this was an interesting observation in itself (Fig. 4.2B). Previous studies
using a more severe TAC model have also demonstrated lower survival rates in Rgs2-/- animals,
albeit to a much smaller extent than our observations (60% survival versus 30%, respectively)
(Takimoto et al., 2009). A possible explanation for these low survival rates is that Rgs2-/- mice
have been shown to have increased susceptibility to atrial fibrillation (AF) via enhanced M3
muscarinic receptor activity, which is known to be involved in vagally induced atrial
fibrillation (Tuomi, Chidiac and Jones, 2010; Jones, Tuomi and Chidiac, 2012). Studies have
also shown that AF can be induced more frequently via electrical stimulation in wild-type TAC
hearts compared to sham surgeries, and that this may be due to mast cell infiltration and fibrosis
in the atrium following TAC (Liao et al., 2010). In addition, the use of a ketamine/xylazine
anaesthetic mix, which depresses cardiac function (Kohn, 1997; Roth et al., 2002), may have
also had an adverse effect. Thus, it is possible that after TAC surgery, a combination of the
loss of RGS2 and additional physiological stressors induced atrial fibrillation and cardiac
dysfunction, from which a majority of our Rgs2-/- animals did not recover.
Chronic Ang II infusion via osmotic pumps at both pressor and sub-pressor doses has been
shown to induce hypertension and cardiac hypertrophy in various mouse lines including C57
Bl/6 mice (Griffin et al., 1991; Bendall et al., 2002; Schultz et al., 2002; Choi et al., 2016;
Tsuruda et al., 2016). Although we observed hypertension in our experimental mice after 28
days of Ang II at 1.44 mg/kg/day (Fig. 4.3), we did not observe cardiac hypertrophy in any of
our experimental or control mice (WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb)). However, functional
echocardiography data suggested significantly decreased ejection fraction and fractional
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shortening in Rgs2-/-Ang II animals compared to basal Rgs2-/- levels, which was not observed
in the other experimental groups (Fig. 4.9). Levels of ANP were also significantly elevated in
Rgs2-/- mice compared to WT controls (Fig. 4.10B). These data suggested that although Ang
II infusion was sufficient to increase blood pressure over 28 days, it was not, at least in our
hands, able to reliably deliver a robust hypertension-induced model of cardiac hypertrophy.
Therefore, we tested approximately double the concentration of Ang II (3.0 mg/kg/day) in WT
and Rgs2-/- mice for 14 days to assess whether a higher dose could induce cardiac hypertrophy
and thus be used for additional studies; no statistically significant increases in heart weight
were observed (Fig. 4.11). It is possible that our Rgs2-/- (and potentially WT) mouse strains
are, for currently unknown reasons, resistant to the development of cardiac hypertrophy, as the
pressure overload and hypertrophy models used in our experiments are well established in the
literature and in our own laboratories (Roy et al., 2016; Lee et al., 2017). Further studies, such
as prolonged or higher doses of Ang II, may clarify the parameters required for a robust model
of Ang II-induced cardiac hypertrophy.
Following a lack of significant hypertrophy in all our mouse strains after chronic Ang II
treatment, we hypothesized that acute delivery of a hypertrophic agent could potentially result
in the development of cardiac hypertrophy. Since our previous study used Ang II, which
activates Gq-stimulated hypertrophic signalling pathways, we selected isoproterenol, a Gs
activating agonist (via β-adrenergic receptors), to ultimately administer in a pilot study at twice
daily doses of 50 mg/kg for 14 days to WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb) mice. Initial heart
weight/tibia length ratios following ISO treatment demonstrated no statistically significant
differences between genotype or treatment groups, although ISO (Fig. 4.13B) has been
previously shown to induce cardiac hypertrophy at concentrations ranging from 15 mg/kg to
100mg/kg (Zhang et al., 2005; Brooks and Conrad, 2009; Sjögren et al., 2016). Future studies
with blood pressure monitoring as well as echocardiography analysis may help determine
whether an isoproterenol model is the appropriate drug of choice for a hypertrophy model in
our studies with Rgs2-/-(eb) mice.
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Conclusions
The present results are generally consistent with studies in the literature that suggest impaired
cardiovascular function in Rgs2-/- mice may be due to enhanced susceptibility to atrial
fibrillation. However, our objective of determining whether the expression of RGS2eb in Rgs2/-

mice (Rgs2-/-(eb)) could decrease previously reported deleterious outcomes following pressure

overload was limited by our inability to achieve a robust cardiac hypertrophy model with
appropriate experimental controls. Subsequent studies using well-established angiotensin and
isoproterenol hypertrophy models also did not produce significant increases in heart weight in
any of our mouse strains. It is possible that future studies with prolonged isoproterenol or
angiotensin II treatment could result in conditions leading to a robust cardiac hypertrophy
model in which the role of RGS2eb in Rgs2-/- mice could be appropriately characterized.
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(RGS2) ALTERS THE EFFECTS OF ACUTE AND
CHRONIC
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ON
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The material in this chapter is based on a manuscript: Lee KN, Gros R, and Chidiac P (2017),
Loss of regulator of G protein signalling 2 (RGS2) alters the effects of acute and chronic diet
restriction on metabolic outcomes in C57 Bl/6 mice. Submitted to International Journal of
Obesity. Manuscript number: 2017IJO01137.
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Introduction
Regulator of G protein signalling (RGS) proteins are a family of GTPase-activating proteins
(GAPs) that bind to G proteins and inactivate them by increasing the intrinsic rate of GTP
hydrolysis and/or act as “effector antagonists”, thus limiting the intensity and duration of
GPCR-initiated signalling (Popov et al., 1997; Ross and Wilkie, 2000; Abramow-Newerly et
al., 2006). RGS2 is part of the B/R4 family of RGS proteins and is found ubiquitously
throughout the body (Schoeber et al., 2006). RGS2 selectively inhibits Gαq- and Gαs-mediated
signalling (some effects on Gαi/o signalling have also been reported) (Heximer et al., 1999;
Anger et al., 2007; Chakir et al., 2011), and can bind to and regulate other non-G protein targets
including eIF2B, TRPV6 calcium channels and tubulin (Wang et al., 2005; Heo et al., 2006;
Schoeber et al., 2006). RGS2 has also been shown to modulate adipocyte differentiation and
proliferation (Imagawa, Tsuchiya and Nishihara, 1999; Nishizuka et al., 2001; Cheng et al.,
2008), and may also regulate basal metabolism via the inhibition of thyroid hormone receptorinduced Gαq signalling (Eszlinger et al., 2004). Furthermore, human polymorphisms leading to
increased RGS2 expression have been associated with metabolic syndrome and an increased
risk for weight gain or obesity in hypertensive patients (Freson et al., 2007; Sartori et al., 2008).
Conversely, Rgs2 deficiency in mice leads to impaired T cell activation, increased anxiety,
reduced male aggression, and moderate hypertension under basal conditions (Oliveira-DosSantos et al., 2000; Heximer et al., 2003).
We have previously reported that Rgs2-/- mice exhibit a lean phenotype, and demonstrated that
resistance to age-related weight gain was accompanied by reduced adipose tissue deposits and
smaller adipocytes, lower levels of serum lipids, and increased insulin sensitivity; a subset of
genes involved in adipocyte differentiation and proliferation were also reduced (Nunn et al.,
2011). In addition, Rgs2-/- mice were found to be hyperphagic in comparison to C57 Bl/6
wildtype (WT) controls, and the two strains exhibited equivalent nutrient absorption (Nunn et
al., 2011). A lean phenotype in the presence of hyperphagia and normal nutrient absorption
would appear to suggest increased physical activity and/or metabolism, however we were not
able in our previous study to detect any increase in resting VO2 in Rgs2-/- mice using a basic
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open flow respirometry system where animals were held in a small chamber and had limited
mobility (Nunn et al., 2011).
Although the lean Rgs2-/- habitus was maintained throughout the mouse lifespan on an ad
libitum standard rodent diet, these animals nonetheless became obese and insulin-resistant
under high-fat diet conditions (Nunn et al., 2011). This suggests that Rgs2-/- mice do not have
a major impairment with respect to their ability to accumulate adipose tissue (evidence for a
role of RGS2 in adipocyte differentiation notwithstanding). It follows that the observed lean
phenotype may reflect underlying changes in energy utilization that limit substrate availability
with respect to adipose formation under normal dietary conditions.
To better understand the role of RGS2 in metabolism and body weight regulation
Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus Instruments,
Columbus, OH, USA) metabolic cages were used in the present study to simultaneously assess
indirect calorimetry parameters and ambulatory activity in freely moving age-matched control
and Rgs2-/- mice under normal and diet-restricted conditions. Here we report that Rgs2-/- mice
displayed significantly increased metabolism compared to WT controls, and that these
differences were exacerbated both by chronic and by acute caloric restriction. No changes in
ambulatory activity were observed, suggesting that internal metabolism, rather than overt
physical activity, is the major contributor to the lean Rgs2-/- phenotype. On ad libitum diets,
although metabolic parameters were observed to decrease over time as mice aged, Rgs2-/- mice
displayed consistently higher rates of metabolism compared to WT animals. In combination
with our previous findings which extensively evaluated the effects of the loss of RGS2 on
various physiological parameters, collectively our data resolve the erstwhile paradox
concerning nutrient intake and metabolic rates in Rgs2-/- mice, and demonstrate an important
role for RGS2 in the regulation of weight and body metabolism.
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Methods
5.2.1

Animals

The generation and genotyping of Rgs2−/− mice have been previously described(Oliveira-DosSantos et al., 2000; Roy et al., 2006). Briefly, Rgs2-/- mice used for experimental procedures
came from congenic Rgs2-/- and WT control (rgs2+/+) colonies that are well established in our
laboratory(Roy et al., 2006). Prior to CLAMS metabolic cage measurements and diet
restriction studies, animals were housed in individual standard shoebox cages and provided ad
libitum access to standard rodent chow pellets containing 18.6% protein, 6.2% fat, and 44.2%
carbohydrates (2018 Teklad global 18% protein diet, Envigo, United Kingdom) and water on
a standard 12:12 h light-dark cycle (light period: 0700 – 1900 h). Male Rgs2-/- and WT controls
in C57 Bl/6 backgrounds were used for all studies. Animals were maintained in accordance
with the Institute of Laboratory Animal Research Guide for the Care and Use of Laboratory
Animals. These studies were approved by the Council on Animal Care at the University of
Western Ontario, and complied with the guidelines of the Canadian Council on Animal Care.

5.2.2

Study design

Animals were monitored using Oxymax CLAMS metabolic cages (Columbus Instruments,
Columbus, OH, USA). During diet studies, individually housed mice were maintained in
CLAMS cages at 24 ± 1°C on a standard 12:12 h light-dark cycle (light period: 0700–1900 h)
with airflow of 0.35L/min(Guzman et al., 2013). Water was available ad libitum in all studies,
while powdered standard rodent chow (2018 Teklad) was available depending on the diet study
performed. Animals were individually housed in plexiglass cages and were acclimatized to
their CLAMS cages for 16-24 hours prior to data acquisition (Guzman et al., 2013).

5.2.3

Assessment of indirect calorimetry and activity

Volume of oxygen consumption (VO2), volume of carbon dioxide production (VCO2),
respiratory exchange ratio (RER), cumulative food and water intake, and physical (ambulatory)
activity were simultaneously measured using CLAMS and Oxymax software (Columbus
Instruments). Measurements for all described parameters were taken every 10 minutes for 24
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hours on a standard 12:12hr light-dark cycle (light period: 0700 – 1900h), and collected data
were averaged to produce both one hour time points as well as 12 hour light and dark averages.
VO2 and VCO2 were normalized to body mass (mL/kg/hr). Cumulative food and water intake
were normalized to 1900 h starting values. RER, an indicator of which macronutrients are
being metabolized, was calculated by dividing VCO2/VO2. An RER of ~1.0 or ~0.8 indicates
almost complete carbohydrate or fat oxidation, respectively, while values that fall between
these extremes suggest a mixture of the energy sources are being metabolized (Richardson,
1929). Energy expenditure (heat) was calculated from RER and VO2, and corrected for body
mass (kcal/hr/kg). Ambulatory activity was obtained using Opto-M3 Activity Monitor and
Oxymax software algorithms (Columbus Instruments). Infrared photo beam breaks were
monitored as counts on the X- and Y-axes; consecutive beam breaks were assessed as
ambulatory activity.

5.2.4

Ad libitum studies

1 month, 3 month, and 12 month-old Rgs2-/- and WT controls were placed on ad libitum
standard chow diets (2018 Teklad) following weaning. Animals were placed in CLAMS cages
for 12 hours of acclimatization followed by 24 hours of data acquisition (start time: 1900 h)
on a standard 12:12 h light-dark cycle (light period: 0700 – 1900 h). Ad libitum diet in CLAMS
cages was provided in powdered form via a freely accessible center feeder.

5.2.5

Chronic diet restriction studies

Individual food intake for 8 week old Rgs2-/- and WT mice was measured daily for two
consecutive weeks to determine average consumption of standard rodent diet (2018 Teklad)
for each animal. Based on measured daily amounts, food intake was reduced by 10% every
two weeks to reach a final daily diet restriction of 30% after six weeks (i.e. 2 weeks each of
10%, 20%, and 30% reduction); body weights were measured weekly. Daily food allowance
was provided in pellet form to all mice at 1100 h. Daily food intake over time was measured
by weighing food pellets at 30 min and 1 to 24 hours after introduction of food. During 30%
diet restriction, blood glucose levels were measured using a glucometer (OneTouch UltraMini
system, Johnson & Johnson, Canada) on tail snip collected blood immediately prior to the
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introduction of food, as well as 15 min, 30 min, 1 h, 2 h, and 3 h after the introduction of food.
Following two weeks of 30% restriction, at which time mice were 3.5 month (14 weeks) old,
animals were placed in CLAMS cages for 12 hours of acclimatization followed by 24 hours of
data acquisition (start time: 1900 h), with access to pre-weighed food pellets at 1100 h.

5.2.6

Acute diet restriction studies

3 month-old Rgs2-/- and WT mice on standard ad libitum rodent diet (2018 Teklad) were placed
in CLAMS cages for 16 hours of acclimatization followed by 36 hours of data acquisition.
Cage feeders with powdered food were replaced with empty feeders for 12 hours (start time:
1900 h), with ad libitum food access returned at 1100 h the following day for another 20 hours
(end time: 1900 h).

5.2.7

Microarray analysis

Total RNA was isolated from the gastrocnemius tissue of ad libitum fed 12 week old male
Rgs2-/- (n=2) and WT (n=2) mice using the TriZol (Invitrogen) extraction method; RNA
integrity was confirmed with Agilent 2100 BioAnalyzer Data Review Software (Agilent, USA)
at the London Regional Genomics Centre. Samples with RNA integrity number (RIN) values
greater than 8 were used for microarray, which was performed at the London Regional
Genomics Centre as previously described (Ratneswaran et al., 2017). Briefly, total RNA was
hybridized to the Affymetrix GeneChip® Mouse Gene 2.0 ST Array containing 35 240 probes.
Gene level, ANOVA p values, and fold changes were calculated using Partek Genomics Suite
version 6.6. Genes with at least a 1.4 fold change and with p<0.05 were used to generate gene
ontology biological processes and cellular component processes diagrams through the
PANTHER gene list analysis program (http://pantherdb.org/) (Mi et al., 2013). In addition, all
genes with p<0.05 were analyzed to identify potential metabolic differences between Rgs2-/and WT animals.

5.2.8

Quantitative reverse transcriptase qPCR

Total RNA was isolated from the gastrocnemius tissue of ad libitum fed 12 week old male
mice using the TriZol (Invitrogen) extraction method. Reverse transcription reaction was
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performed using the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor
(Invitrogen, Canada). SensiFAST SYBR No-ROX Kit mastermix (FroggaBio, Canada) was
used for real-time thermal cycling. Primers for genes of interest (Table 5.3) were designed
using the OligoPerfect Designer (ThermoFisher, Canada), OligoCalc (Kibbe, 2007) and
Primer-BLAST (NCBI) programs. Samples were amplified for 35 cycles using a CFX384 realtime thermal cycler (Bio-Rad, Canada). The mRNA quantity for each gene of interest was
determined using standard curve analysis and normalized to 28S ribosomal expression.

5.2.9

Statistical analysis

All data were analyzed using GraphPad Prism 6.01 (GraphPad Software, San Diego, CA, USA)
and presented as mean ± SEM. Statistical analyses were performed using two-way analysis of
variance (ANOVA) followed by Bonferroni’s post-test and unpaired Student’s two-tailed ttest. Differences were considered significant at P < 0.05.
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Table 5.1. Primers for qPCR of metabolism-related genes
Gene

Forward primer 5'-3'

Reverse primer 5'-3'

serca1

GACGTTTGTTGGTGTTGTGG

GCAATGGCTGTACCCTTGTT

adcy2

GGAGATCGAAACCATGGAGA

TGGAGGCAAACATGACACA

adcy5

TCGTGCTGGCTCTGTATCTG

GTCCTTGGGCAGAATGTTGT

adrb1

CAGGCGCTGAGTCTCTCTCT

TGCCGTCTTTGTTTTTAGCC

adrb2

AAAGAGCACAAAGCCCTCAA

GTTGACGTAGCCCAACCAGT

atp5g1

AGGAACCCATCTCTCAAGCA

AGGCGACCATCAAACAGAAG

cs

AGGATCCCATGTTCAAGCTG

TTCATCTCCGTCATGCCATA

dio2

GATGCTCCCAATTCCAGTGT

TGAACCAAAGTTGACCACCA

hk2

GGGTAGCCACGGAGTACAAA

TGGATTGAAAGCCAACTTCC

pygm

GACATGGAGGAGTTGGAGGA

CATAGCGAAGCCAGTCATCA

ryr1

CTCCTGGTGATGGGTGTCTT

TTCCTTCTCGTGTGCCTCTT

slc16a2

TCCCTTCCTCATCAAAATGC

GCCGGTAAGTGAGTGAGAGC

slc2a4

GATTCTGCTGCCCTTCTGTC

ATTGGACGCTCTCTCTCCAA

thra

CAAGATCACCCGGAATCAGT

TGCAGTGAGCGAATCATCTC

ucp3

TCAAAGCAGCAGGACTCAGA

GAGAGCAGGAGGAAGTGTGG
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Results
5.3.1

Increased metabolism over time in Rgs2-/- mice on ad libitum diet

To determine the effects of loss of RGS2 on basal metabolism, indirect calorimetry, activity,
as well as food and water intake were measured in 1 month, 3 month, and 12 month-old Rgs2/-

and WT mice. In newly weaned 1 month-old Rgs2-/- and WT animals, VO2, VCO2, energy

expenditure (heat), ambulatory activity, as well as food and water intake were comparable
between phenotypes (Fig. 1A, B, C, D and Fig. 2A and B). Although both groups were more
metabolically and physically active during the 12 hour dark cycle (due to the nocturnal nature
of mice), there was no significant difference between the described parameters. Interestingly,
RER during the 12 hour light cycle was noticeably increased in Rgs2-/- mice (Fig. 1A),
suggesting increased carbohydrate metabolism compared to WT controls. Body weights at 1
month were still similar between groups, with significant weight separation observed at the 3
month and 12 month time points (Table 1).
Consistent with our previous observations (Nunn et al., 2011), lean 3 month-old Rgs2-/- mice
were found to be hyperphagic in comparison to WT controls (Fig. 2A,), and were also found
to consume significantly more water during the 12 hour dark cycle (Figure 2B). If increased
metabolism is to account for the lean phenotype of Rgs2-/- mice, it would be expected that both
O2 consumption (VO2) and CO2 production (VCO2) would be elevated to some extent. In both
strains of mice, these parameters were increased compared to levels during the light cycle,
indicative of the nocturnal activity of mice (Fig. 1A and B). However, Rgs2-/- mice displayed
additional increases in dark cycle VO2 and VCO2 levels compared to WT mice. Interestingly,
significant increases in energy expenditure (heat) between the light and dark cycles were
detected only in Rgs2-/- mice (Fig. 1D). RER also appeared to be higher in Rgs2-/- mice at 3
months, again suggesting increased carbohydrate metabolism (Fig. 1C). Similar to 1 month old
mice, changes in ambulatory activity were not found between strains, implying that observed
metabolic differences do not arise from increased physical activity (Table 1).
Further strain separation of several metabolic parameters was observed in 12 month old
animals. VO2, VCO2, and energy expenditure were significantly elevated during the dark cycle
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in Rgs2-/- compared to WT animals (Fig. 1A, B, and D), although food intake was not
statistically different at 12 months (Fig. 2A). Patterns in RER (Fig. 1C) and ambulatory activity
(Table 1) were similar to those observed for 3 month old mice. Overall, these ad libitum data
suggest that Rgs2-/- mice may have a higher basal metabolic demand than WT animals, and
that this is maintained throughout their lifespan.

5.3.2

Chronic caloric restriction unmasks metabolic differences

between Rgs2-/- and WT mice
Given that some but not all measured parameters pointed to higher metabolic demand in Rgs2/-

mice under normal ad libitum diet conditions and the observed lean phenotype, we reasoned

that reducing food intake via a chronic 30% diet restriction might reveal further differences
between Rgs2-/- animals and WT controls. Caloric restriction was introduced gradually, with
provided daily food reduced by 10% for the first two weeks and then 20% for two subsequent
weeks prior to the 30% reduction (Figure 3G). Animals were weighed weekly to ensure they
did not drop below acceptable protocol levels. Similar to other diet restriction studies
(Weindruch et al., 1986; Faulks et al., 2006), body weights remained essentially constant in
both Rgs2-/- and WT mice (Figure 3G). Since WT Bl/6 mice tend to steadily gain weight as
they age (Nunn et al., 2011), the lack of such an increase over six weeks indicated that the diet
restriction regimen was successful. All indirect calorimetry parameters were significantly
altered in Rgs2-/- animals compared to WT controls following 30% diet restriction, with Rgs2/-

mice exhibiting higher levels of VO2, VCO2, RERs, and energy expenditure (heat) (Fig. 3A,

B, C, and D). Notably, RER increased substantially in both strains following the introduction
of food and reached an elevated plateau, which was significantly higher in Rgs2-/- than WT
mice; RER reached and remained at 1.0 or greater in Rgs2-/- mice, a level indicative of energy
metabolism based almost entirely on carbohydrate usage (Fig. 3C). Similar to 3 month-old ad
libitum studies, physical activity did not appear to play a role in the increased energy
expenditure of Rgs2-/- mice (c.f. Tables 1 and 2).
During the 30% diet restriction, the rate of food consumption by Rgs2-/- mice was more than 4
times the rate of the WT diet-restricted mic (Figure 3E). All mice finished their food prior to
the next daily feeding, and consequently knockout mice were essentially fasted for
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approximately 20 hours before their next meal versus about 12 hours for WT animals, with
significantly lower blood glucose levels than WT mice directly prior to food introduction
(Figure 3H). Although there were clear strain-related differences evident under caloric
restriction, it is possible that the unexpected difference in the duration of fasting might have
had a distorting effect on the measurement of metabolic parameters. To control for behavioural
differences in food consumption, in further experiments we subjected both WT and KO mice
to an acute 16 hour fast and acquired CLAMS data to assess metabolic and physical activity.

5.3.3

Decreased energy conservation in Rgs2-/- mice during and after

acute fast
Fasting typically results in energy conservation, which can be demonstrated via
decreased VO2 and VCO 2 levels, and indeed such changes were observed in both WT
and Rgs2-/- animals following food removal (Figure 4A and B, respectively), along with a
sustained decrease in RER in both strains to a level consistent with primarily fat metabolism
(Fig. 4C). During this fasting period, Rgs2-/- mice consumed more oxygen than WT controls
(Fig. 4A) indicating a greater metabolic rate. Upon food reintroduction, Rgs2-/- animals shifted
from fat metabolism back towards almost complete carbohydrate metabolism (as indicated by
RER) more rapidly than their WT counterparts (Fig. 4C), with significant difference between
VO2 , VCO 2 and energy expenditure (Fig. 4A, B, and D).
The rapid increases in VO2, VCO2, RER, energy expenditure (heat), as well as food and water
intake that were observed in our chronic diet restriction Rgs2-/- mice were less pronounced than
in our fasting study, suggesting that chronic caloric deprivation and/or prolonged and unequal
fasting times may have increased strain-related metabolic differences. Similar to our ad
libitum and chronic diet results, there was no discernable difference between genotypes
for ambulatory activity (Table 2), suggesting again that weight loss in RGS2
knockout mice is due to internal energy metabolism rather than overt physical activity. Taken
together, these findings collectively suggest that Rgs2-/- plays an important role in the
regulation of basal metabolism and energy expenditure.

155

A

B

Figure 5.1. Ad libitum diet, indirect calorimetry, VO2 and VCO2
Indirect calorimetry was performed in 1 month, 3 month, and 12 month old mice to measure
(A) VO2, and (B) VCO2. White and black bars under time course tracings denote 12 h light
and dark cycles, respectively. Bar graphs below time course tracings represent average 12 h
light/dark cycles for WT and KO mice. Data represent means ± SEM, n=4, 7-8, and 7 for in 1
month, 3 month, and 12 month old animals, respectively. Data within each graph were
analyzed using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons,
*P<0.05 and **P<0.01.
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A

B

Figure 5.2. Ad libitum diet, indirect calorimetry, RER and heat
Indirect calorimetry was performed in 1 month, 3 month, and 12 month old mice to measure
(A) energy expenditure (heat). (B) RER was calculated from VCO2/VO2. White and black bars
under time course tracings denote 12 h light and dark cycles, respectively. Bar graphs below
time course tracings represent average 12 h light/dark cycles for WT and KO mice. Data
represent means ± SEM, n=4, 7-8, and 7 for in 1 month, 3 month, and 12 month old animals,
respectively. Data within each graph were analyzed using two-way ANOVA with Bonferroni’s
post hoc test for multiple comparisons, *P<0.05 and **P<0.01.
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A

B

Figure 5.3. Ad libitum diet, food and water intake
(A) Food and (B) water intake were measured simultaneously with indirect calorimetry in
CLAMS cages. White and black bars under time course tracings denote 12 h light and dark
cycles, respectively. Bar graphs below time course tracings represent average 12h light/dark
cycles for WT and KO mice. Data represent means ± SEM, n=4, 7-8, and 7 for in 1 month, 3
month, and 12 month old animals, respectively. Data within each graph were analyzed using
two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons, *P<0.05 and
**P<0.01.
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Table 5.2. Ambulatory activity and body weights, ad libitum diet
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Table 5.3. Ambulatory activity and body weights, chronic and fasting diets

WT

rgs2 -/-

4

4

30% restriction:
n
BWT (g)

26.0 ± 0.9

18.8± 0.7***

Light activity (counts x

103 )

9.9 ± 2.1

13.9± 0.3

Dark activity (counts x

103 )

22.1 ± 2.6

17.2 ± 3.1

16hr fast:
n

11

11

BWT (g)

26.8 ± 1.0

23.5 ± 0.9*

16hr fast activity (counts x 103 )

38.3 ± 1.5

45.8 ± 8.6

16hr post fast activity (counts x 103 )
16.7 ± 0.4**
19.9 ± 2.7**
Abbreviations: BWT, body weight. Ambulatory activity represents combined counts from x and y
axes. Data represent means ± s.e.m. Body weights were compared using Student’s t-test.
Ambulatory activities were compared using two-way ANOVA with Bonferroni’s post hoc test for
multiple comparisons, dark vs. light cycle within genotypes and 16 h fast vs. 16 h post-fast within
genotypes,**P<0.05, **P<0.01 and ***P<0.001.
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B

C

D

Figure 5.4. Chronic diet restriction, indirect calorimetry
3 month old male Rgs2-/- and WT mice were subjected to 30% chronic diet restriction
following 2 weeks each of 10% and 20% restriction. Indirect calorimetry was performed to
measure (A) VO2, (B) VCO2, and (D) energy expenditure (heat), which were normalized to
body weight. (C) RER was calculated from VCO2/VO2. White and black bars under time
course tracings denote 12 h light and dark cycles, respectively. Bar graphs below time course
tracings represent average 12 h light/dark cycles for WT and KO mice. Data represent means
± SEM, n=4 per group. Data in individual graphs were analyzed using two-way ANOVA with
Bonferroni’s post hoc test for multiple comparisons, *P<0.05, **P<0.01 and ***P<0.001.
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A

B

C

D

Figure 5.5. Chronic diet restriction
(A) Food and (B) water intake were measured simultaneously with indirect calorimetry in
CLAMS cages. (C) Body weights were recorded weekly to monitor effects of 10%, 20% and
30% caloric restriction. (D) Glucose levels under 30% caloric restriction were recorded
immediately prior and 15 min, 30 min, 1 h, 2 h, and 3 h post-feeding. White and black bars
under time course tracings denote 12 h light and dark cycles, respectively. Bar graphs below
time course tracings represent average 12 h light/dark cycles for WT and KO mice. Data
represent means ± SEM, n=4 per group. Data in individual graphs were analyzed using twoway ANOVA with Bonferroni’s post hoc test for multiple comparisons, *P<0.05, **P<0.01
and ***P<0.001.
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A

B

Figure 5.6. Acute 16 h fast, indirect calorimetry
3 month old male Rgs2-/- and WT mice were subjected to a 16 h fast followed by reintroduction
of ad libitum diet. Indirect calorimetry was performed to measure (A) VO2 and (B) VCO2.
White and black bars under time course tracings denote 12 h light and dark cycles, respectively.
Bar graphs below time course tracings represent average 12h light/dark cycles for WT and KO
mice. Data represent means ± SEM, n=11 per group. Data within each graph were analyzed
using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons, *P<0.05,
**P<0.01 and ***P<0.001.
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A

B

Figure 5.7. Acute 16 h fast, indirect calorimetry
(A) energy expenditure (heat), was normalized to body weight, and (B) RER was calculated
from VCO2/VO2. White and black bars under time course tracings denote 12 h light and dark
cycles, respectively. Bar graphs below time course tracings represent average 12h light/dark
cycles for WT and KO mice. Data represent means ± SEM, n=11 per group. Data within each
graph were analyzed using two-way ANOVA with Bonferroni’s post hoc test for multiple
comparisons, *P<0.05, **P<0.01 and ***P<0.001.
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A

B

Figure 5.8. 16 h fast, food and water intake
(A) Food and (B) water intake were measured simultaneously with indirect calorimetry in
CLAMS cages, and normalized to body weight. White and black bars under time course
tracings denote 12 h light and dark cycles, respectively. Bar graphs below time course tracings
represent average 12h light/dark cycles for WT and KO mice. Data represent means ± SEM,
n=11 per group. Data within each graph were analyzed using two-way ANOVA with
Bonferroni’s post hoc test for multiple comparisons, *P<0.05, **P<0.01 and ***P<0.001.
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5.3.4

Altered expression of metabolic genes in Rgs2-/- mice

Genes involved with calcium signalling and metabolism were examined in gastrocnemius
tissue to determine potential differences in expression between Rgs2-/- and WT mice on an ad
libitum diet. Metabolic genes to analyze with qPCR were chosen based on reviews of the
current literature involving skeletal tissue metabolism (Salvatore et al., 2013), and purported
expression changes from the performed microarray. A majority of genes reported to be
significantly different or unchanged in the micro array could not be validated by qPCR (Suppl.
Table C2); thus, microarray data has not been included in the results or discussion in this
chapter, but can be viewed (along with PANTHER analysis of biological and cellular
processes) in the Appendix (Suppl. Table C2, Suppl. Fig. C2 and C3).
Following qPCR of selected genes, ryanodine1 (ryr1), glycogen phosphorylase (pygm), and
glucose transporter 4 (Glut4/Slc2a4) gene expression were all significantly increased in Rgs2/-

mice compared to WTs (Fig. 5.9B, E, and F). Furthermore, deiodinase type 2 (Dio2)

expression was significantly enhanced in Rgs2-/- mice (Fig. 5.10A). Gene expression for serca1
(Atp2a1), hexokinase 2 (Hk2), citrate synthase (Cs), thyroid hormone receptor alpha (Thra),
thyroid hormone-specific transporter MCT8 (Slc16a2), ATP synthase subunit F(0) complex
subunit C1 (Atp5g1), mitochondrial uncoupling protein 3 (Ucp3), β1 and β2-adrenergic
receptors, and adenylyl cyclase 2 and 5 were not found to be significantly altered in Rgs2-/mice compared to WT animals (Fig. 5.9, 5.10, and 5.11).
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Figure 5.9. Gene expression, calcium signalling and metabolic markers
(A) Serca2a (Atp2a1), (B) ryanodine receptor type 1 (Ryr1), (C) citrate synthase (Cs), (D)
hexokinase II (Hk2), (E) glycogen phosphorylase (Pygm), and (F) glut-4 (Slc2a4) gene
expression was assessed by qPCR in gastrocnemius tissue of Rgs2-/- and WT mice. Data
represent means ± SEM, n=4-6 per group. Data were analyzed by Student’s t-test, *P<0.05.
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Figure 5.10. Gene expression, metabolic markers
(A) Deiodinase type 2 (Dio2), (B) thyroid hormone receptor alpha (Thra) and (C) thyroid
hormone-specific transporter MCT8 (Slc16a2), (D) ATP synthase subunit F (0) complex
subunit C1 (Atp5g1), and (E) mitochondrial uncoupling protein 3 (Ucp3) gene expression was
assessed by qPCR in gastrocnemius tissue of Rgs2-/- and WT mice. Data represent means ±
SEM, n=4-6 per group. Data were analyzed by Student’s t-test, *P<0.05.
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Figure 5.11. GPCR-related gene expression
(A) beta-1 adrenergic receptor (Adrb1), (B) beta 2 adrenergic receptor (Adrb2), (C) adenylyl
cyclase 2 (Adcy2), and D) adenylyl cyclase 5 (Adcy5) gene expression was assessed by qPCR
in gastrocnemius tissue of Rgs2-/- and WT mice. Data represent means ± SEM, n=4-6 per
group. Data were analyzed by Student’s t-test.
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Discussion
The present study expands on our previous work, in which we found Rgs2-/- mice to be resistant
to normal, age-related weight gain (Nunn et al., 2011). This observed decrease in body weight
was also accompanied by increased insulin sensitivity, smaller adipocytes, decreased adipose
tissue deposits, and lower levels of serum lipids. In addition, nutrient absorption was
comparable to WT controls (Nunn et al., 2011). We were previously unable to reconcile
obvious changes in lipid metabolism and body weight with measured metabolic rates; using
the more sensitive CLAMS cages, we demonstrate in this study that metabolic rates as
measured by indirect calorimetry are increased in Rgs2-/- mice. These effects are further
enhanced by both chronic and acute diet restrictions, and also suggest that Rgs2-/- mice may
have enhanced carbohydrate metabolism. To our knowledge, we are the first group to report a
metabolic phenotype in Rgs2-/- mice.
Our ad libitum studies demonstrate that basal metabolic indices in 3 month and 12 month old
Rgs2-/- mice were elevated compared to WT controls. A lack of observable differences in VO2,
VCO2, and energy expenditure at the 1 month time point may be age related; at this stage, both
WT and Rgs2-/- animals are still in a rapid growth phase (Somerville et al., 2004), which could
obscure the slight differences seen in the older age groups. When viewed collectively over
time, VO2 and VCO2 values do fall with increasing age (Figure 1A and B), which is expected
as body metabolism slows (LeBrasseur et al., 2009). However, Rgs2-/- mice consistently
displayed higher VO2 and VCO2 levels compared to WT controls (Fig. 1A and B). Since
changes in the 2-5% range can induce significant long term alterations in energy balance (Even
and Nadkarni, 2012), the small, but sustained elevations in VO2 and VCO2, particularly during
dark cycles, may contribute to the observed lean phenotype.
In our previous studies, we determined that although Rgs2-/- mice had reduced fat stores and
smaller adipocytes, they were not resistant to high fat diet-induced obesity, and developed
insulin resistance to a similar degree as WT mice (Nunn et al., 2011). This suggested that Rgs2/-

mice do not have major impairments with respect to their ability to accumulate adipose tissue,

and that alterations to carbohydrate or protein rather than fat metabolism could be additional
factors in the development of the lean phenotype. Since our ad libitum RER calculations
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suggested that carbohydrate metabolism was slightly increased in Rgs2-/- mice (Fig. 1C), we
challenged adult, 3 month-old animals to a chronic 30% diet restriction to further evaluate
metabolic parameters. Both strains did not lose substantial body weight (Fig. 3G); final body
weights after two weeks of 30% diet restriction (which was also preceded by two weeks each
of 10% and 20% restrictions) were approximately 3% and 6% higher in Rgs2-/- and WT controls
compared to initial starting ad libitum body weights, respectively. Although this suggested that
a 30% restriction can be handled by both strains, and that ad libitum diet well exceeds
necessary caloric requirements, Rgs2-/- feeding behaviour rapidly changed on the restricted
diet, such that hyperphagia was exacerbated to such an extent that feeding and fasting times
were significantly altered compared to control mice. RER recordings indicated that upon food
consumption, KO mice quickly reached an almost full carbohydrate metabolizing state (RER
around 1.0) versus WT mice who continued to demonstrate some fat metabolism (RER around
0.9) (Fig. 3C). Even though increased fasting length due to rapid food consumption may have
affected indirect calorimetry readings, the differences between strains is still a relevant
observation. VO2, VCO2, RER, and energy expenditure (heat) parameters rapidly increased
and were sustained at elevated levels for several hours during and after food consumption;
these rapid shifts in metabolism were not observed in WT controls (Fig. 3A, B, C, and D).
To rule out potential confounding effects of the unexpected strain-related difference in food
consumption patterns in our chronic restriction studies, food intake was controlled via 16 hour
acute fasting studies (Fig. 4). Overall, strain-related differences were of a similar nature under
both caloric restriction protocols, albeit less pronounced under acute conditions. Indirect
calorimetry recordings during the acute fasting period furthermore suggested a delay in the
ability of Rgs2-/- mice to lower their metabolism (for energy conservation) compared to WT
animals. Conversely, it appears that Rgs2-/- mice are able to shift to carbohydrate metabolism
in the presence of food at a faster rate than WT mice, as evidenced by higher RERs (Fig. 4C),
although it is possible that due to their decreased adiposity, increased carbohydrate metabolism
is a compensatory, rather than causative response of the observed lean phenotype (Sun et al.,
2012).
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Since physical activity was found to be similar across strains, our metabolic parameters across
multiple diet modalities suggest that decreased body weights in Rgs2-/- mice arise instead from
internal metabolism. qPCR analysis of gastrocnemius tissue suggests that several
metabolically-relevant genes may be altered in Rgs2-/- compared to WT mice. Skeletal
ryanodine receptor type 1 (Ryr1) mediates calcium release; as the main ion channel in the
sarcoplasmic reticulum, it is a key determinant of muscle force (Beard, Wei and Dulhunty,
2009). Cells overexpressing Ryr1 have been shown to have higher mitochondrial ATP
concentrations, as well as increased ATP production in response to cytosolic Ca2+ elevations.
Thus, the observed increases in Ryr1 gene expression in Rgs2-/- mice could indicate increased
levels of ATP production, and indirectly suggest increased ATP utilization in skeletal tissue,
which could contribute to the lean phenotype. In addition, increased Rgs2-/- gene expression of
glycogen phosphorylase (Pygm) (the rate-limiting enzyme of glycogenolysis) (Fig. 5.9D)
correlates with previous studies which have demonstrated that cultured human muscle cells
overexpressing glycogen phosphorylase display increased glucose transporter (GLUT-4)
(slc2a4) expression with no changes in hexokinase II (the rate limiting enzyme in glycolysis)
(Baqué et al., 1998), expression patterns which we also observed in Rgs2-/- mice compared to
WT controls (Fig. 5.9C and E).
Changes in Dio2 gene expression also suggest increased metabolism in Rgs2-/- mice (Fig.
5.10A). Since DIO2 catalyzes the conversion of the inactive prohormone thyroxine (3,5,3',5'tetraiodothyronine, T4) to the active thyroid hormone (3,5,3'-triiodothyronine, T3) (Gereben
et al., 2008; Arrojo e Drigo et al., 2013), it would follow that local cellular production of T3
could increase due to elevated levels of DIO2. Thyroid hormone plays a major role in energy
expenditure and glucose homeostasis; thyroid hormone signalling can modulate metabolic rate
by either uncoupling the ATP synthesis in the mitochondria or decreasing the metabolic
efficiency of skeletal muscle (Salvatore et al., 2013), effectively “wasting” energy as dissipated
heat (de Lange et al., 2001; Silva, 2006). In addition, GLUT-4 expression (and therefore
glucose uptake in cells) is T3 dependent; in conjunction, GLUT-4 translocation to the cell
surface is an insulin-dependent event, and normal muscle responsiveness to insulin has been
shown to require the DIO2-mediated conversion of T4 to T3 (Mills et al., 1987; Zorzano,
Palacin and Guma, 2005; Grozovsky et al., 2009). Altogether, the observed increases in gene
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expression for Ryr1, Pygm, Slc2a4 (GLUT-4), and Dio2 suggest that both glucose metabolism
and resting metabolic rate may be altered in Rgs2-/- mice compared to WT animals.
Although the exact mechanisms behind the lean phenotype are yet to be determined, RGS2 has
been shown to have various effects on energy storage and usage; in vitro studies have
demonstrated the role of RGS2 in mediating GIP (glucose-dependent insulinotropic
polypetide)-induced insulin release from pancreatic β cells (Tseng and Zhang, 1998), as well
as GLUT-4 (insulin-responsive glucose transporter) translocation in adipocytes (Imamura et
al., 1999). Thus, RGS2 may be involved in glucose entrance in adipocytes. RGS2 is also
transiently and rapidly upregulated in differentiating mouse preadipocyte cells, and appears to
promote the differentiation of adipocytes and expression of adipogenic markers (Imagawa,
Tsuchiya and Nishihara, 1999; Nishizuka et al., 2001). Other energy-dependent processes
affected by RGS2 include the regulation of protein synthesis (Nguyen et al., 2009; Chidiac et
al., 2014), as well as ATP hydrolysis by PMCA (plasma membrane Ca2+ ATPase) and SERCA
(sarco/endoplasmic reticulum Ca2+) pumps (Wang et al., 2004). Human polymorphisms which
result in the over or under expression of RGS2 have demonstrated the clinical relevance of
RGS2 in the context of metabolism. A common polymorphism in the 3’ untranslated region of
RGS2 has been shown to decrease RGS2 expression, has been associated with hypertension,
and is considered to be a genetic marker that can predict male predisposition to weight gain
and obesity (Sartori et al., 2008). Conversely, a C to G substitution in the RGS2 promoter
region has been shown to increase RGS2 expression in adipocytes and is associated with the
metabolic syndrome (Freson et al., 2007). Altogether, our current findings suggest an
important role for RGS2 in weight regulation and body metabolism.

Conclusions
Using simultaneous measurements of indirect calorimetry and activity, we have demonstrated
increased metabolism in Rgs2-/- mice compared to WT controls in both ad libitum and diet
restriction studies. Obesity is a common, costly, and serious disease, with more than 2/3 of US
adults considered to be overweight or obese (Flegal et al., 2012). This growing epidemic makes
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the study of potential regulators of metabolic signaling both timely and necessary. Given that
increased RGS2 expression may be involved in obesity and metabolic disease in humans, and
our findings that a lack of RGS2 leads to decreased body weight and improved metabolic
profiles, RGS2 may be an important target for the future development of anti-obesity strategies.

174

References
Abramow-Newerly, M., Roy, A. A., Nunn, C. and Chidiac, P. (2006) ‘RGS proteins have a
signalling complex: Interactions between RGS proteins and GPCRs, effectors, and auxiliary
proteins’, Cell. Signal., 18(5), pp. 579–591.
Anger, T., Klintworth, N., Stumpf, C., Daniel, W. G., Mende, U. and Garlichs, C. D. (2007)
‘RGS protein specificity towards Gq- and Gi/o-mediated ERK 1/2 and Akt activation, in
vitro.’, J. Biochem. Mol. Biol., 40(6), pp. 899–910.
Arrojo e Drigo, R., Fonseca, T. L., Werneck-de-Castro, J. P. S. and Bianco, A. C. (2013) ‘Role
of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling’,
Biochim. Biophys. Acta - Gen. Subj., 1830(7), pp. 3956–3964.
Baqué, S., Montell, E., Camps, M., Guinovart, J. J., Zorzano, A. and Gòmez-Foix, A. M.
(1998) ‘Overexpression of Glycogen Phosphorylase Increases GLUT4 Expression and
Glucose Transport in Cultured Skeletal Human Muscle’, Diabetes, 47(8).
Beard, N. A., Wei, L. and Dulhunty, A. F. (2009) ‘Control of muscle ryanodine receptor
calcium release channels by proteins in the sarcoplasmic reticulum lumen: Proceedings of the
australian physiological society symposium: EC coupling and fatigue’, in Clin. Exp.
Pharmacol. Physiol., pp. 340–345.
Chakir, K., Zhu, W., Tsang, S., Woo, A. Y. H., Yang, D., Wang, X., Zeng, X., Rhee, M. H.,
Mende, U., Koitabashi, N., Takimoto, E., Blumer, K. J., Lakatta, E. G., Kass, D. A. and Xiao,
R. P. (2011) ‘RGS2 is a primary terminator of β2-adrenergic receptor-mediated Gi signaling’,
J. Mol. Cell. Cardiol., 50(6), pp. 1000–1007.
Cheng, Y.-S., Lee, T.-S., Hsu, H.-C., Kou, Y. R. and Wu, Y.-L. (2008) ‘Characterization of
the transcriptional regulation of the regulator of G protein signaling 2 (RGS2) gene during
3T3-L1 preadipocyte differentiation’, J. Cell. Biochem. Wiley Subscription Services, Inc., A
Wiley Company, 105(3), pp. 922–930.

175

Chidiac, P., Sobiesiak, A. J., Lee, K. N., Gros, R. and Nguyen, C. H. (2014) ‘The eIF2Binteracting domain of RGS2 protects against GPCR agonist-induced hypertrophy in neonatal
rat cardiomyocytes’, Cell. Signal., 26(6), pp. 1226–1234.
Eszlinger, M., Holzapfel, H.-P., Voigt, C., Arkenau, C. and Paschke, R. (2004) ‘RGS 2
expression is regulated by TSH and inhibits TSH receptor signaling’, Eur. J. Endocrinol.,
151(3), pp. 383–390.
Even, P. C. and Nadkarni, N. A. (2012) ‘Indirect calorimetry in laboratory mice and rats:
principles, practical considerations, interpretation and perspectives’, Am. J. Physiol. - Regul.
Integr. Comp. Physiol., 303(5), pp. R459–R476.
Faulks, S. C., Turner, N., Else, P. L. and Hulbert, A. J. (2006) ‘Calorie restriction in mice:
Effects on body composition, daily activity, metabolic rate, mitochondrial reactive oxygen
species production, and membrane fatty acid composition’, Journals Gerontol. Ser. ABiological Sci. Med. Sci., 61(8), pp. 781–794.
Flegal, K. M., Carroll, M. D., Kit, B. K. and Ogden, C. L. (2012) ‘Prevalence of obesity and
trends in the distribution of body mass index among US adults, 1999-2010’, JAMA, 307(5), p.
491.
Freson, K., Stolarz, K., Aerts, R., Brand, E., Brand-Herrmann, S.-M., Kawecka-Jaszcz, K.,
Kuznetsova, T., Tikhonoff, V., Thijs, L., Vermylen, J., Staessen, J. A. and Van Geet, C. (2007)
‘−391 C to G substitution in the regulator of G-protein signalling-2 promoter increases
susceptibility to the metabolic syndrome in white European men: consistency between
molecular and epidemiological studies’, J. Hypertens., 25(1), pp. 117–125.
Gereben, B., Zavacki, A. M., Ribich, S., Kim, B. W., Huang, S. A., Simonides, W. S., Zeöld,
A. and Bianco, A. C. (2008) ‘Cellular and molecular basis of deiodinase-regulated thyroid
hormone signaling’, Endocr. Rev. William Heinemann, London, pp. 898–938.
Grozovsky, R., Ribich, S., Rosene, M. L., Mulcahey, M. A., Huang, S. A., Patti, M. E., Bianco,
A. C. and Kim, B. W. (2009) ‘Type 2 Deiodinase Expression Is Induced by Peroxisomal
176

Proliferator-Activated Receptor-γ Agonists in Skeletal Myocytes’, Endocrinology, 150(4), pp.
1976–1983.
Guzman, M. S., De Jaeger, X., Drangova, M., Prado, M. A. M., Gros, R. and Prado, V. F.
(2013) ‘Mice with selective elimination of striatal acetylcholine release are lean, show altered
energy homeostasis and changed sleep/wake cycle’, J. Neurochem., 124(5), pp. 658–669.
Heo, K., Ha, S. H., Chae, Y. C., Lee, S., Oh, Y.-S., Kim, Y.-H., Kim, S.-H., Kim, J. H.,
Mizoguchi, A., Itoh, T. J., Kwon, H. M., Ryu, S. H. and Suh, P.-G. (2006) ‘RGS2 promotes
formation of neurites by stimulating microtubule polymerization’, Cell. Signal., 18(12), pp.
2182–2192.
Heximer, S. P., Knutsen, R. H., Sun, X., Kaltenbronn, K. M., Rhee, M.-H., Peng, N., Oliveirados-Santos, A., Penninger, J. M., Muslin, A. J., Steinberg, T. H., Wyss, J. M., Mecham, R. P.
and Blumer, K. J. (2003) ‘Hypertension and prolonged vasoconstrictor signaling in RGS2deficient mice’, J. Clin. Invest., 111(4), pp. 445–452.
Heximer, S. P., Srinivasa, S. P., Bernstein, S., Bernard, J. L., Maurine, E., Hepler, J. R.,
Blumer, K. J., Bernstein, L. S. and Linder, M. E. (1999) ‘G protein selectivity is a determinant
of RGS2 function’, J. Biol. Chem., 274(48), pp. 34253–34259.
Imagawa, M., Tsuchiya, T. and Nishihara, T. (1999) ‘Identification of inducible genes at the
early stage of adipocyte differentiation of 3T3-L1 Cells’, Biochem. Biophys. Res. Commun.,
254(2), pp. 299–305.
Imamura, T., Vollenweider, P., Egawa, K., Clodi, M., Ishibashi, K., Nakashima, N., Ugi, S.,
Adams, J. W., Brown, J. H. and Olefsky, J. M. (1999) ‘G Alpha-q/11 protein plays a key role
in insulin-induced glucose transport in 3T3-L1 adipocytes’, Mol. Cell. Biol., 19(10), pp. 6765–
6774.
Kibbe, W. A. (2007) ‘OligoCalc: an online oligonucleotide properties calculator.’, Nucleic
Acids Res., 35(Web Server issue), pp. W43-6.
de Lange, P., Lanni, A., Beneduce, L., Moreno, M., Lombardi, A., Silvestri, E. and Goglia, F.
177

(2001) ‘Uncoupling Protein-3 Is a Molecular Determinant for the Regulation of Resting
Metabolic Rate by Thyroid Hormone’, Endocrinology, 142(8), pp. 3414–3420.
LeBrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P. M. and Brown,
T. A. (2009) ‘Myostatin inhibition enhances the effects of exercise on performance and
metabolic outcomes in aged mice’, Journals Gerontol. - Ser. A Biol. Sci. Med. Sci., 64(9), pp.
940–948.
Mi, H., Muruganujan, A., Casagrande, J. T. and Thomas, P. D. (2013) ‘Large-scale gene
function analysis with the PANTHER classification system’, Nat. Protoc. Nature Research,
8(8), pp. 1551–1566.
Mills, I., Barge, R. M., Silva, J. E. and Larsen, P. R. (1987) ‘Insulin stimulation of
iodothyronine 5′-deiodinase in rat brown adipocytes’, Biochem. Biophys. Res. Commun.,
143(1), pp. 81–86.
Nguyen, C. H., Ming, H., Zhao, P., Hugendubler, L., Gros, R., Kimball, S. R. and Chidiac, P.
(2009) ‘Translational control by RGS2’, J. Cell Biol., 186(5), pp. 755–765.
Nishizuka, M., Honda, K., Tsuchiya, T., Nishihara, T. and Imagawa, M. (2001) ‘RGS2
promotes adipocyte differentiation in the presence of ligand for peroxisome proliferatoractivated receptor γ’, J. Biol. Chem. American Society for Biochemistry and Molecular
Biology, 276(32), pp. 29625–29627.
Nunn, C., Zhao, P., Zou, M.-X., Summers, K., Guglielmo, C. G. and Chidiac, P. (2011)
‘Resistance to age-related, normal body weight gain in RGS2 deficient mice’, Cell. Signal.,
23(8), pp. 1375–1386.
Oliveira-Dos-Santos, A. J., Matsumoto, G., Snow, B. E., Bai, D., Houston, F. P., Whishaw, I.
Q., Mariathasan, S., Sasaki, T., Wakeham, A., Ohashi, P. S., Roder, J. C., Barnes, C. A.,
Siderovski, D. P. and Penninger, J. M. (2000) ‘Regulation of T cell activation, anxiety, and
male aggression by RGS2.’, Proc. Natl. Acad. Sci. U. S. A., 97(22), pp. 12272–7.
Popov, S., Yu, K., Kozasa, T. and Wilkie, T. M. (1997) ‘The regulators of G protein signaling
178

(RGS) domains of RGS4, RGS10, and GAIP retain GTPase activating protein activity in
vitro.’, Proc. Natl. Acad. Sci. U. S. A., 94(14), pp. 7216–20.
Ratneswaran, A., Sun, M. M.-G., Dupuis, H., Sawyez, C., Borradaile, N. and Beier, F. (2017)
‘Nuclear receptors regulate lipid metabolism and oxidative stress markers in chondrocytes’, J.
Mol. Med. Springer Berlin Heidelberg, pp. 1–14.
Richardson, H. B. (1929) ‘The respiratory quotient’, Physiol. Rev., 9(1), pp. 61–125.
Ross, E. M. and Wilkie, T. M. (2000) ‘GTPase-activating proteins for heterotrimeric G
proteins: Regulators of G protein signaling (RGS) and RGS-like proteins’, Annu Rev Biochem,
69(1), pp. 795–827.
Roy, A. A., Nunn, C., Ming, H., Zou, M.-X. X., Penninger, J., Kirshenbaum, L. A., Dixon, S.
J. and Chidiac, P. (2006) ‘Up-regulation of endogenous RGS2 mediates cross-desensitization
between Gs and Gq signaling in osteoblasts.’, J. Biol. Chem., 281(43), pp. 32684–93.
Salvatore, D., Larsen, P. R., Salvatore, D., Simonides, W. S., Dentice, M., Zavacki, A. M. and
Larsen, P. R. (2013) ‘Thyroid hormones and skeletal muscle —new insights and potential
implications’, Nat. Rev. Endocrinol, 10, pp. 206–214.
Sartori, M., Ceolotto, G., Dorigatti, F., Mos, L., Santonastaso, M., Bratti, P., Papparella, I.,
Semplicini, A., Palatini, P. and HARVEST Group (2008) ‘RGS2 C1114G polymorphism and
body weight gain in hypertensive patients’, 57(3), pp. 421–427.
Schoeber, J. P., Topala, C. N., Wang, X., Diepens, R. J., Lambers, T. T., Hoenderop, J. G. and
Bindels, R. J. (2006) ‘RGS2 inhibits the epithelial Ca 2+ channel TRPV6’, J. Biol. Chem.,
281(40), pp. 29669–29674.
Silva, J. E. (2006) ‘Thermogenic Mechanisms and Their Hormonal Regulation’, Physiol. Rev.,
86(2), pp. 435–464.
Somerville, J. M., Aspden, R. M., Armour, K. E., Armour, K. J. and Reid, D. M. (2004)
‘Growth of C57Bl/6 mice and the material and mechanical properties of cortical bone from the
179

tibia’, Calcif. Tissue Int., 74(5), pp. 469–475.
Sun, C., Tian, L., Nie, J., Zhang, H., Han, X. and Shi, Y. (2012) ‘Inactivation of MARK4, an
AMP-activated protein kinase (AMPK)-related kinase, leads to insulin Hypersensitivity and
resistance to diet-induced obesity’, J. Biol. Chem., 287(45), pp. 38305–38315.
Tseng, C. C. and Zhang, X. Y. (1998) ‘Role of regulator of G protein signaling in
desensitization of the glucose-dependent insulinotropic peptide receptor.’, Endocrinology.
Oxford University Press, 139(11), pp. 4470–5.
Wang, X., Huang, G., Luo, X., Penninger, J. M. and Muallem, S. (2004) ‘Role of regulator of
G protein signaling 2 (RGS2) in Ca(2+) oscillations and adaptation of Ca(2+) signaling to
reduce excitability of RGS2-/- cells’, J. Biol. Chem. American Society for Biochemistry and
Molecular Biology, 279(40), pp. 41642–41649.
Wang, X., Zeng, W., Soyombo, A. A., Tang, W., Ross, E. M., Barnes, A. P., Milgram, S. L.,
Penninger, J. M., Allen, P. B., Greengard, P. and Muallem, S. (2005) ‘Spinophilin regulates
Ca2+ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of
G-protein-coupled receptors’, Nat. Cell Biol., 7(4), pp. 405–411.
Weindruch, R., Walford, R. L., Fligiel, S. and Guthrie, D. (1986) ‘The retardation of aging in
mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake.’, J. Nutr.,
116(4), pp. 641–654.
Zorzano, A., Palacin, M. and Guma, A. (2005) ‘Mechanisms regulating GLUT4 glucose
transporter expression and glucose transport in skeletal muscle’, Acta Physiol. Scand., 183(1),
pp. 43–58.

180

6

DISCUSSION AND CONCLUSIONS

181

Summary and Discussion
6.1.1

Chapter 3 – Cardiomyocyte specific overexpression of a 37
amino acid domain of RGS2 inhibits cardiac hypertrophy and
improves function in response to pressure overload in mice

Cardiac hypertrophy is a known risk factor for cardiovascular diseases such as heart failure,
and involves de novo protein synthesis in the post-mitotic cardiomyocyte population of the
heart (Anversa et al. 2007; Carvalho 2010). RGS2 has been well established as an inhibitor of
cardiomyocyte hypertrophy via its inhibitory effects on Gq and Gs-mediated signalling (Roy et
al. 2006; Zou et al. 2006; Nunn et al. 2010; Zhang et al. 2011). We have previously reported
that RGS2 can also inhibit protein synthesis through a 37 amino acid domain within its RGS
domain (Nguyen et al. 2009), which we have termed RGS2eb. We observed these effects in
both cell lines and cultured neonatal cardiomyocytes (Chidiac et al. 2014; Nguyen et al. 2009),
and thus hypothesized that the cardiomyocyte-specific overexpression of RGS2eb could result
in the in vivo inhibition of protein synthesis, and potentially offer protection against the
development of hypertrophy in an experimental model of pressure overload. The aim of the
studies described in Chapter 3 of this thesis was to determine the extent of cardiac hypertrophy
in transgenic RGS2eb (RGS2eb TG) mice compared to WT sham and transverse aortic
constriction (TAC) animals, and whether there were associated benefits to cardiovascular
function.
Following 28 days of TAC, mice with cardiomyocyte specific overexpression of RGS2eb were
resistant to the development of significant cardiac hypertrophy compared to WT TAC mice.
At the cellular level, measurements of cardiomyocyte cross-sectional area showed a
corresponding increase in cell size for WT but not RGS2eb TG mice after TAC. In addition,
systolic and diastolic indices of cardiac function via pressure-volume loop analyses suggested
that RGS2eb TG animals were able to maintain significantly improved cardiac function
following TAC compared to WT animals. Furthermore, the expression of the “fetal” genes βMHC and ANP, which are often upregulated during conditions of hypertrophy and heart
failure, was completely abrogated in RGS2eb TG compared to WT TAC mice. These results
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are consistent with our overall hypothesis that expression of the eIF2B-interacting domain of
RGS2, RGS2eb, can protect against pathological cardiac hypertrophy and dysfunction in vivo,
and that this may be via the direct inhibition of protein synthesis. Along with our previous
studies, which showed the ability of RGS2eb to inhibit drug-induced cardiomyocyte
hypertrophy, our current findings suggest that the RGS2eb region is an important contributor to
the reported beneficial cardiac effects of RGS2.

6.1.2

Chapter 4 – Effects of transverse aortic constriction and drug
induced experimental pressure overload hypertrophy on Rgs2-/mice with cardiomyocyte specific overexpression of RGS2eb

The aim of Chapter 4 was to explore whether the cardioprotective effects of RGS2 eb that we
observed in Chapter 3 could be extended to an Rgs2-/- model of experimentally-induced cardiac
hypertrophy. Rgs2-/- mice are highly sensitive to TAC-induced cardiac hypertrophy and heart
failure (Takimoto et al. 2009), and have been shown to have mild to moderate levels of
hypertension (Oliveira-Dos-Santos et al. 2000; Heximer et al. 2003). The use of Rgs2-/- mice
could provide further clarity into the cardioprotective role of the RGS2eb region, endogenous
RGS2 was still present in the Rgs2+/+(eb) mice from our earlier studies (Lee et al. 2017). Based
on our observations in Chapter 3, we hypothesized that the cardiomyocyte specific expression
of RGS2eb in Rgs2-/- mice (Rgs2-/-(eb)) could potentially decrease the severity of cardiac
hypertrophy and heart failure resulting from experimentally induced pressure overload, thereby
compensating for the absence of full-length RGS2.
For our Chapter 4 studies, we generated novel transgenic Rgs2-/- mice with cardiomyocyte
specific overexpression of RGS2eb (Rgs2-/-(eb)). However, when we initially began our TAC
studies with Rgs2-/- and WT mice, we found that the mortality rate for Rgs2-/- animals
significantly exceeded that of WT controls following TAC surgery, suggesting an impaired
ability to recover from cardiovascular insult. Due to the unexpectedly high mortality rate of
Rgs2-/ - mice, the TAC model was determined to be unsuitable for the evaluation of cardiac
hypertrophy, and was discontinued before the addition of Rgs2-/-(eb)mice to the study. We thus
proceeded to examine the effects of drug-induced models of hypertension on Rgs2-/- mice.
Starting with an angiotensin II model of chronic agonist infusion via osmotic pumps
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(1.44mg/kg/day), we observed that although there was hypertension in our angiotensin II
treated animals, significantly detectable cardiac hypertrophy did not develop in any
experimental angiotensin II groups (WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb)) compared to saline
control mice. Further studies with angiotensin II infusion at higher concentrations (3.0
mg/kg/day for 14 days) using WT and Rgs2-/- mice also failed to induce clearly detectable
cardiac hypertrophy. Thus, we went on to perform pilot studies with twice daily injections of
isoproterenol (ISO) for 14 days; our preliminary results suggest that a full study with prolonged
injections beyond 14 days may result in cardiac hypertrophy. Such a reproducible model of
cardiac hypertrophy would then allow for the effective examination of whether the inhibitory
effects of RGS2eb on protein translation is sufficient to provide cardioprotection in a null RGS2
background.

6.1.3

Chapter 5 – Loss of RGS2 alters the effects of acute and chronic
diet restriction on metabolic outcomes in C57 BL.6 mice

Cardiovascular dysfunction, including pathological cardiac hypertrophy, is known to be
directly influenced by obesity and weight gain, which are major risk factors for cardiovascular
diseases such as coronary heart disease, atrial fibrillation, hypertension, venous
thromboembolisms, and congestive heart failure (Klein et al. 2004; Poirier et al. 2006; Tedrow
et al. 2010; Wattanakit et al. 2012). Adiposity is determined by energy expenditure versus
energy intake, and possible sources of energy imbalance in cases of obesity or weight loss
could come from the dysregulation of food intake/nutrient absorption, lipid storage, metabolic
rate, physical activity, or CNS-related changes.
Multiple GPCRs have been shown to be involved in energy metabolism, and alterations in G
protein signalling (which is regulated by RGS proteins) can lead to both lean and obese
phenotypes (Colombo et al. 1998; Nambu et al. 2011; Grillet et al. 2005; Cho et al. 2008). We
have previously reported that Rgs2-/- mice exhibit a lean phenotype, are hyperphagic, have
smaller adipose tissue deposits and adipocytes, and are ultimately resistant to age-related
weight gain (Nunn et al. 2011). In addition, comparable nutrient absorption suggested that
increased physical activity and/or metabolism could be underlying factors to the observed lean
phenotype. However, although the lean phenotype was present throughout the Rgs2-/- mouse
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lifespan on an ad libitum standard rodent diet, these animals nonetheless became obese and
insulin-resistant under high-fat diet conditions (Nunn et al. 2011), suggesting that Rgs2-/- mice
do not have a major impairment with respect to their ability to accumulate adipose. Thus, we
hypothesized that the observed lean phenotype may reflect underlying changes in energy
utilization. The aim of our studies in Chapter 4 was to understand the role of RGS2 in
metabolism and body weight regulation using CLAMS metabolic cages to simultaneously
assess indirect calorimetry parameters and ambulatory activity in freely moving age-matched
control and Rgs2-/- mice under normal and diet-restricted conditions. Analysis of ad libitum
data showed Rgs2-/- mice had significantly increased metabolism compared to WT controls,
and that these differences were exacerbated both by chronic and acute caloric restriction. Since
no changes in ambulatory activity were observed, these observations suggest that internal
metabolism, rather than overt physical activity, is the major contributor to the lean Rgs2-/phenotype. Furthermore, since skeletal muscle is a major site of metabolism (Salvatore et al.
2013) qPCR for metabolically-related genes in the gastrocnemius tissue of WT and Rgs2/--

mice suggest that both glucose metabolism and resting metabolic rate may be altered in Rgs2-

/-

mice compared to WT animals. Altogether, our current findings in combination with our

previous reports demonstrate an important role for RGS2 in the regulation of weight and body
metabolism.

Future directions
In Chapter 3, we demonstrated the cardioprotective potential of RGS2eb in an in vivo model of
cardiac hypertrophy. Currently, the majority of drugs for cardiovascular diseases target GPCRs
(Rask-Andersen, Almén, and Schiöth 2011). Although these medications can offer significant
benefits to patients, heart failure continues to be a global leading cause of morbidity and
mortality. In addition, inhibiting GPCR signalling often results in “off-target” effects due to
the broad cascade of signalling pathways that they control (Allen and Roth 2011). The
specificity of RGS2eb for the inhibition of protein synthesis at the level of translation initiation
could potentially mitigate such issues and lead to improved therapeutics. Indeed, interest in
RGS2 and other RGS proteins as possible drug targets is on the rise (Sjogren et al. 2012;
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Sjögren and Neubig 2010; Sjögren, Blazer, and Neubig 2010; Le and Coffman 2003; Go et al.
2013; Turner et al. 2012; Sjögren et al. 2016). Future steps in characterizing the potential of
RGS2eb as a cardioprotective factor could involve its direct delivery to the heart after
experimentally-induced cardiac injury in lieu of our current cardiac-specific overexpression
model, where activation of the RGS2eb transgene in the heart occurs soon after birth.
Recombinant adeno-associated viruses (rAAVs) could be a potential avenue for RGS2eb
delivery to the heart, as they are currently the most widely used vectors for safe, long-term
gene delivery and expression in the heart due to their ability to transduce post-mitotic cells
such as cardiomyocytes (Zsebo et al. 2014). rAAVs are unique among viruses used for gene
therapy in that the wild-type (AAV) virus has not been shown to cause human disease (Thomas,
Ehrhardt, and Kay 2003). In addition to their low immunogenicity, rAAVs demonstrate
efficient long-term transgene expression and low rates of insertional mutagenesis; previous
experiments using various combinations of AAV capsids (which control receptor-mediated
cellular entry) and rAAV pseudotypes have established rAAV2/1, rAAV2/6, rAAV2/8,
rAAV2/9, and rAAV2/10 as the most cardiotropic (Pacak and Byrne 2011). Multiple in vivo
studies and clinical trials lend credence to the use of rAAVs as a delivery system for RGS2eb
to the heart (Zsebo et al. 2014; Li et al. 2003; Hoshijima et al. 2002; Asfour et al. 2002; Kawase
et al. 2008; McTiernan et al. 2007), which could be explored in future studies.
In Chapter 4, the substantially lower survival rates of Rgs2-/- mice compared to WT
counterparts following TAC surgery support studies in the literature that suggest that impaired
cardiovascular function in Rgs2-/- mice may be due to enhanced susceptibility to atrial
fibrillation (Jones, Tuomi, and Chidiac 2012). Although our specific aims and hypotheses for
this chapter focused on cardiac hypertrophy and related functional effects, the observed Rgs2/-

mortality rates suggest that further exploration of this reaction to TAC surgery could prove

interesting. In terms of understanding any potential roles of RGS2eb in Rgs2-/- mice, protocol
optimization is certainly required for our studies. Although cardiac hypertrophy was not
induced in our experimental angiotensin II animals, the presence of hypertension reflected
successful infusion of the drug into agonist-treated mice. Since hypertension-induced
hypertrophy via angiotensin II is a less severe model of hypertrophy compared to TAC
surgeries, prolonged angiotensin II infusion beyond our current 28 day study design may
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clarify the timeline for cardiac hypertrophy development in our mouse strains; similar studies
would extend to our pilot isoproterenol models.
The Chapter 5 studies expand on our previous work, in which we found Rgs2-/- mice to be
resistant to normal, age-related weight gain (Nunn et al. 2011). We were previously unable to
reconcile obvious changes in lipid metabolism and body weight with measured lower
metabolic rates; using the more sensitive CLAMS cages, we demonstrate in this study that
metabolic rates as measured by indirect calorimetry are in actuality increased in Rgs2-/- mice.
These effects are further enhanced by both chronic and acute diet restrictions, and also suggest
that Rgs2-/- mice may have enhanced carbohydrate metabolism. To our knowledge, we are the
first group to report a metabolic phenotype in Rgs2-/- mice. Future studies to fully characterize
this phenotype could examine the effects of various physical activity modalities; since skeletal
muscle is one of the most metabolically active tissues, and we observed the upregulation of
several genes which regulate glucose and basal metabolism, studies using physical activity as
a variable (e.g. treadmill running) could prove interesting. Furthermore, a detailed assessment
of additional metabolic genes (perhaps via RNA-seq analysis) is warranted given the currently
observed effects of Dio2, Glut-4, Ryr1, and Pygm gene expression, and could ultimately lead
to a clearer understanding of the specific mechanisms and key GPCRs which drive the Rgs2-/lean phenotype.

Conclusions
Cardiovascular diseases and metabolic dysregulation affect millions around the world, and the
study of their underlying factors and mechanisms could lead to the identification of novel drug
targets for improved treatment. The first part of this thesis examined the cardioprotective
potential of RGS2eb, and we determined that cardiac hypertrophy could indeed be inhibited
following TAC by the targeted expression of this truncated protein, with accompanying
improvements in cardiac function. Although we were limited in our characterization of the
Rgs2-/-(eb) mouse line in the second part of our thesis, the poor survival rates that we observed
in Rgs2-/- animals following TAC surgery may lead to additional studies examining RGS2
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activity in the context of cardiac electrophysiology. The metabolic role of RGS2 is explored in
the third part of this thesis, and reveals that loss of RGS2 leads to significant upregulation in
metabolic genes and basal metabolism. Altogether, these studies provide new insights into the
role of RGS2 in cardiovascular health and metabolism.
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Appendix C: Supplementary information

Table C1. Measurement and calculation definitions for VisualSonics analysis of
cardiac function
Measurement definitions:
Label
LVAW;d
LVAW;s
LVPW;d
LVPW;s
LVID;d
LVID;s

Description
Left ventricular
Left ventricular
Left ventricular
Left ventricular
Left ventricular
Left ventricular

Calculation definitions:
Name
LV Vol;d (M-Mode)
LV Vol;s (M-Mode)
%EF (M-Mode)
%FS (M-Mode)
LV Mass (M-Mode)
LV Mass Cor (M-Mode)

Description
Left ventricle volume diastole
Left ventricle volume systole
LV ejection fraction
LV fractional shortening
LV mass uncorrected
LV mass corrected

anterior wall (diastole)
anterior wall (systole)
posterior wall (diastole)
posterior wall (systole)
internal diameter (diastole)
internal diameter (systole)

Units
mm
mm
mm
mm
mm
mm

Units
µL
µL
%
%
mg
mg

Formula
((7.0 / (2.4 + LVID;d)) * LVID;d3 )
((7.0 / (2.4 + LVID;s)) * LVID;s3)
100 * ((LV Vol;d – LV Vol;s) / LV Vol;d)
100 * ((LVID;d – LVID;s) / LVID;d)
1.053 * ((LVID;d + LVPW;d + IVS;d)3– LVID;d3)
LV Mass (M-Mode) * 0.8
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Figure C1. Body weights and survival, 14 days of twice daily saline or 50 mg/kg ISO
14 day (A) Saline and (B) ISO-treated mice were weighed daily, with (C)(D) survival recorded
for each treatment and genotype. Data represent means ± SEM, n=3-8 per group using two
way ANOVA with Bonferroni’s post hoc test for body weight data and Log rank test for
survival curves.
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Table C2. Selected microarray genes, fold change, and significance
Of the genes below, only Dio2 expression and significance were validated by qPCR.
Gastrocnemius tissue, n=2 per group (WT and KO).

Gene

p-value

fold change

fold change description

Adcy2

0.380

3.428

KO up vs WT

Adcy5

0.001

-1.478

KO down vs WT

Adrb1

0.011

1.239

KO up vs WT

Adrb2

0.507

1.785

KO up vs WT

Atp2a1

0.414

17.464

KO up vs WT

Atp5g1

0.074

1.434

KO up vs WT

Cs

0.287

1.930

KO up vs WT

Dio2

0.036

1.343

KO up vs WT

Hk2

0.355

5.699

KO up vs WT

Pygm

0.419

20.016

KO up vs WT

Ryr1

0.430

11.336

KO up vs WT

Slc16a2

0.440

-3.300

KO down vs WT

Slc2a4

0.378

7.765

KO up vs WT

Thra

0.477

1.402

KO up vs WT
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A

B

cellular process (GO:0009987) (19; 24.4%)
metabolic process (GO:0008152) (14; 17.9%)
developmental process (GO:0032502) (9; 11.5%)
multicellular organismal process (GO:0032501)(8; 10.3%)
localization (GO:0051179) (6; 7.7%)
response to stimulus (GO:0050896) (6; 7.7%)
biological regulation (GO:0065007) (5; 6.4%)
immune system process (GO:0002376) (4; 5.1%)
cellular component organization or biogenesis (GO:0071840) (3; 3.8%)
biological adhesion (GO:0022610) (2; 2.6%)
reproduction (GO:0000003) (1; 1.3%)
locomotion (GO:0040011) (1; 1.3%)

Figure C2. Biological processes, Rgs2-/- down vs. WT
(A) Microarray genes with a higher expression in Rgs2-/- mice vs. WT (1.4 fold or higher and
P<0.05) were analyzed by the PANTHER gene list program for functional classifications. (B)
The metabolic process section was further expanded for secondary level process details. Chart
legends are read as: category name (accession) (# genes; percent of gene hit against total #
process hits).
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Figure C3. Biological processes, Rgs2-/- up vs. WT
(A) Microarray genes with a lower expression in Rgs2-/- mice vs. WT (1.4 fold or higher and
P<0.05) were analyzed by the PANTHER gene list program for functional classifications. (B)
The metabolic process section was further expanded for secondary level process details. Chart
legends are read as: category name (accession) (# genes; percent of gene hit against total #
process hits).
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A

B

Figure C4. Cellular components and molecular function for microarray genes, Rgs2/-

genes up or down vs. WT

(A) Microarray genes with a higher expression in Rgs2-/- mice vs. WT (1.4 fold or higher and
P<0.05) were analyzed by the PANTHER gene list program for cellular components and
molecular function, as were (B) genes with lower expression. Chart legends are read as:
category name (accession) (# genes; percent of gene hit against total # process hits).
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